

This page intentionally left blank.

CONTENTS

02 Acronym List

04 From the Executive Director

05 Biomarkers: Using Biology to Better Diagnose, Prevent, and Treat PTSD

12 Major Research Initiatives in Fiscal Year 2017

18 Promoting PTSD Education: Training, Dissemination, and Communication

25 About the National Center for PTSD

28 APPENDIX A
Fiscal Year 2017 Research Narrative

38 APPENDIX B
Fiscal Year 2017 Funding

45 APPENDIX C
Fiscal Year 2017 Publications

58 APPENDIX D
Fiscal Year 2017 In Press and Advance Online Publications

65 APPENDIX E
Fiscal Year 2017 Scientific Presentations

75 APPENDIX F
Fiscal Year 2017 Educational Presentations

78 APPENDIX G
Fiscal Year 2017 Editorial Board Activities

Acronyms Used in the Text

| | | |
|---|--|--|
| AI Artificial Intelligence | DSPS Dissociative Subtype of PTSD Scale | ICD-11 International Classification of Diseases, Version 11 |
| AIMS Anger and Irritability Management Skills | EBP Evidence-Based Practice | IPV Intimate Partner Violence |
| CAPS-5 Clinician-Administered PTSD Scale for DSM-5 | EBT Evidence-Based Treatment | LATR Later-Adulthood Trauma Reengagement |
| CBCT Cognitive-Behavioral Conjoint Therapy | EEG Electroencephalography | LIGHT Longitudinal Investigation of Gender, Health, and Trauma |
| CBT Cognitive-Behavioral Therapy | EMDR Eye Movement Desensitization and Reprocessing | MBC Measurement-Based Care |
| CBT-I Cognitive-Behavioral Therapy for Insomnia | ENIGMA Enhancing Neuroimaging Genetics Through Meta-Analysis | mGluR5 Metabotropic Glutamatergic Receptor |
| CE Continuing Education | EWAS Epigenome-Wide Association Study | MMPI-2 Minnesota Multiphasic Personality Inventory-2 |
| CPT Cognitive Processing Therapy | FKBP5 FK506 Binding Protein 5 | MRI Magnetic Resonance Imaging |
| CSP Cooperative Studies Program | fMRI Functional Magnetic Resonance Imaging | MST Military Sexual Trauma |
| CTE Chronic Traumatic Encephalopathy | GABAergic Gamma-Aminobutyric Acid-Ergic | MVP Million Veteran Program |
| DoD Department of Defense | GWAS Genome-Wide Association Study | NCPTSD National Center for PTSD |
| DSM-5 <i>Diagnostic and Statistical Manual of Mental Disorders--Fifth Edition</i> | HSR&D Health Services Research & Development | NDHS Neurocognition Deployment Health Study |

NEPEC

Northeast Program Evaluation Center

NF-κB-activation

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells

NHRVS

National Health and Resilience in Veterans Study

NIH

National Institutes of Health

NIMH

National Institute of Mental Health

NPAS4

Neuronal PAS Domain Protein 4

OEF

Operation Enduring Freedom

OIF

Operation Iraqi Freedom

OMHSP

Office of Mental Health and Suicide Prevention

OND

Operation New Dawn

OSI | VERC

Office of Strategic Integration| Veterans Engineering Resource Center

PBI Network

Practice-Based Implementation Network

PCP

Primary Care Provider

PC-PTSD-5

Primary Care PTSD Screen for DSM-5

PCT

Present-Centered Therapy

PDSI

Psychotropic Drug Safety Initiative

PE

Prolonged Exposure

PET

Positron Emission Tomography

PGC

Psychiatric Genomics Consortium

PILOTS

Published International Literature on Traumatic Stress

PTSD

Posttraumatic Stress Disorder

RNA

Ribonucleic Acid

RTP

Residential Treatment Program

SERV

Survey of Returning Veterans

SGK 1

Serum and Glucocorticoid-Regulated Kinase

SPECT

Single-Photon Emission Computed Tomography

STAIR

Skills Training in Affective and Interpersonal Regulation

STRONG STAR

South Texas Research Organizational Network Guiding Studies on Trauma and Resilience

SV2A

Synaptic Vesicle Glycoprotein 2A

TBI

Traumatic Brain Injury

TMS

Transcranial Magnetic Stimulation

TNF-α

Tumor Necrosis Factor Alpha

TRAIN

TrainingFinder Real-Time Affiliate Integrated Network

TVMI

The Veterans Metric Initiative

UP

Unified Protocol

UPS48

Ubiquitin-Proteasome System

USUHS

Uniformed Services University of the Health Sciences

VA

Department of Veterans Affairs

VALOR

Veterans After-Discharge Longitudinal Registry

VHA

Veterans Health Administration

WoVeN

Women Veterans Network

WTC

World Trade Center

From the Executive Director



Over the past three decades, great strides have been made in understanding, diagnosing, and treating posttraumatic stress disorder (PTSD). The National Center for PTSD, through our seven centers of excellence around the

country, and through our collaborations with scientists in government, academia, and the medical community, has been responsible for many of the breakthroughs that have dramatically improved the lives of our nation's Veterans and other trauma-exposed individuals.

National Center investigators have been on the cutting edge of studying the biology of PTSD since the Center opened in 1989. In recent years, advances in technology have significantly enhanced our ability to study the biology of PTSD, and National Center investigators are leveraging many of these new approaches. Novel neuroimaging technologies have improved our ability to study the structure and function of the brain. Advances in genetics have led to a better understanding of how a person's DNA could affect their response to traumatic events. Large-scale projects, like VA's Million Veteran Program (MVP), are enabling investigators to do research with great precision on large samples. We are especially proud of the establishment of VA's National PTSD Brain Bank—spearheaded by National Center founder and former Executive Director Matthew Friedman.

Much of this work is focused on identifying biomarkers: measurable biological factors that can improve our ability to diagnose, treat, and even prevent PTSD. For example, a biomarker might be a specific gene or brain-activity pattern that predicts risk for PTSD, or the likelihood of

responding to a particular treatment. The introductory section of this Annual Report highlights some of the research on biomarkers taking place in several of the National Center's Divisions, and provides a glimpse of what the implications might be for our Veterans, Servicemembers, and others affected by PTSD.

Other efforts, across all our Divisions, have led to additional important advances in PTSD research, education, and outreach. Within our research portfolio, we have devoted increased attention to the topic of PTSD and suicide, which was adopted in FY 2017 as one of our key operational priorities. Several studies have been completed and others are underway to better identify risk factors for suicide and targets for prevention efforts. Within our education portfolio, we have been especially active in using new communications technologies to reach clinicians and to communicate directly with Veterans including development of a variety of videos, web resources, and mobile apps. These efforts and many others are described more fully in the Major Research Initiatives and Promoting PTSD Education sections of this Annual Report.

We at the National Center are pleased and proud to be at the forefront of developing and disseminating tools and treatments that will improve the lives of the nation's Veterans, now and in the future.

Paula P. Schnurr, PhD Executive Director

Dr. Paula P. Schnurr is the Executive Director of the National Center for Posttraumatic Stress Disorder; she served as Deputy Executive Director from the time of the National Center's founding in 1989 to 2014. She is a Professor of Psychiatry at the Geisel School of Medicine at Dartmouth and Editor of the Clinician's Trauma Update-Online.

Biomarkers: Using Biology to Better Diagnose, Prevent, and Treat PTSD

Throughout much of the history of our understanding of posttraumatic stress disorder (PTSD), the condition was viewed as a problem of psychological maladjustment, with little recognition of how the biology of the brain was contributing to or being affected by a person's reaction to traumatic stress. Over time, the biological underpinnings of PTSD have been increasingly recognized, including sleep cycle abnormalities, evidence of autonomic hyper-reactivity, and dysregulation of hormones involved in the stress response.

Investigators at the National Center for PTSD have long been at the cutting edge of research focused on the biology of PTSD. In the 1980s and 1990s, National Center investigators identified the first biomarker (measurable biological factor) in Veterans with PTSD: disturbances in neural signaling via norepinephrine. In 1989, the Center initiated the first adequately powered multicenter biomarker study of PTSD. This project, which evaluated heart rate increases in response to trauma reminders, was also the first VA Cooperative Studies Program (CSP) study of PTSD. Additionally, the National Center was the first to discover alterations in specific signaling molecules in the brain among Veterans with PTSD, using single-photon emission computed tomography (SPECT) and positron



John Krystal, MD, Director, Clinical Neurosciences Division; Photo credit: Robert Lisak

Advances in technology over the past several years have greatly enhanced scientists' ability to answer those questions. In 2014, VA developed the first-ever [National Posttraumatic Stress Disorder Brain Bank \(PTSD Brain Bank\)](#). This is a human tissue bank that collects, processes, stores, and distributes research specimens for future scientific studies, giving scientists a powerful tool for directly examining the brain tissue of people affected by PTSD. Advances in genetics have created new pathways for exploration, leading to a better understanding of the role genetics plays in an individual's susceptibility to the disorder, as well as to how experiences such as traumatic stress can change the way a person's genes are expressed (a field called epigenetics). The continued development of imaging technologies such as magnetic resonance imaging (MRI) and PET has enabled investigators to better observe the brain at rest and in action as it processes and responds to specific tasks and information.

A major goal of this work is to develop biomarkers of PTSD risk and specific PTSD subtypes that will guide assessment, diagnosis, prevention, and treatment efforts. Dr. John Krystal, Director of the National Center's Clinical Neurosciences Division in West Haven, Connecticut, believes this work is valuable in several ways. "We want to use biology to inform diagnosis, prevention, and treatment of PTSD—for instance, how this knowledge can help us



The National Posttraumatic Stress Disorder Brain Bank is a human tissue bank that collects, processes, stores, and distributes research specimens for future scientific studies.

emission tomography (PET) technologies. In the 1990s, investigators were the first to observe that the volume of the hippocampus (a region of the brain associated with memory and fear) was smaller in PTSD patients. But, despite these early findings, many questions remained about what was happening in the brains of people with PTSD.

predict whether a person might respond to a particular treatment.” He adds, “But we also want to use biomarkers to understand the underlying biology and figure out the *why*—that is, why a person responds in a particular way. Biomarkers are always expressions of something deeper.”

The sections that follow describe some of the key research initiatives at the National Center aimed at identifying and understanding biomarkers for PTSD risk, resilience, and treatment response.

Genetics of PTSD

Not everyone who experiences a traumatic event will develop PTSD. Each person’s brain responds to trauma in its own way, directed to some degree by that person’s genetic code. In just the past 20 years or so, the field of genetics has advanced tremendously. National Center investigators have used these exciting new technologies to understand the role of genetics in PTSD. They have been aided in their quest by having access to data from the National PTSD Brain Bank and VA’s [Million Veteran Program \(MVP\)](#), which collects genetic and health data from Veterans (see sidebars).

The MVP provides scientists with the unprecedented capability to do in-depth genetic analysis due to the large number of Veterans participating. Data collection from



Joel Gelernter, MD, Investigator, Clinical Neurosciences Division

more than 300,000 Veterans has been completed, and analyses of these data are already underway. This high volume of data allows scientists to perform genome-wide association studies (GWAS), a powerful methodology for understanding the genetic basis of disorders.

Dr. Joel Gelernter, a psychiatrist and staff investigator at the Clinical Neurosciences Division, has been at the forefront of GWAS and highlights the importance of these types of studies. “In earlier studies, investigators might interrogate a small set of genes that they think are related to the syndrome of interest. But that approach is



The [Million Veteran Program \(MVP\)](#) is a national program of VA’s Office of Research and Development with the objective of studying how genes affect health. MVP aims to collect blood samples and health information from one million Veterans to build one of the world’s largest medical databases, and the largest that will be able to focus specifically on understanding issues connected to military service. Investigators will use the database to study diseases like heart disease, cancer, and diabetes; PTSD is one of the highest priorities.

At present, over 600,000 Veterans have agreed to participate in the MVP, and data have been collected from more than 300,000 of them. Participation by Veterans is entirely voluntary and confidential, and the response has been extremely positive. Dr. John Krystal is excited about the possibilities opened up by this program. “For the first time we will have accumulated sample sizes large enough to see findings that are replicable.”

The MVP is already generating promising avenues of research; Dr. Joel Gelernter’s study of reexperiencing, for example, was able to utilize data from 150,000 subjects including genetic information and data from a lifestyle survey. It is hoped that research findings based on MVP will lead to new ways of preventing and treating illnesses in Veterans. Dr. Gelernter is enthusiastic about the possible avenues that will be opened up by the MVP. “MVP has turned out to be just as wonderful a resource as the most optimistic people predicted.”




Ronald Duman, PhD, Investigator and Rose Terwilliger, BS, Research Associate, Clinical Neurosciences Division

inherently limited by what you know beforehand. GWAS can look at markers that are dispersed throughout the human genome—typically looking at 250,000 or more markers—without being burdened by prior ideas.” These studies can identify unanticipated aspects of PTSD biology and can find overlaps in genetics with other disorders such as depression.

In one of the first PTSD studies associated with the MVP, Dr. Gelernter identified genes potentially involved in the phenomenon of reexperiencing, in which a person has repeated disturbing memories, thoughts, and/or images that are so severe that the trauma appears to be happening again. Results of this study will be published in 2018. National Center investigators have also collaborated with the Psychiatric Genomics Consortium (PGC) PTSD Workgroup. GWAS analyses from PGC data suggested that differences in multiple genes contributed to the risk for PTSD. These analyses also suggested that PTSD had a relatively high degree of genetic overlap with schizophrenia, especially compared with the overlap with other disorders, such as depression, which were expected to share heritability.


Molecular Psychiatry



Duncan et al. (2018), *Molecular Psychiatry*, 23, 666–673. PTSD heritability for males (M) and females (F) separately and in comparison with other psychiatric disorders. BIP: bipolar disorder; LDSC: linkage disequilibrium score regression; MDD: major depressive disorder; SCZ: schizophrenia.

These findings highlight the likelihood that many genes play a role in the development of PTSD. According to Dr. Ronald Duman, a neuroscientist and staff investigator at the Clinical Neurosciences Division, “We are looking beyond the idea of finding one gene that is responsible for PTSD—that is too simplistic. It’s clear now that the expression of many, many genes is involved, and that we need to look at the entire array to identify gene mutations that underlie psychiatric conditions.”

In addition to specific genes that may make someone more or less likely to develop PTSD, traumatic experience itself may alter gene expression. Dr. Erika Wolf, a psychologist and staff investigator at the Behavioral



Science Division, has been studying epigenetic changes—that is, changes that influence the degree to which a particular gene can be expressed to produce specific proteins. Her research has found a relationship between epigenetic changes and cellular aging: specifically, that the brains and bodies of patients with PTSD can age at a biological rate that is faster than the rate that might be expected from their chronological age. For these patients, the manifestations of aging, such as the onset of metabolic changes or cognitive decline, might be occurring prematurely.

According to Dr. Wolf, “Converging areas of our research—using genetic, metabolic, inflammatory, and neuronal markers—provide evidence that PTSD is associated with accelerated aging. This is particularly concerning, given that much of our research has focused on young Veterans in their early 30s; and it highlights the need to better identify Veterans with an accelerated aging profile and to intervene early with them.”

Neural Connectivity in PTSD: From Synapse to Systems

Some of the earliest studies of PTSD focused on examining the volume and structure of specific regions of the brain, particularly areas such as the hippocampus and amygdala, which are involved in emotion and memory. Today, investigators are using sophisticated imaging techniques to look beyond that static picture and focus instead on connections and interactions within the brain—from the connections between individual cells to the connections between larger brain regions.

One promising avenue of study involves the neurons and synapses in the brain. Neurons are the main brain cells responsible for processing and transmitting information; they communicate with each other primarily through chemical connections (synapses). Each neuron could have as many as 10,000 synapses, and the synapses are constantly being created and eliminated based on life




Irina Esterlis, PhD, Investigator and colleagues, Clinical Neurosciences Division


experiences. National Center scientists are discovering that people with PTSD have decreased synaptic density—that is, a reduced number of synapses in various brain regions.

According to Dr. Krystal, “When you lose synaptic connectivity [density], the fidelity of communication decreases, and plasticity of the networks—or their ability to adapt—decreases. Things that are ingrained, like traumatic memories, can stay ingrained, and the person’s ability to learn new adaptive strategies is compromised.” It is also possible that reduced synaptic density is a precursor to PTSD, making a person more vulnerable to severe reactions to traumatic stress, which in turn reduces synaptic density even further. Finding ways to increase synaptic connectivity in PTSD patients may help treat the disorder; one medication that appears promising

Increasing Synaptic Connectivity



Left: Low numbers of dendritic spines in dendrites of layer V pyramidal neurons after 21 days of chronic uncontrollable stress. Right: Reversal by a single dose of ketamine 1 day later. Red arrows highlight dendritic spines present after ketamine.



Ketamine is hypothesized to exert its effects by stimulating glutamate release, which triggers a chain of neural effects shown here.

Krystal et al. (2017), *Curr Psychiatry Rep*, 19, 74.

for this purpose is ketamine, which has been shown to have antidepressant effects associated with increases in synaptic connectivity.

At the synapse, communication occurs when neurotransmitters released from one neuron bind to a specific receptor on a neighboring neuron. Dr. Irina Esterlis, a neuropsychologist and staff investigator at the Clinical Neurosciences Division, investigates receptors in the brains of people with mental illness. One receptor that may be critical in PTSD is called mGluR5 (metabotropic glutamatergic receptor 5), a synaptic receptor for glutamate, the predominant excitatory neurotransmitter in the brain. This receptor is involved in the brain's response to stress and anxiety, and helps regulate neural networks and synaptic activity in the brain. "We had been studying this [receptor] for several years in patients with depression or serious drug use problems," says Dr. Esterlis. "When we turned our attention to PTSD, we found a pattern that was very different from these other disorders." This finding suggests that there is something unique about the function of this receptor in patients with PTSD.

Examining neural connectivity at a broader level, National Center investigators are studying networks throughout the brain, or how specific regions of the brain work together to


respond to particular situations. For example, three areas of the brain—the amygdala, hippocampus, and prefrontal cortex—are involved in a person's ability to determine the difference between dangerous stimuli and safe stimuli in the environment. Imaging studies from the Clinical Neurosciences Division have shown that connectivity of the hippocampus with other brain regions is associated with the severity of PTSD. Other studies have shown abnormal decision-making and fear regulation in patients with PTSD.

With advances in neuroimaging, especially PET, much of the research on mGluR5 and other receptors can be done with living patients. Dr. Esterlis has found that the PTSD Brain Bank is very helpful in her work. "Our studies of live people give us great information. We can connect the findings to the person's symptoms, cognition, job performance, [and] many other functions. But you can't figure out why this is happening unless you can actually examine the tissue." Dr. Esterlis says she hopes to be able to study patients soon after their traumatic experience to observe the development of PTSD, and to determine whether mGluR5 function is indeed an accurate biomarker for PTSD.

Dr. Krystal predicts that a better understanding of mGluR5 can lead to the development of novel therapeutic approaches. "We are characterizing the uniqueness of PTSD as a disorder, as distinct from major depression, for the first time. Now we can say not just what PTSD is, but also what it is *not*. This is important, because until now every pharmacologic treatment approved for PTSD was a treatment for depression. The unique biology of PTSD will push us to think about therapies in new ways."

Dr. Chadi Abdallah, a psychiatrist and staff investigator at the Clinical Neurosciences Division, sees promising avenues for future examination. "We are discovering that there is a common pathology across many stress-related disorders including PTSD, depression, anxiety disorders, and others. But there are also significant differences. We need to work on identifying the specifics for each of these disorders, in order to develop more effective treatments."

mGluR5 Availability



Holmes et al. (2017), *Proc Natl Acad Sci U S A*, 114, 8390-8395. mGluR5 availability in PTSD: PET findings. (A) Representative PTSD subject and healthy control subject. (B) mGluR5 availability in PTSD (n = 16) compared with HC (n = 16). (C) Correlation between mGluR5 availability in the dorsolateral prefrontal cortex and scores on the avoidance subscale of the PTSD Checklist.

Inflammation and PTSD

According to Dr. Mark Miller, a psychologist and staff investigator at the Behavioral Science Division, "PTSD is a psychiatric disorder that, when chronic, is associated

with a whole cascade of biochemical changes in the body. If these are not addressed and treated, they will exert neurodegenerative effects in the brain.” He adds, “Mental illness can have an effect that remodels the brain, causing permanent alterations in structure and function that further promote illness and disability.”

In the 1990s, investigators at the Clinical Neurosciences Division were the first to describe this paradoxical finding about patients with PTSD: these patients tended to show reductions, rather than the predicted elevations, in levels of the stress hormone cortisol. As cortisol is a key coordinator of inflammatory responses in the body, disturbances in cortisol release set the stage for considerations of disturbances in inflammatory response in PTSD.

Inflammation occurs when the body’s immune system responds to an environmental attack such as an infectious agent. Environmental stress and PTSD may also stimulate the immune system and inflammation, and various genes and proteins are involved in that process. Research has consistently shown that PTSD patients have elevated levels of inflammation, as measured through blood work. Dr. Miller’s work has demonstrated that inflammation occurs in the brain as well. Using tissue from the PTSD Brain Bank, his genetic studies have found elevated levels of inflammatory genes in the tissue of the prefrontal cortex of the brains of PTSD patients. Inflammation associated with PTSD may also contribute to the accelerated aging phenomenon.

If inflammation plays a significant role in developing PTSD and in the effects PTSD has on the body, it may be possible to develop medications to target these processes.



Chadi Abdallah, MD, Investigator, Clinical Neurosciences Division

Changes made to the patient’s lifestyle, including better nutrition and increased exercise, could also be beneficial. PTSD patients often suffer from sleep disturbances; given that sleep plays an important restorative function that can counteract the effects of inflammation and oxidative stress, higher quantity and quality of uninterrupted sleep could be beneficial as well.

Implications for Veterans of Tomorrow

National Center investigators hope their exploration of the biology of PTSD will identify biomarkers that will improve clinicians’ ability to diagnose and treat patients, and that might even be used to prevent the disorder. Biomarkers associated with PTSD might help clinicians make a definitive diagnosis of PTSD in complicated clinical situations or might assist with determining which treatment should be used for an individual patient. Biomarkers may help prevent PTSD by identifying individuals at high risk and providing targets for intervention to prevent onset of the disorder. Identification of biomarkers may also lead to the development of new treatments. According to Dr. Duman, “If we can get a biomarker for PTSD, leading to a new treatment, that would be a big home run.”

The National Center’s work on biomarkers has important implications for customized treatments, often referred to as “precision medicine.” According to Dr. Krystal, “Right now we have one flavor of PTSD, but we might find that there are many varieties. This is important because some treatments are only going to work if the patient has the relevant abnormality in his or her biochemistry.”



Mark Miller, PhD and Erika Wolf, PhD, Investigators, Behavioral Science Division;
Photo credit: Derrick Morin

For example, a recent study tested an anti-inflammatory medication for depression, but found that a patient had to have a particular biochemical signature for the treatment to be effective. “When we can bring these assessments to the level that we can use them to inform treatment,” says Dr. Krystal, “we can do a better job in prescribing medications.”

Genetic and epigenetic research can improve treatment in other ways as well. For example, Dr. Wolf says, “We hope to be able to use biological indices to see who should get what interventions. If we find that a person has a genetic risk or propensity for obesity, for instance, we might avoid medications whose side effects include weight gain. That person might be sent to an exercise intervention instead.”

Dr. Matthew Friedman, Senior Advisor to the National Center and Director of the PTSD Brain Bank, says, “The future of medicine will be pharmacogenetics. It won’t be long before you can get a genetic workup just like you get blood work today, so that we can match the treatment with the particular person. The only way to do this is to understand how the brain is changing.”

Dr. Krystal sees a complex road ahead. “Right now what we have is a jigsaw puzzle with a few randomly matched pieces in it. Seeing how all the different pieces come together, and therefore being able to see the ultimate picture, is still a long way away.”

VA’s National PTSD Brain Bank



VA’s National Posttraumatic Stress Disorder Brain Bank (PTSD Brain Bank) was formally established in 2014, thanks in part to Congressional support led by U.S. Senator Patrick Leahy (D-VT). It is the first and only facility of its kind devoted exclusively to PTSD, and consists of a consortium of five VA Medical Centers as well as the Uniformed Services University of Health Sciences (USUHS). The PTSD Brain Bank is headquartered at the National Center’s Executive Division in White River Junction, Vermont, and is under the direction of Dr. Matthew Friedman. Dr. Friedman is the former Executive Director of the National Center for PTSD and currently serves as a Senior Advisor to the National Center. He was a leader in establishing VA’s National PTSD Brain Bank and serves as its Director.

The PTSD Brain Bank currently has 168 brains, including 56 PTSD brains, and has received commitments of more than 100 additional brains by the end of 2018. Donors can be either Veterans or non-Veterans. Because of the importance of acquiring suitable comparison tissue, the PTSD Brain Bank also collects tissue from donors who had no psychiatric illness during their lifetimes, or who suffered from a non-PTSD disorder such as depression.

Donations of tissue to the PTSD Brain Bank can occur in two ways. In many cases, consent for donation is obtained from next-of-kin shortly after their loved one dies. Other tissue comes from individuals who enroll in advance and personally consent to have their brain tissue go to the PTSD Brain Bank after death (called antemortem donors). The advantage of acquiring commitments from antemortem donors is that detailed data can be collected on their medical and psychological histories while they are alive.

The PTSD Brain Bank’s physical hub is in Boston, where it is programmatically linked with the brain banks of VA Boston and Boston University, both of which are also dedicated to advancing the understanding and treatment of other illnesses including Alzheimer’s disease, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and Gulf War Illness. Relationships with other brain banks can result in useful comparative studies, such as one study currently in process that is comparing data on suicide in individuals with CTE/TBI with individuals who have PTSD.

According to Dr. Friedman, “We can leverage these other resources to do things that would have been unimaginable. This is like a dream come true.”

Pictured: Matthew Friedman, MD, PhD Director of VA’s National PTSD Brain Bank, Senior Advisor to the National Center for PTSD, and former Executive Director of the National Center for PTSD

Major Research Initiatives in Fiscal Year 2017

The National Center's research activities are driven by operational priorities, first established in 2013, which help organize and focus research on areas most likely to have the greatest benefit to Veterans. Five priorities were initially set: biomarkers, treatments, care delivery, implementation, and the *Diagnostic and Statistical Manual of Mental Disorders—Fifth Edition (DSM-5)*. A sixth priority—PTSD and suicide—was added in FY 2017 to reflect the critical nature of this area of research and the associated portfolio, which has recently grown in both size and scope.

During FY 2017, researchers at the National Center led 136 funded studies—ranging from investigations at a single location to projects across multiple sites—including partner organizations in the government, universities, and agencies outside of the United States. Investigators published 282 peer-reviewed journal articles, book chapters, and books; additionally, there were 140 in-press and advance online publications.

The sections that follow highlight some of the research initiatives undertaken during FY 2017 to address these six operational priorities. See Appendix A for a more complete description of research projects that took place at each of the National Center's seven Divisions ([Executive Division](#), White River Junction, Vermont; [Behavioral Science](#)

[Division](#), Boston, Massachusetts; [Clinical Neurosciences Division](#), West Haven, Connecticut; [Dissemination and Training Division](#), Palo Alto, California; [Evaluation Division](#), West Haven, Connecticut; [Pacific Islands Division](#), Honolulu, Hawaii; and [Women's Health Sciences Division](#), Boston, Massachusetts).

Biomarkers

The National Center is dedicated to research aimed at identifying biomarkers (i.e., measurable biological factors) that inform the prevention, diagnosis, and treatment of PTSD. Key aspects of this work from FY 2017 (i.e., genetics, neural connectivity, and inflammation) are highlighted in the section called "Biomarkers: Using Biology to Better Diagnose, Prevent and Treat PTSD." In addition, other important studies are underway. Investigators at the Behavioral Science Division have received funding to collect genetic information from saliva samples from individuals participating in [Project VALOR](#) (Veterans After-Discharge Longitudinal Registry), a longitudinal registry of over 1,600 male and female combat OEF/OIF/OND (Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn) Veterans. Researchers




OPERATIONAL PRIORITIES

at the Clinical Neurosciences Division have conducted genome-wide genetic and epigenetic analyses on data collected from participants in the longitudinal National Health and Resilience in Veterans Study (NHRVS). Investigators at the Women's Health Sciences Division are continuing to conduct biomarker studies with particular relevance to women, including a study examining the role of neurobiological and psychosocial factors that impact negative pregnancy outcomes in women with PTSD.

PTSD and Suicide

This new area of focus aims to better understand the relationship between PTSD and suicide, and to develop strategies to prevent suicide among Veterans with PTSD. An extensive amount of research has shown an association between PTSD and suicidal ideation and behaviors, most



recently among Veterans returning from combat in Iraq and Afghanistan. Over the past fiscal year, National Center investigators engaged in studies aimed at identifying risk factors for suicide and at developing interventions that may help prevent suicidal behavior.

During FY 2017, researchers at the National Center published studies that identified associations among suicidal ideation and completed suicide with PTSD reexperiencing and dysphoric arousal symptoms, alcohol misuse, and unplanned hospital discharge (i.e., against medical advice or patient-initiated discharge). Another study found gender differences including the finding that sexual harassment during deployment was a potential risk factor for suicidal ideation in women. Ongoing efforts to identify potential risk factors for suicidal behavior are utilizing large, longitudinal data sets in Veteran and non-Veteran populations; future work will leverage [VA's National Posttraumatic Stress Disorder Brain Bank \(PTSD Brain Bank\)](#) to identify neurobiological markers associated with suicide risk.

Investigators at the Behavioral Science Division who are working on developing better suicide prevention strategies have shown that having high-quality safety plans may be a key strategy in suicide prevention. In a sample of Veterans at high risk for suicide, higher-quality safety plans were associated with fewer suicidal behavior reports; but, a significant minority of the sample had either an incomplete safety plan or no safety plan at all. At the Clinical Neurosciences Division, investigators are using brain imaging to assess neurobiological correlates of the acute anti-suicidal effects of ketamine in Veterans with PTSD. This work may help identify other brain-based targets for interventions aimed specifically at reducing suicide risk.


Treatment Engagement, Efficiency, and Effectiveness

The National Center has long been a leader in the development of evidence-based treatments (EBTs) and outcomes research. One of the most ambitious efforts is the groundbreaking Cooperative Studies Program investigation (CSP #591) of Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT). Nine hundred Veterans will be enrolled in this study, with recruitment expected to be completed in early 2018. Findings will help VA leadership, clinicians, and Veterans make informed choices about the delivery of PTSD care in VA, and will also be broadly relevant to the scientific and clinical communities outside VA. Another ongoing trial is evaluating two psychotherapies (PE and Seeking Safety) for comorbid alcohol use disorder and PTSD.



Erika Wolf, PhD and Denise Sloan, PhD, Investigators, Behavioral Science Division

Delivery of Care



Resick, Wachen, et al. (2017), *JAMA Psychiatry*, 74, 28-36. Change in PTSD measures across the study period. PSS-I: Posttraumatic Symptom Scale-Interview. PCL-S: PTSD Checklist-Specific. CPT: Cognitive Processing Therapy.

National Center investigators are also focused on developing strategies for enhancing engagement with care. Ongoing efforts include developing a self-report measure of patients' likelihood of engaging in care and in investigating reasons for premature dropout from treatment. In one study, investigators are identifying reasons why patients complete or drop out of PE and CPT, and are developing an intervention to improve retention.

Another area of focus is increasing efficiency and effectiveness in the delivery of care. In one study, researchers compared individual CPT with group CPT and found that both treatments led to improved symptoms, although individual CPT was more effective. A newly funded study with active-duty Servicemembers is comparing whether CPT delivered over five days is as effective as CPT delivered over six weeks. Other efforts include investigating strategies for maintaining therapy-related gains after treatment completion.

The National Center is engaged in novel stand-alone and adjunctive treatments for PTSD and associated conditions. Psychotherapeutic approaches being tested include Written Exposure Therapy, a cognitive-behavioral intervention for trauma-related guilt and shame, and a brief counseling intervention designed for women Veterans who have experienced intimate partner violence (IPV). National Center investigators are also looking at


complementary and alternative ways to treat conditions associated with PTSD, such as Tai Chi for pain.

Evidence-based pharmacologic interventions for PTSD are relatively limited, so National Center investigators are exploring approaches to treatment that have mechanisms of action different from existing PTSD treatments, including ketamine, ganaxolone (a steroid medication that may reduce anxiety), and focal brain stimulation. Adjunctive approaches being tested include ketamine-enhanced PE and topiramate-enhanced PE. Treatment strategies in development include oxytocin-enhanced psychotherapy and neurofeedback.

Care Delivery, Models of Care, and System Factors

Improving access to PTSD treatments in many different settings, including in the home, is an important objective of the National Center. To this end, investigators are examining the delivery of care through the use of technologies such as telehealth, web-based interventions, and mobile apps. A recent trial showed that [PTSD Coach](#), a mobile app that assists with self-management, led to greater reduction in PTSD symptoms compared with a control group. An ongoing study is assessing the adjunctive use of this app with evidence-based psychotherapy for PTSD. Another project involves

PTSD Coach Mobile App



Kuhn et al. (2017), *J Consult Clin Psych*, 85, 267-273. Changes in PTSD symptoms measured with PCL in PTSD Coach group versus waitlist group.



modifying [VetChange](#), a web-based intervention for alcohol use disorders, to include features that facilitate collaboration between providers and Veterans.

Other efforts are focused on testing approaches for improving care delivery across health care systems. One initiative is a large, multisite trial comparing two strategies for enhancing therapists' delivery of CPT. Each strategy involves placing therapists within therapist communities that utilize different approaches to ensuring

National Center investigators are also developing tools that can be used in clinical settings to improve access to care. One study is examining participatory systems dynamics, a collaborative stakeholder model in which system problems are identified, changes are proposed, and the impact of the changes on the outcome of interest is predicted in a data-driven fashion. The study is testing whether the use of the model improves timely access to high-quality services in VA outpatient settings.

Implementation


The National Center is committed to developing research, strategies, and infrastructure to promote implementation of best practices. Investigators continue to be involved in the implementation of evidence-based screening and treatment across VA, including ongoing assessment of the rate at which PE and CPT are gaining acceptance and usage.

New studies at the Dissemination and Training Division include evaluations of methods for simplifying assessment of the quality of Cognitive Behavioral Therapy (CBT) for PTSD, and of competing strategies for enhancing and sustaining the delivery of treatment. These strategies attempt to optimize fidelity to the standard treatment protocol—through either expert consultation and online resources or continuous quality improvement approaches—to improve fit and address barriers to treatment delivery. Another new study aims to increase the use of evidence-based psychotherapy for PTSD in the military health system, and to identify barriers and

Team Participatory System Dynamics

fidelity to the CPT protocol. Another study is focused on outpatient VA prescribing of benzodiazepines and atypical antipsychotics following academic detailing around best practices.

Practitioner Registry



* Active Registry clinicians can cross over to the Newsletter Only Control group at 12 months
 ** Newsletter Only Controls may opt to participate in Active Registry at 12 months



Tara Galovski, PhD, Director, Women's Health Sciences Division

facilitators of implementation in this setting. One study nearing completion focuses on assessing and increasing implementation of many core elements of the [VA/DoD Clinical Practice Guideline for PTSD](#) in three service delivery sectors: VA, DoD, and the general community.


National Center investigators are also testing and disseminating practices for addressing family violence. The [Strength at Home](#) protocol for reducing and preventing IPV is being rolled out across eight VA Medical Centers, and is also being evaluated in a sample of active-duty Servicemembers and their partners. Investigators at the Women's Health Sciences Division are identifying best clinical practices for screening programs on IPV within VA women's health primary care settings, with the ultimate goal of disseminating these practices to all VA primary care clinics.

The National Center is also helping to develop the infrastructure for implementation science research. Investigators across multiple Divisions are playing key roles in the VA Measurement-Based Care (MBC) initiative,

which will generate data that can be used in future investigations of treatment planning, treatment response, and use of evidence-based practices (EBPs). Another approach includes developing a practitioner-based implementation network across VA and DoD.

DSM-5

The *Diagnostic and Statistical Manual of Mental Disorders–Fifth Edition (DSM-5)* is an established classification and diagnostic tool that specifies the diagnostic criteria for all currently recognized psychological disorders. During FY 2017, the National Center continued to update PTSD assessments for the *DSM-5* and to explore the utility of



the *DSM-5* PTSD criteria. One study involved establishing reliability and validity of the [Clinician-Administered PTSD Scale for DSM-5 \(CAPS-5\)](#) in a Veteran population. Investigators also compared the *DSM-5* PTSD criteria to the proposed PTSD criteria in the International Classification of Diseases, Version 11 (*ICD-11*) and found that the *DSM-5* criteria were more effective in diagnosing PTSD in Veterans. Another ongoing effort is aimed at continued validation of the *DSM-5* version of the [Primary Care PTSD Screen \(PC-PTSD-5\)](#), which is mandated for PTSD screening in VA primary care clinics.



Honors and Awards Received by National Center Staff in FY 2017

Cassidy Gutner, PhD

Women's Health Sciences Division

Outstanding Reviewer, *Behavior Therapy*

Jasmeet Hayes, PhD

Behavioral Science Division

Best Abstract in Neurotrauma Research, International Brain Injury Association

Early Career Investigator Award, International Brain Injury Association

Adrienne Heinz, PhD

Dissemination and Training Division

Best Poster Award, Experiential Technology Conference

Brian Marx, PhD

Behavioral Science Division

Outstanding Contributions to the Science of Trauma Psychology, APA Division 56

Carmen McLean, PhD

Dissemination and Training Division

Anne Marie Albano Early Career Award for Excellence in Science and Practice Integration, Association for Behavioral and Cognitive Therapies

PTSD Clinicians Exchange Team including: Josef Ruzek, PhD; Erica Simon, PhD; and Kile Ortigo, PhD

Dissemination and Training Division

Communicator Award (Websites-General-Health), Academy of Interactive & Visual Arts

W3 Silver Award, Academy of Interactive & Visual Arts

Lauren Sippel, PhD;

Jeremy Tevis, BFA;

Margaret Willoughby, BA

Executive Division

First Place, VHA Communications Award for the FY 2015 Annual Report: Implementation Science

Denise Sloan, PhD

Behavioral Science Division

Toy Caldwell-Colbert Award for Distinguished Educator in Clinical Psychology, APA Division 12

Fellowships and Travel Awards

Thomas Adams, PhD

Clinical Neurosciences Division

Travel Award, American College of Neuropsychopharmacology

Lynnette Averill, PhD

Clinical Neurosciences Division

Travel Award, American College of Neuropsychopharmacology

Cassidy Gutner, PhD

Women's Health Sciences Division

NIH Implementation Research Institute Fellow

NIH Clinical Research Student Loan Repayment Award

Kate Iverson, PhD

Women's Health Sciences Division

NIH Implementation Research Institute Fellow

Lindsey Zimmerman, PhD

Dissemination and Training Division

2017 System Dynamics Society Summer School Scholarship, MIT Sloan School of Management


Promoting PTSD Education: Training, Dissemination, and Communication

Since the National Center's inception, education and dissemination efforts have been part of the organization's mission. The National Center uses a variety of channels both to inform and to obtain feedback from Veterans, clinicians, and the public at large, including initiatives ranging from face-to-face training programs to published literature to the latest technologies. These efforts are facilitated by the extensive network of partnerships among professionals at the seven National Center Divisions and clinicians throughout VA, other government agencies, academia, and the mental health community.

The sections that follow describe some of the many avenues the National Center follows to help ensure that the most up-to-date research knowledge and the best clinical practices are made available as efficiently as possible to help Veterans and others with PTSD. We are proud early adopters of technology—from databases to social media, from apps to avatars—yet we never lose sight of the value in developing relationships with professionals and the public that evolve into long-lasting connections.

PTSD Awareness and Engagement in Treatment

Now more than ever, people with PTSD have a variety of effective treatments to choose from. Whether they opt for trauma-focused psychotherapy—the proven first-line treatment for PTSD—or medications, patients should have an expectation for recovery and for relief of symptoms. At



present, however, research that would help match patients to specific treatments is still in its early stages, so choosing among the various options can be challenging.

Research such as VA's Cooperative Studies Program (CSP) #591—a study comparing the effectiveness of two types of evidence-based psychotherapy—may soon yield clues about which PTSD treatments are best for which patients. Currently, a shared decision-making process, in which the patient and provider collaborate to decide on a treatment plan, is the best practice for choosing a treatment. The [PTSD Treatment Decision Aid](#), a free online tool launched by the National Center in FY 2016, was designed as an element in this process. Users answer questions that help them clarify their treatment goals, watch videos of providers explaining each treatment, and compare treatments using an interactive chart. Afterward, patients can print a summary of their symptoms, goals, and preferences that they can discuss with their providers as part of the shared decision-making process. In FY 2017, the Decision Aid was updated to correspond to the [2017 VA/DoD Clinical Practice Guideline for PTSD](#). An accompanying [Clinician's Guide](#) (PDF) has useful tips for



Current research may soon yield clues about which PTSD treatments are best for which patients.

Trauma-focused Psychotherapy Works Best
Now more than ever, there are effective treatments for PTSD.

- Cognitive Processing Therapy (CPT)**
CPT teaches you how to change the upsetting thoughts and feelings you have had since your trauma.
- Prolonged Exposure (PE)**
PE teaches you to gradually approach trauma-related memories, feelings and situations that you have been avoiding since your trauma.
- Eye Movement Desensitization and Reprocessing (EMDR)**
EMDR helps you process and make sense of your trauma while paying attention to a back and forth movement or sound (like a finger waving side to side, a light, or a tone).

Medication Can Help
If you prefer to take medication, you have four good options. But remember, you will need to keep taking medication in order to keep feeling better.

- Sertraline
- Paroxetine
- Fluoxetine
- Venlafaxine

THE BEST TREATMENT FOR PTSD: The evidence is in.
Trauma-focused psychotherapy is the first-line treatment for PTSD. It lasts only about three months, and research shows that for most people its effects last long after treatment is over.

Did You Know?

- Trauma-focused Psychotherapy**
53 OUT OF 100 people who receive trauma-focused psychotherapy will no longer have PTSD after about 3 months of treatment.
- Medication**
42 OUT OF 100 people who take medication will no longer have PTSD after about 3 months of treatment.
- No Treatment**
BUT ONLY 9 OUT OF 100 people who don't get treatment will no longer have PTSD after about 3 months.

PTSD Treatment Decision Aid www.ptsd.va.gov/apps/decisionaid

AboutFace: Veterans talk about PTSD and PTSD treatment www.ptsd.va.gov/apps/aboutface/

National Center for PTSD www.ptsd.va.gov

October 2017

ABOUTFACE Home Watch Learn More Get Help

PTSD We've been there.
After a traumatic event — like combat, an assault, or a disaster — it's normal to feel scared, keyed up, or sad at first. But if it's been months or years since the trauma and you're not feeling better, you may have PTSD (posttraumatic stress disorder).

Watch the intro

This is AboutFace
In these videos, Veterans, family members, and clinicians share their experiences with PTSD and PTSD treatment. Choose a topic below to hear what they have to say.

- What is PTSD? --
- How does PTSD affect loved ones? --
- Am I ready for help? --
- What is treatment like? --
- How can treatment help me? --
- Our advice to you, --

Up Close
As a combat photographer, Stacy Pearsall sees the unspeakable. Rather than lose what she values most, she turns to treatment.
Hear Stacy's story
See all Up Close stories

providers who incorporate the Decision Aid into their practices.

The recommendations in the VA/DoD Clinical Practice Guideline for PTSD are also reflected in an infographic developed by the National Center in FY 2017, called [The Best Treatment for PTSD: The Evidence is In \(PDF\)](#), which conveys the message to patients that trauma-focused psychotherapy has the best evidence for successfully treating PTSD. With eye-catching graphics and a direct message, the infographic is a quick way for Veterans to learn about treatment options. A second infographic, called [Primary Care: The Best Treatment for PTSD Starts with You \(PDF\)](#), was developed for primary care providers (PCPs).

Whiteboard Videos

Medications for PTSD
SSRIs: SERTRALINE (ZOLOFT)
SNRIs: VENLAFAXINE (EFFEXOR)

Eye Movement Desensitization and Reprocessing (EMDR) for PTSD

PTSD and the Brain

Three new animated videos were then developed in response to the updated Guideline, building on an [earlier whiteboard series](#). The videos—on Eye Movement Desensitization and Reprocessing (EMDR), medications supported by the Guideline, and PTSD and the brain—will debut on the National Center’s website in FY 2018.

One of the most successful ways the National Center has promoted the understanding of the impact of treatments is through an online gallery called [AboutFace](#), which debuted in 2012. Videos on the site feature Veterans, family members, and providers who all talk directly about how treatment for PTSD has turned Veterans’ lives around. Topics focus on how treatment has reduced Veterans’ symptoms, improved their quality of life, and helped them forge better relationships with friends and family members. The site was completely redesigned in FY 2017, and now gives viewers better access to the videos and enables filtering and searching by topic.

Self-Help and Treatment Companion Resources


The National Center has long been at the forefront in creating tools that people can use to support their mental health and well-being, either on their own or with the assistance of a provider. Since the launch of the award-winning [PTSD Coach](#) in 2011, the National Center has released 15 mobile apps, all available for free to users worldwide.

Two new [apps](#) were released in FY 2017: the AIMS (Anger and Irritability Management Skills) app ([Apple](#) | [Android](#)), based on the VA online course Anger and Irritability Management Skills, can be used by anyone coping with anger problems. [STAIR Coach](#) is an app for people participating in Skills Training in Affective & Interpersonal Regulation (STAIR), an evidence-based psychotherapy designed to improve emotion regulation. Also released were next-generation versions of PTSD Coach, PE Coach, and CBT-I (Cognitive-Behavioral Therapy for Insomnia) Coach. In a continuing effort to establish parity among platforms, four mobile apps were released on the Android platform in FY 2017.

The Military Sexual Trauma (MST) Recovery App is under development by a team of investigators from the Women's Health Sciences Division in Boston, Massachusetts, and the Dissemination and Training Division in Palo Alto, California. This app is designed for both male and female survivors of MST experiences and is focused on promoting recovery.



Margaret "Peggy" Willoughby, Associate Director for Information and Communication, Executive Division, and Amy Street, PhD, Deputy Director, Women's Health Sciences Division



Although not intended as a replacement for mental health care, the app can be used independently or in conjunction with psychotherapy.

In parallel with the development of the STAIR app, National Center experts built WebSTAIR, a free online site that guides users through a range of tools designed to enhance communication skills, improve emotion regulation, and address interpersonal relationship problems. National Center investigators are recruiting study participants to determine WebSTAIR's effectiveness with varying levels of coaching support. Recruitment efforts are focusing on women Veterans with MST living in rural areas. The project is being evaluated in terms of effectiveness and implementation. A public version of the site is expected to be available on the National Center's website in FY 2018.

Two new online courses designed to help family members have been completed and are also expected to be released in FY 2018. These courses are adaptations of CRAFT (Community Reinforcement and Family Training), an empirically supported treatment that is intended to help family members cope more effectively with a Veteran's symptoms of PTSD and addiction, respectively, and to help them encourage their loved one to enter treatment.

The National Center for PTSD's efforts to foster self-help and to improve interpersonal relationships also extend to face-to-face programs. WoVeN (Women Veterans Network), led by the Women's Health Sciences Division

Woven

Women Veterans Network

in collaboration with the Boston University School of Medicine, aims to create a sustainable network for women Veterans that focuses on fostering personal connections. WoVeN also launched a [website](#) in FY 2017. In addition to community-building activities, the site includes educational content relevant to women Veterans who want to learn more about mental health and ways to get care including information about PTSD and MST. WoVeN is funded by a Walmart Foundation grant to the Boston University School of Medicine.

Educational Resources for Professionals

The PTSD 101 series has long been the National Center's flagship [continuing education \(CE\)](#) offering. The series, which offers free CE credits, comprises more than 30



Margaret "Peggy" Willoughby, Associate Director for Information and Communication and Cybele Merrick, MA, MS, Associate Director for Education, Executive Division

hour-long courses. Four new courses were created in FY 2017 and will be live in FY 2018: Shared Decision-Making for PTSD, Cognitive-Behavioral Conjoint Therapy for PTSD, Treating PTSD and Suicide Risk, and PTSD: From Neurobiology to Treatment. Many National Center CE courses are available through [TRAIN \(TrainingFinder Real-time Affiliate Integrated Network\)](#), thus enabling investigators and providers who work outside the VA system to access the courses as well and to earn CE credits.

For providers within VA, the National Center partnered with Women's Health Services to create Providing Trauma-Sensitive Medical Care to Women Veterans. Available as a 60-minute course or as a brief overview, the course covers ways traumatic experiences can affect women Veterans' presentation in the medical setting, some unique issues



The PTSD 101 series comprises more than 30 hour-long courses and offers free CE credits.

they may create for their medical care, and steps medical providers can take to become more sensitive to trauma-specific needs. The course also covers issues such as how to respond to disclosure of trauma, and strategies for preventing and managing trauma-related reactions during appointments.

The National Center also released three toolkits for professional audiences:

- [The Police Officer Toolkit: PTSD and Military Veterans](#) aims to help police officers interact more effectively with Veterans who have PTSD. The toolkit also offers strategies for coping with traumatic stress in oneself or when dealing with colleagues in law enforcement.
- The [Clergy Toolkit](#) is a resource for those who provide pastoral care to Veterans with PTSD.
- The [Provider Self-Care Toolkit](#) includes education and resources to help mental health care providers deal with professional burnout and secondary traumatic stress. Related information is available in a companion course, [Provider Strategies for Coping with Burnout and Secondary Traumatic Stress](#).

During FY 2017 the [Community Provider Toolkit](#) was enhanced with sections focusing on using technology

in care and on treatment of [Lesbian, Gay, Bisexual](#), and [Transgender](#) (LGBT) Veterans. User research and concept development for a revised version of the Community Provider Toolkit was also completed in FY 2017.

PILOTS (Published International Literature on Traumatic Stress)


The [Published International Literature on Traumatic Stress \(PILOTS\)](#) database was created at the National Center in 1989, shortly after the National Center was founded and well before the internet was established as a research tool. PILOTS provides free, online access to an international, cross-disciplinary collection of journal articles, reports, books, and dissertations on psychological trauma and its consequences. Although the primary audience for PILOTS is clinicians and investigators, the database is also used by students, the media, and the general public. Users can download the full text of articles written by National Center staff members, which also serves to increase the reach of the Center's research.



In FY 2017 PILOTS had over 59,000 records, and users ran more than 20 million searches in the database

PILOTS offers a custom thesaurus focused on PTSD and trauma, and thorough notation of psychological scales and measures, enabling searchers to efficiently and precisely navigate the abundant scholarly literature related to PTSD accessible through the database.

In FY 2017 PILOTS had over 59,000 records, and users ran more than 20 million searches in the database. To keep pace with the growth of academic publishing, PILOTS began adding in-process records, allowing new records to be uploaded and searched prior to full indexing. The Resource Center staff, which produces the PILOTS database, also began offering weekly email alerts to VA employees of new PTSD publications, thus saving clinicians' time as well as assisting VA staff in staying up-to-date with the latest literature.




Support for Providers in the Field

Beginning in 2008 with the national training initiatives for CPT and PE, the National Center launched the VA PTSD Mentoring Program, designed to promote best practices in the clinical and administrative components of specialty care. The program connects PTSD program directors with seasoned PTSD professionals within their regions who act as mentors. This year the Mentoring Program developed the online PTSD Clinical Team Director Course (available in [TMS](#)) to foster the utilization of effective practices on the administrative side of PTSD clinics. Through this new initiative, Mentoring Program staff work with program directors to help them meet the increased demand for treatment by restructuring existing programs and implementing best practices.

Complementing these national efforts, the Executive Division in White River Junction, Vermont, with support from VHA Office of Rural Health, is expanding its program that uses academic detailing and facilitation to improve the treatment of Veterans in rural New England (VISN 1).

The Executive Division is expanding its program that uses academic detailing and facilitation to improve the treatment of Veterans in rural New England.



In FY 2017 a clinical pharmacist and psychologist started working on disseminating the recommendations in the revised [VA/DoD Clinical Practice Guideline for PTSD](#) to prescribing clinicians. The goal is to foster the provision of evidence-based PTSD care including increasing referrals to effective psychotherapy and reducing the prescribing of benzodiazepines for PTSD. The program is also developing an online rural provider dashboard and a rural provider

toolkit to support VA providers working in rural clinics.

The [PTSD Consultation Program](#) began in 2011 with the mission of connecting VA providers with expert PTSD consultants via phone or email, and was expanded in 2015 to offer consultation and resources to community providers outside VA who see Veterans with PTSD. The effort to reach more providers has been supported by a targeted web-based and direct mail marketing campaign. Consultation requests from community and VA providers grew by 50 percent in the past year, with a total of over 2,100 consultations completed; approximately a quarter of all requests came from outside VA. The Consultation Program continues to offer a well-attended monthly webinar series with topics based on questions coming into the program.



Treating Veterans with PTSD?

Consult with expert PTSD clinicians for FREE today!



PTSD PTSD Consultation Program
FOR PROVIDERS WHO TREAT VETERANS

PTSDconsult@va.gov
(866) 948-7880
www.ptsd.va.gov/consult

Practice-Based Implementation Network



The [Practice-Based Implementation Network \(PBI Network\)](#) is a network of VA PTSD field sites and individual clinicians collaborating with the National Center to test new practices and approaches to implementation. In FY 2017 the PBI Network piloted a learning collaborative to train and support clinicians as they integrated new phone and internet technologies into their practices. The Technology Community of Practice developed for the initiative brought together providers and experts in both mobile apps and online programs, and in December 2017 will become an ongoing resource for providers across VA.

Monthly calls highlight new releases, such as the updated version of CBT-I Coach and a clinical dashboard to support care, and allow providers to ask experts questions as well as share their own experiences and knowledge. The development of additional implementation materials—such as handouts for family members supporting loved ones in therapy—is underway in an effort to continue to respond to provider requests and to improve implementation with Veterans.

The [PTSD Clinician's Exchange](#), the National Center's practitioner registry, continues to link participating treatment providers in VA, DoD, and the general community with practical training and resources related to 25 best practices. The goal is to increase providers' familiarity with these practices and enhance their perceptions of benefit to patients. In the past year the registry has also been accessed by a network of subject matter experts to respond to clinician inquiries about specific best practices.



The PTSD Clinician's Exchange links participating treatment providers in VA, DoD, and the general community with practical training and resources.

The National Center partnered with quality improvement programs in the Office of Mental Health and Suicide Prevention and with the Office of Strategic Integration | Veterans Engineering Resource Center (OSI|VERC) to develop Modeling to Learn, a nationwide online quality improvement training program for multidisciplinary frontline addiction and mental health teams. The aim of the program is to expand Veterans' access to treatments most likely to prevent chronic impairment, relapse, suicide, and overdose.

Modeling to Learn empowers teams to evaluate trade-offs among critical priorities and to identify local quality improvement strategies that best utilize existing staff resources. The program includes an online SharePoint site with tools to review team data and online system dynamics models that help teams develop improvement plans. Another key component is a workshop series that enables participating psychiatrists, psychologists, social workers, nurses, counselors, and certified peer support specialists to earn CE credits in their field of practice.

Modeling to Learn

Experiments that empower effective action

Communication Stats at a Glance



Over 8 Million Website Views
www.ptsd.va.gov



40,485 Newsletter Subscribers



138,252 Facebook Followers



52,915 Newsletter Subscribers



34,443 Twitter Followers



303,198 Downloads of 16 Mobile Apps



223,677 Newsletter Subscribers



Over 1 Million App Downloads Since 2011, when first VA app (PTSD Coach) released

About the National Center for PTSD



History

The National Center for PTSD was created in 1989 within the U.S. Department of Veterans Affairs in response to a Congressional mandate (PL 98-528) to address the needs of Veterans and other trauma survivors with PTSD. The National Center was developed with the ultimate purpose of improving the well-being, status, and understanding of Veterans in American society. The mandate called for a center of excellence that would set the agenda for research and education on PTSD without direct

responsibility for patient care. Convinced that no single VA site could adequately serve this unique mission, VA initially established the National Center as a consortium of five Divisions.

Organization

The National Center now consists of seven VA academic centers of excellence across the United States, with headquarters in White River Junction, Vermont. Two Divisions are located in Boston, Massachusetts; two in West Haven, Connecticut; one in Palo Alto, California; and one in Honolulu, Hawaii. Each contributes to the overall Center mission through specific areas of focus.

The National Center for PTSD is an integral and valued component of VA's Office of Mental Health and Suicide Prevention (OMHSP), which is within the Veterans Health Administration (VHA). OMHSP and the National Center receive budget support from VA, although the Center also leverages this support through successful competition for extramural research funding.



The National Center for PTSD was formed in 1989



It has seven Divisions across the U.S., each with a distinct area of focus



The National Center had 136 externally funded studies and 422 publications in FY 2017

National Center for PTSD Quick Facts

Leadership in Fiscal Year 2017



Paula P. Schnurr, PhD

Executive Director,
[Executive Division, VT](#)

Professor of Psychiatry, Geisel School of Medicine at Dartmouth




Rani Hoff, PhD, MPH

Division Director
[Evaluation Division, CT](#)

Director of the Northeast Program Evaluation Center

Professor of Psychiatry, Yale University School of Medicine



Matthew J. Friedman, MD, PhD

Senior Advisor and Founding Executive Director
[Executive Division, VT](#)

Professor of Psychiatry and of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth



Terence M. Keane, PhD

Division Director
[Behavioral Science Division, MA](#)

Professor of Psychiatry and Assistant Dean for Research, Boston University School of Medicine



Jessica L. Hamblen, PhD

Acting Deputy Executive Director and Deputy for Education
[Executive Division, VT](#)

Associate Professor of Psychiatry, Geisel School of Medicine at Dartmouth



John H. Krystal, MD

Division Director
[Clinical Neurosciences Division, CT](#)

Robert L. McNeil, Jr. Professor of Translational Research and Chairman of the Department of Psychiatry, Yale University School of Medicine



Tara E. Galovski, PhD

Division Director
[Women's Health Sciences Division, MA](#)

Associate Professor of Psychiatry, Boston University School of Medicine



Josef Ruzek, PhD

Division Director
[Dissemination and Training Division, CA](#)

Professor (Clinical Professor-Affiliated), Stanford University; Associate Professor, Palo Alto University

Fiscal Year 2017 Advisory Boards

Scientific Advisory Board

Chair: John Fairbank, PhD

National Center for Child Traumatic Stress, Duke University Medical Center

Col. Dave Benedek, MD, LTC, MC, USA

Uniformed Services University of the Health Sciences

Susan E. Borja, PhD

National Institute of Mental Health

Sandro Galea, MD, DrPH

Boston University School of Health

JoAnn Kirchner, MD

VA Mental Health Quality Enhancement Research Initiative, Central Arkansas Veterans Healthcare System; University of Arkansas for Medical Sciences

Alfred Montoya, MHA

White River Junction VA Medical Center

Thomas C. Neylan, MD

San Francisco VA Medical Center; University of San Francisco School of Medicine

Alan L. Peterson, PhD, ABPP

University of Texas Health Science Center

Kerry Ressler, MD, PhD

McLean Hospital, Harvard Medical School

Barbara O. Rothbaum, PhD, ABPP

Emory University School of Medicine

Elizabeth Yano, PhD, MSPH

VA Greater LA Healthcare System, UCLA Fielding School of Public Health

Ex-Officio: Theresa Gleason, PhD

VA Clinical Science Research & Development

Educational Advisory Board

Chair: Dean Kilpatrick, PhD

National Crime Victims Research & Treatment Center, Medical University of South Carolina

Thomas J. Berger, PhD

Vietnam Veterans of America

Craig Bryan, PsyD, ABPP

National Center for Veterans Studies, The University of Utah

Ann Feder, LCSW

Department of Veterans Affairs, VISN 2

Michael Fisher, MSW

Readjustment Counseling Services, Department of Veterans Affairs

Michael R. Kauth, PhD

VA South Central MIRECC

Kacie Kelly, MS

George W. Bush Presidential Center

Jackie Maffucci, PhD

Iraq and Afghanistan Veterans of America

Lisa A. Marsch, PhD

Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Geisel School of Medicine at Dartmouth

David S. Riggs, PhD

Center for Deployment Psychology, Uniformed Services University of the Health Sciences

Appendix A: Fiscal Year 2017 Research Narrative

Behavioral Science Division

The Behavioral Science Division in Boston, Massachusetts, conducts research on adjustment after military deployment, assessment methods, genomic and neuroscience mechanisms linked to psychopathology, and innovative approaches to clinical intervention and treatment delivery.

Prospective Cohort Studies

Division researchers are working on two large prospective cohort studies that collect information from strategically selected groups of people over time. The first, [Project VALOR \(Veterans After-Discharge Longitudinal Registry\)](#), is working with a registry of 1,649 male and female combat Veterans who became users of Department of Veterans Affairs (VA) services after 2002. The project collects data about health outcomes associated with posttraumatic stress disorder (PTSD), supplemented by clinical information from VA electronic medical records. Data collection for the fourth sampling wave is now complete, with 1,205 participants (73% of the initial cohort); examination of PTSD symptom trajectories and predictors of those trajectories are in process. The next phase of the project involves collecting saliva samples from participants for future genomic analyses.

The second large investigation, the [Neurocognition Deployment Health Study \(NDHS\)](#), began data collection at the outset of the Iraq War in 2003. Military personnel were assessed before deployment and at several intervals afterward—making it the first prospective, longitudinal study to address the psychological impact of war zone stress. The study design allows examination of long-term emotional and neuropsychological outcomes, as well as health-related quality of life and occupational functioning. Initial papers have described PTSD outcomes; longitudinal neuropsychological outcomes; and relationships among PTSD, traumatic brain injury (TBI), and neuropsychological outcomes. Data preparation and analysis are underway for an associated study that examines the adjustment of both partners and children of the Servicemembers and Veterans in the cohort.

Biomarkers

Biomarker (measurable biological factors) research at the Division includes a rapidly growing portfolio of genetic and neuroimaging studies, working with collaborators such as the [Translational Research Center for TBI and Stress Disorders \(TRACTS\)](#) Center of Excellence, the [National PTSD Brain](#)

[Bank](#), the Psychiatric Genomics Consortium (PGC), and the [Enhancing Neuroimaging Genetics through Meta-Analysis \(ENIGMA\) PTSD Working Group](#). During FY 2017, Division investigators contributed to the largest neuroimaging study of PTSD conducted to date (see Duncan et al., 2017). They also found evidence in both blood and brain tissue that suggests a role for inflammation in the pathophysiology of PTSD; and they published findings consistent with the accelerated-aging hypothesis that addresses the biological impact of PTSD.

Other Division investigators are examining biomarkers of PTSD and blast-related TBI in Veterans of Iraq and Afghanistan war zones. Through this research, investigators aim to clarify the relative contribution of mild TBI and psychiatric conditions to various deficits experienced by military personnel with blast injury, as well as long-term negative consequences such as neurodegenerative disease. The biomarkers are drawn from structural and functional neuroimaging, epigenetic indicators, candidate genes, and examination of polygenic risk.

Recent published work has identified genes that moderate hippocampal volume in mild TBI and PTSD. Other published and in-progress work has examined how risk for Alzheimer's disease and Parkinson's disease moderates cortical thickness and volume following mild TBI. Future work will examine blood-based biomarkers such as those associated with neuronal injury and inflammation.

Division investigators are using functional and structural magnetic resonance imaging (MRI) to identify neural circuitry involved in PTSD. Structural MRI data point to specific hippocampal subfield volumes that are negative correlates of PTSD and that may play a role in the persistence of PTSD symptoms. Additional work is being conducted to examine the relationship between hippocampal subfield volume and overgeneralization of memory in PTSD. Data from functional MRI projects also suggest reduced function in specific brain regions within the prefrontal cortex during attempts at memory suppression. This finding identifies a possible

Appendix A: Fiscal Year 2017 Research Narrative

mechanism for intrusive thoughts in PTSD that might be targeted in treatment.

Treatment Research

The Division continues to conduct pioneering research on treatments for PTSD, with the key aims of overcoming barriers to seeking care, reducing dropout, and increasing efficiency of care delivery. A prime example is the internet-based treatment [VetChange](#), designed for Iraq and Afghanistan combat Veterans who report risky use of alcohol and PTSD-related distress. The initial clinical trial produced evidence that VetChange was effective in reducing both drinking and PTSD symptoms.

The research version of VetChange was subsequently modified to include a mobile-friendly public website. This version, which is applicable to Veterans of all eras, is now under evaluation. A [mobile app](#) that has key VetChange features was recently developed in conjunction with the Dissemination and Training Division and will soon begin a pilot test phase. In addition, a major extension of the VetChange web intervention is underway to directly integrate with clinical care delivered by VA providers and to evaluate its effectiveness in VA clinics.

Other Division efforts include developing and testing efficient, therapist-delivered interventions or treatment extenders, with the goal of finding approaches that require less professional staff time and that are easier for patients to complete. A prime example is a five-session Prolonged Exposure (PE)-based treatment for PTSD that has shown strong effects with non-Veteran patients. Current and planned studies are testing whether this brief intervention is as effective as Cognitive Processing Therapy (CPT), and whether it can be implemented successfully with Veterans and active-duty Servicemembers.

Research on factors that link PTSD with aggression toward intimate partners has led to the development and evaluation of interventions that reduce or prevent aggression within at-risk military families. Positive clinical trials have been published; and the interventions are being implemented at multiple sites in the VA health care system and on one military installation. A new pilot study is planned that will adapt and test one of these programs for use in an underserved urban civilian setting.

In the area of complementary interventions, a five-year study has begun examining the impact of two active 12-week treatments on chronic pain in Gulf War Illness. In this project, Tai Chi, a mind-body exercise associated with both physical and mental health benefits, is compared with a wellness promotion group that is based on VA's Whole Health approach. Manuals for both group treatments have been developed, and the first cohort of Veterans has begun the interventions.

Division investigators are also examining a phenomenon termed later-adulthood trauma reengagement (LATR),

in which older combat Veterans actively reengage with wartime memories in an effort to build coherence and/or to find meaning in the experience. It is theorized that the LATR process may either lead to growth and positive outcomes or result in negative outcomes such as increased symptomatology. A current study of LATR is examining the utility of a 10-week psychosocial discussion group for older combat Veterans who report experiences consistent with the LATR process. Three cohorts are complete, and recruitment for the fourth cohort will begin in early 2018.

Lastly, Division investigators are evaluating evidence-based psychotherapy programs operating under the VA Boston PTSD Clinic. Recent findings demonstrated that changes in clinic intake procedures are associated with increased rates of retention in evidence-based psychotherapies.

Assessment

Data collection is underway on a study designed to validate a cutoff score for PTSD status based on the most recent version of the [Primary Care Screen for PTSD for DSM-5 \(PC-PTSD-5\)](#) for the *Diagnostic and Statistical Manual of Mental Disorders—Fifth Edition (DSM-5)*. The study is part of a larger effort to validate DSM-5 versions of measures that have been developed by National Center investigators. The project recruits Veterans from VA primary care locations and uses the [Clinician-Administered PTSD Scale for DSM-5 \(CAPS-5\)](#) as the criterion index. The study will also explore the extent to which the optimal PC-PTSD-5 cutoff score varies across subgroups of Veterans and will provide initial information about the acceptability of the screening measure for these patients.

A recent study evaluated Restructured Form scales from the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) as predictors of PTSD-related outcomes. One paper based on this work demonstrates that the MMPI-2 Restructured Form scales can differentiate high PTSD symptom severity alone from high severity accompanied by dissociation—a difference that has implications for treatment decisions. A second paper provides formal psychometric support for the utility of the [Dissociative Subtype of PTSD Scale \(DSPS\)](#) in a clinical sample of Veterans. Data collection is also underway for an investigation into the utility of the MMPI-2 Restructured Form scales in relation to chronic pain and treatment outcomes for Veterans who receive care in a VA pain clinic.

Division investigators are collaborating with research teams from the MITRE Corporation and MIT Lincoln Laboratory to develop a nonintrusive method of PTSD detection that utilizes voice analysis. This work uses neurocomputational modeling to identify vocal markers based on timing and coordination of speech to determine the presence and severity of PTSD. The nonintrusive nature of this approach increases its potential for real-world application.

Another ongoing project is designed to inform postmortem donor classification for the [VA National PTSD Brain Bank](#). Data are being collected from living elderly Veterans to determine their status for PTSD and comorbid disorders; this criterion information is then used to evaluate the predictive potential of information obtained from an informant interview and medical record review. The goals are to determine the best predictors from indirect sources and to provide an assessment template for use by the PTSD Brain Bank.

Epidemiology and Risk/Resilience

A collaborative project with investigators from VA Boston Healthcare System takes a lifespan, multidisciplinary approach to studying the impact of military service. This effort has facilitated research and advanced the traumatic stress field through creation of a website that provides information about military service variables found in a large number of publicly accessible longitudinal data sets. Research facilitated by this effort is reported in the forthcoming book *Long-Term Outcomes of Military Service: The Health and Well-Being of Aging Veterans*.

Clinical Neurosciences Division

The Clinical Neurosciences Division in West Haven, Connecticut, focuses on research designed to uncover biomarkers (measurable biological factors) of disease mechanisms, as well as on clinical research that investigates paradigms of risk and resilience. The Clinical Neurosciences Division utilizes an interdisciplinary approach that includes neuroimaging, treatment, genetics, and epidemiological studies targeted at translating discoveries from the lab into interventions for treating posttraumatic stress disorder (PTSD) and comorbid conditions.

Neuroimaging Studies

Clinical Neurosciences Division investigators are working to characterize biochemical, structural, and functional abnormalities underlying PTSD. This body of work suggests connections between how the nervous system and brain, in particular, respond to extreme stress. Investigators are also working on the integration of neuroimaging and genomics to understand how genetic and environmental influences come together to create unique phenotypes of PTSD. Other work includes projects using advanced machine-learning methods and artificial intelligence (AI) to investigate disruptions in brain network circuitry.

Neurochemical & Molecular Brain Imaging

A recent body of research, conducted by Clinical Neurosciences Division researchers and Department of Veterans Affairs ([VA's National Posttraumatic Stress Disorder Brain Bank \(PTSD Brain Bank\)](#)), strongly points to alterations in the glutamatergic and glucocorticoid (cortisol) systems that underlie brain network impairment and dysfunction in PTSD. Research using positron emission tomography (PET) technology has shown that mGluR5 (metabotropic glutamatergic receptors) may be a promising treatment target in depression and PTSD, as it plays a role in the modulation of glutamate neurotransmission.

Studies have shown that mGluR5 is present in higher levels in trauma survivors with PTSD compared to those without PTSD; mGluR5 density is highest in the hippocampus and putamen, two brain regions that hold specific relevance for PTSD. Additional pilot data found that mGluR5 is even higher in PTSD patients with comorbid suicidal ideation. Investigators have also demonstrated that mGluR5 availability is related to glutamate levels in stress-related psychopathology as well as to changes following drug administration, suggesting

that normalization of glutamate neurotransmission by modulating mGluR5 may be an important component of successful treatment. Investigators are building on findings from animal work showing that glucocorticoids can modulate the glutamatergic system; these efforts could increase understanding of the neurobiology of PTSD and provide novel targets for treatment development.

Investigators continue to study neuroinflammatory processes in PTSD using PET technology. Prior work has indicated a link between immune alterations and PTSD following trauma exposure; and investigators are now studying whether activation of microglial cells contributes to PTSD pathogenesis. Preliminary data have been collected to evaluate the role of activated microglia in mediating PTSD expression. Other work aims to study the relationship between peripheral inflammatory markers such as TNF- α (tumor necrosis factor alpha) and trauma-related symptoms. By characterizing the type and extent of neuroinflammation in PTSD, it may be possible to uncover new targets for treatment with anti-inflammatory agents; findings may also inform new research evaluating long-term effects of increased inflammation that occur in response to chronic stress. Additionally, pilot data collected in a second project of PTSD and arterial inflammation is currently undergoing analysis, and may contribute to efforts to reduce cardiac mortality in PTSD patients.

Additionally, investigators are conducting preclinical and clinical studies to measure synaptic density alterations in PTSD and in other trauma- and stress-related disorders. They are using a PET tracer for SV2A (synaptic vesicle glycoprotein 2A), which is a likely biological marker of brain synaptic plasticity (the ability of the brain to reorganize synaptic connections in response to learning or from injury). The SV2A tracer is an extremely valuable tool, as stress-related

Appendix A: Fiscal Year 2017 Research Narrative

synaptic loss is believed to be an essential contributor to PTSD pathophysiology, treatment failure, and functional impairment. The next phase of this work will include a clinical study with nonhuman primates, as well as clinical participants with depression and PTSD, to evaluate changes to synaptic density following the administration of ketamine, a medication that affects the glutamate system. This study is building on prior preclinical work showing that damage to synaptic connections caused by chronic stress is rapidly reversed by ketamine.

Structural and Functional Brain Imaging

Sophisticated functional and structural neuroimaging are important tools used to study brain metabolism and brain circuitry in PTSD. Recent findings from this work have shown that global brain connectivity is a potential marker for stress-related dysfunction and a possible target for treatment. Studies have also found that disruptions between neural pathways in the anterior hippocampus—an area involved in forming, organizing, and storing memories—is associated with higher PTSD severity.

Data from projects that characterize brain circuitry using EEG (electroencephalography) testing and fMRI (functional magnetic resonance imaging) have shown that decreased hippocampal volume in patients with PTSD is associated with reduced functional connectivity in other areas of the brain. Additional imaging research includes the study of neuroanatomical correlates of abnormal fear regulation, information processing, and decision-making in the context of ambiguity and risk in patients with PTSD.

Morphometric Brain Imaging

The Clinical Neurosciences Division continued its collaboration with [PGC-ENIGMA \(Psychiatric Genomics Consortium-Enhancing Neuroimaging Genetics Through Meta-Analysis\)](#), a large-scale coalition partnering in the analysis of neuroimaging and genetic data. Investigators recently replicated the finding that the volumes of the hippocampus and amygdala are smaller in Veterans with PTSD. Although the literature has been largely concentrated on studies of overall volume of these brain regions, recent studies by Clinical Neurosciences Division researchers have utilized novel morphometric and subfield approaches to localize PTSD-related atrophy within specific regions within the hippocampus and amygdala. Further work is using high-resolution MRI to study the association between cortical thickness and suicidal ideation in combat-exposed Veterans. Preliminary analyses suggest that suicidal ideation may be associated with altered cortical thickness in brain areas key to the neurobiology of PTSD, and may serve as a potential biomarker for increased risk of suicidality.

Treatment Research

Investigators have previously shown that ketamine has rapid antidepressant effects that are associated with changes

in the brain's functional connectivity, thus improving neuroplasticity. Researchers are now testing the therapeutic effects of ketamine in a PTSD population over longer periods of time to study the durability of treatment response in PTSD. Data from this study is also examining ketamine's potential procognitive and anti-suicidal effects in PTSD. Additional work includes a study to evaluate ketamine's potential to augment the treatment effects of Prolonged Exposure (PE) therapy to determine whether improved neuroplasticity can positively affect fear inhibition and memory reconsolidation.

Researchers continue to explore intervention strategies that might improve fear extinction among trauma survivors who do not respond to standard treatment approaches. One such avenue of work includes the use of real-time fMRI neurofeedback. Resting-state functional connectivity (that is, regional changes in brain activity when the brain is not involved in a task) data from an fMRI neurofeedback project revealed that neurofeedback led to changes in brain connectivity during traumatic memory recall that were consistent with clinical improvement. Investigators will continue to study the clinical utility of this emerging technique in the treatment of PTSD.

Other pharmacotherapeutic agents currently under study include riluzole, a glutamate modulating agent; the immunosuppressant rapamycin; and neuropeptide Y, an endogenous neuropeptide.

Genetic and Molecular Studies

The Clinical Neurosciences Division is a major contributor to the field of genetics, utilizing neurogenomics to explore interactions among genotypes, phenotypes, and the environment via a range of bioinformatic approaches. Using tissue from the PTSD Brain Bank, investigators have shown that a specific gene—SGK1 (serum and glucocorticoid-regulated kinase 1)—that is expressed at lower levels in people with PTSD, was also lower in stressed animals, and that overexpressing this gene in animals made them more resilient to stress. Ongoing efforts include studying SGK1 as a potential marker for PTSD and investigating strategies for raising SGK1 levels in the brain as a potential new treatment. Several other genes of interest—including FKBP5 (FK506 binding protein 5) and NPAS4 (neuronal PAS domain protein 4)—have also been targeted in reverse transcription polymerase chain reaction analysis, a technique used to detect Ribonucleic Acid (RNA) expression.

Researchers have recently teamed with experts in high-level computational analyses to examine thousands of gene expression changes and DNA methylation in hundreds of subjects. This combined effort has led to identification of major networks of gene expression in PTSD patients—as compared with patients who have major depressive disorder and with control subjects—as well as alterations in single genes of interest in individuals with PTSD. Further bioinformatics

Appendix A: Fiscal Year 2017 Research Narrative

studies are expected to result in identification of key network and hub genes that contribute to PTSD pathophysiology.

Clinical Neurosciences Division investigators continue to participate in the ongoing [Million Veteran Program \(MVP\)](#). Investigators recently completed a genome-wide association study (GWAS) in approximately 150,000 subjects, evaluating how genetic and environmental influences (phenotypes) come together to affect symptom reexperiencing. Work was also conducted on an epigenome-wide association study (EWAS) of PTSD in 1,135 Veterans—including both dimensional and categorical measures of PTSD as well as subphenotypes of reexperiencing, avoidance, numbing, and dysphoric and anxious arousal. Once finalized, this project will be the largest EWAS of PTSD conducted to date. Preliminary results suggest that the UPS48 (ubiquitin-proteasome system 48) gene, which is involved in the regulation of NF- κ B-activation (nuclear factor kappa-light-chain-enhancer of activated B cells), plays

an important role. NF- κ B-activation is a key regulator of inflammation, which is also implicated in synaptic plasticity and memory.

Epidemiological Studies

Investigators are continuing to study the link between the neurobiology and epidemiology of PTSD. Several new studies were conducted in FY 2017 using data from the [National Health and Resilience in Veterans Study \(NHRVS\)](#) and the World Trade Center (WTC) Health Program. Recently published reports have examined questions on public health relevant to Veterans including factors that protect against the development of suicidal thinking, the role of attachment style in moderating effects of FKBP5 polymorphisms and childhood abuse in predicting PTSD symptoms, a comparison of International Classification of Diseases 11 (ICD-11) and DSM-5 criteria for PTSD, and trajectories of posttraumatic growth.

Dissemination and Training Division

The Dissemination and Training Division in Palo Alto, California, conducts research on patient needs and preferences, implementation science, the development of novel and adapted treatments that attend to patient preferences, and the development and testing of treatments that employ the potential benefits of technology-based delivery of services.

Patient Needs and Preferences

Several projects are aimed at developing and evaluating strategies to quickly identify patient needs, patients at risk, and patient preferences. A Health Services Research & Development Service study is developing a brief measure of patient characteristics associated with effective engagement in care. The measure is expected to guide identification of the type and amount of service resources needed to engage Veterans into care.

A second study related to patient needs will develop and cross-validate a risk-screening tool that identifies patients at risk for subsequent mental health problems. The study will focus on racial and ethnic minority patients who have been found to experience disparities in trauma exposure and mental health care.

Dissemination and Training Division investigators, working with collaborators at the Women's Health Sciences Division, completed research and evaluation work on screening and treatment for military sexual trauma (MST). The Dissemination and Training Division is also participating with the Executive Division to validate the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5).

Implementation Research

A new study is evaluating how to simplify assessment of the quality of delivery of cognitive-behavioral therapy (CBT) for PTSD, depression, and anxiety disorders. A second ongoing study on Cognitive Processing Therapy (CPT) is evaluating

competing strategies intended to enhance and sustain the delivery of a PTSD treatment: one strategy emphasizes fidelity to the protocol through expert consultation and online resources, and the other focuses on using continuous quality improvement strategies to improve fit and to address barriers to treatment delivery. Investigators involved in evaluating the national rollout for Prolonged Exposure (PE) are investigating the effectiveness of different training models on trainee delivery of PE.

In collaboration with the Minneapolis Department of Veterans Affairs (VA) Medical Center, investigators completed a study identifying organizational factors that differentiate whether VA PTSD clinics have high or low usage of evidence-based psychotherapies. This project led to a new study that will take place in FY 2018, led by Minneapolis VA with co-investigators at two National Center Divisions, to test an implementation toolkit in VA PTSD clinics. The project also led to approval of a new multisite study to test whether a tailored set of implementation strategies increases the use of PE within the military health system, above and beyond the impact of standard provider training. This mixed-methods study will engage stakeholders at various levels and then match implementation strategies to site-specific barriers and facilitators.

New efforts are underway to improve patient access to care, including reduced patient wait times, by using participatory systems dynamics: a collaborative stakeholder model in which specific system problems are identified, changes are proposed,

Appendix A: Fiscal Year 2017 Research Narrative

and the impact of the change on the outcome of interest is predicted in a data-driven fashion. The team is hoping to secure funding to assess the cost-effectiveness of this approach and to test its mechanisms of action.

A long-term project is the development of a practitioner network across both VA and Department of Defense (DoD) that can test strategies for implementing best practices. The network is currently engaged in quality improvement projects, but can also become a resource for implementation science research in the future. Lastly, a study that focuses on assessing and increasing implementation of many core elements of the [VA/DoD Clinical Practice Guideline for PTSD](#) in all three service delivery sectors (VA, DoD, and the general community) is nearing completion.

Treatment Research

Dissemination and Training Division investigators are conducting several trials that evaluate patient outcomes in treatments adapted for use in a variety of settings and under a variety of delivery methods. A hybrid effectiveness and implementation study will compare two non-trauma-focused treatments delivered to women Veterans in their homes via video teleconference: Skills Training in Affective and Interpersonal Regulation (STAIR), which is an 8-session individual treatment for a variety of patients with PTSD, and Present-Centered Therapy (PCT), which is a non-trauma-focused therapy that focuses on current life problems related to PTSD. The goals of the study are to assess the relative effectiveness of these treatments, and to identify barriers and facilitators for using video to deliver treatment.

The efficacy of a web version of PE (Web-PE) in reducing symptoms of PTSD in military personnel and Veterans is being tested. Web-PE is delivered online with therapist oversight and facilitation, and could have significant potential to increase the reach of PE to those who cannot otherwise access traditional face-to-face care.

A large multisite clinical trial is now evaluating the effectiveness of flexibly delivered STAIR plus PE among civilian

public sector women, and will examine how variations in delivery affect patient outcomes. Lastly, investigators are evaluating adaptive changes in cardiac autonomic status, physical activity, social cognition, and social interaction in real time among Veterans participating in VA's Service Animal Training Intervention program.

Technology-Based Treatments and Treatment Delivery

Several ongoing studies are assessing the benefits of phone- and web-based technologies to increase Veteran access to mental health care and to enhance outcomes. Following two successful pilot studies of the [PTSD Coach mobile app](#), a new project will assess the efficacy of PTSD Coach compared with traditional treatment for reducing PTSD symptoms in Veterans utilizing primary care service. Several pilot studies of mobile phone apps are underway including a pilot study of app-based personalized and semiautomated coaching integrated into PTSD Coach; a pilot study of a couples-based intervention using mobile apps; and two ongoing trials of the [Mindfulness Coach app](#) in Veterans with PTSD and as an adjunct for Veterans receiving other types of medical care.

A mobile cognitive-control training for the treatment of alcohol use and PTSD will determine the efficacy of a novel neurocognitive intervention for improving recovery outcomes. The first investigation of [Moving Forward](#) (an online problem-solving intervention for Veterans that teaches skills for overcoming stressful problems and helps them meet their goals) has been completed, with Veterans reporting less avoidance of problem solving as well as greater satisfaction with the online course when helped by a peer mentor.

In collaboration with investigators from the Minneapolis VA, the Dissemination and Training Division is conducting a study to test a web-based intervention to help National Guard families encourage their loved ones to seek mental health care. Key questions concerning the methods and the extent to which social networks can be utilized to increase treatment engagement, and to improve mental and physical health outcomes, is being investigated in a study of another highly stressed population: cancer survivors.

Evaluation Division

The Evaluation Division in West Haven, Connecticut, supports the National Center's mission through a programmatic link with Department of Veterans Affairs (VA)'s [Northeast Program Evaluation Center \(NEPEC\)](#). NEPEC has broad responsibilities within the VA Office of Mental Health and Suicide Prevention (OMHSP) to evaluate their programs including those for specialized treatment of posttraumatic stress disorder (PTSD).

Program Monitoring and Evaluation

NEPEC has continued to monitor and assess PTSD treatment at VA. The monitoring includes both residential and outpatient specialty treatment programs, as well as PTSD treatment by trained providers not working within one of the PTSD specialty programs. The Evaluation Division via NEPEC also monitors

efforts to improve psychotropic medication prescribing practices at the Veterans Health Administration (VHA). Two of the measures in this initiative are the use of antipsychotics to treat PTSD and the use of benzodiazepines without an appropriate diagnosis or medical indication. Although NEPEC is primarily engaged in evaluation research, it also works on

independent research projects related to the treatment of PTSD.

Prospective Cohort Studies

Recruitment has finished for the Survey of Returning Veterans (SERV) study, which is a repeated panel study of gender differences in psychiatric status and functioning among OEF/OIF/OND (Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn) Veterans. SERV recruited 850 participants who were interviewed at three-month intervals for at least a year; a sizeable subset continued interviewing for up to three years. Over 40% of the sample is women. Follow-up rates are 80–85%. Analyses have begun, and the Evaluation Division is looking for investigators interested in analyzing the SERV data, or in leveraging the SERV sample in add-on or other primary data collection studies. Papers have been published on military sexual trauma (MST) and PTSD as they relate to unit cohesion, gender differences in prevalence rates of disorders over time, and characteristics of Veterans endorsing sex addiction items. Other papers and presentations are in progress on insomnia and PTSD symptoms, suicidal ideation and behaviors, and behavioral addictions. SERV data and an add-on study have been used to develop a pornography addiction scale that is currently in testing for psychometric properties; results in international samples are positive.

Treatment Research

The Evaluation Division continues research on PTSD health service research, pain management, and the role of pain in the treatment of PTSD, as well as on sex differences in the health of returning Veterans. Data collection for a study of the implementation of two evidence-based treatments (EBTs)—Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT)—in 38 VA residential treatment programs (RTPs) for PTSD has been completed. Findings continue to be published on provider perspectives on perceived effective residential treatment ingredients, provider perceptions of dissuading factors to the use of PE and CPT, and changes in implementation of PE and CPT over time.

The Evaluation Division has a number of investigators using administrative data to explore treatment patterns and outcomes of PTSD care. Studies have been published on medication used for the treatment of PTSD, as well as on correlates of self-reported PTSD symptom severity scores over time. During FY 2018, the Evaluation Division will further examine the role of pain in specialized PTSD treatment and in the treatment of comorbid disorder, and will continue publishing results from the SERV interviews. The national Psychotropic Drug Safety Initiative (PDSI) has entered its fourth year and has been tracking data on changes in practice in prescribing for PTSD. The Evaluation Division continues its work with technical advisors at the PTSD Mentoring Program and at the OMHSP to provide technical assistance, and continues to respond to requests from specialized programs and staff in the field on policy, operations, handbook implementation, and the provision of evidence-based practices (EBPs).

The Measurement-Based Care (MBC) in Mental Health Initiative, which was formally launched by OMHSP in June 2016, completed its first year of work; and 58 facilities and 179 mental health clinics were enrolled as Champion Sites for implementing MBC. Two Evaluation Division staff are supporting the initial pilot program evaluation; members of the Executive Division and the Dissemination and Training Division are involved in the senior leadership of the Initiative. Additional investigators from within the Center are closely involved in the evaluation study itself, as well as in the Communications, Education and Training, and Coaching work groups. The National Center investigators from the Dissemination and Training Division have secured a contract with the RAND Corporation to perform in-depth interviews with MBC project directors, frontline provider-Veteran dyads, and individual providers to better understand their experiences with MBC. As the Initiative moves into its second year, NCPTSD members will continue to be active participants as investigators and as Initiative leaders.

Executive Division

The Executive Division, in White River Junction, Vermont, provides leadership, directs program planning, and promotes collaboration to facilitate optimal functioning of the other Divisions both individually and collectively. The Executive Division specializes in the development and evaluation of innovative and authoritative educational resources, in programs that disseminate and implement best management and clinical practices, and in the use of technologies to reach a broad range of audiences. The Executive Division also oversees the administration of Department of Veterans Affairs (VA)'s National Posttraumatic Stress Disorder (PTSD) Brain Bank.

Treatment Research

The Executive Division has a long history of participation in VA's Cooperative Studies Program (CSP). During FY 2017, enrollment continued for CSP #591, a groundbreaking study

comparing Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT). The study is expected to reach the enrollment goal of 900 Veterans at 17 sites across the country in early 2018. Findings will help VA leadership, clinicians, and Veterans

Appendix A: Fiscal Year 2017 Research Narrative

make informed choices about the delivery of PTSD care in VA, and will also be broadly relevant to the scientific and clinical communities outside VA.

In collaboration with the Behavioral Science Division, the Executive Division is leading a study to provide further validation of the *Diagnostic and Statistical Manual of Mental Disorders—Fifth Edition (DSM-5)* version of the [Primary Care PTSD Screen for DSM-5 \(PC-PTSD-5\)](#), which is currently used across VA for mandatory PTSD screening. Although initial validation has been completed, the ongoing study, which uses the [Clinician-Administered PTSD Scale for DSM-5 \(CAPS-5\)](#) as the criterion index, will provide more definitive information regarding the most appropriate cutoff scores and will allow investigation of the screen's ability to detect PTSD in key subgroups such as women.

Investigators continue to focus on issues that frequently co-occur with PTSD. Follow-up assessments have been completed for a trial looking at cognitive-behavioral therapy (CBT) along with usual outpatient addiction care compared with usual care alone for Veterans with PTSD and substance use disorders; analyses are underway. Data collection for a second trial comparing two psychotherapies for comorbid alcohol use disorder and PTSD (PE and Seeking Safety) will be completed during winter 2018. A new trial evaluating the combination of topiramate and PE for co-occurring PTSD and alcohol use disorder has been funded; recruitment launched in November 2017. Investigators continue collaborations with the PTSD specialty clinics and with the residential PTSD/substance use treatment program at the San Diego VA to develop ways to use clinical data for research. An ongoing pilot study is investigating the safety and efficacy of a novel form of synchronized transcranial magnetic stimulation (sTMS) for PTSD with comorbid depression. Lastly, a trial to evaluate a brief protocol to reduce guilt and shame related to a traumatic event among Veterans of Iraq and Afghanistan is midway through recruitment.

Investigators completed a pilot study that evaluated Veterans' reactions to [AboutFace](#), a web-based video gallery of Veterans with PTSD who share their personal stories about PTSD and how treatment has turned their lives around. Veterans assigned to AboutFace had positive attitudes toward the program and improved attitudes toward mental illness from baseline to the two-week follow-up, as compared with those in a control group.

Implementation Research

The Executive Division continues work on several initiatives aimed at assessing models of care and at improving evidence-based practice. Investigators continue to analyze data and to publish results from a national survey that assessed the treatment needs and preferences of Veterans and non-Veterans with PTSD symptoms. Results of this survey also informed the development of the first publicly available

online treatment decision aid for PTSD, which was released to the National Center website in March 2017. The [PTSD Treatment Decision Aid](#) is interactive and enables users to identify preferences among treatment options and print that information to share with their providers.

An initiative funded by the Office of Rural Health (ORH) will examine the impact of facilitation and an academic detailing model, in which pharmacists reach out directly to clinicians to improve PTSD treatment practices in rural clinics throughout VISN 1 (VA New England Healthcare System). A published manuscript that focused on the impact of a multifaceted academic detailing program noted improvements in PTSD care consistent with clinical practice guidelines, as well as reductions in prescribing of benzodiazepines, antipsychotics, and prazosin during the educational intervention. These findings suggest that academic detailing and other educational programming can effectively address gaps in quality PTSD care.

In addition to projects aimed at improving clinical practices, investigators are continuing to assess the state of VA care for PTSD. Work is ongoing on a project that applies novel informatics and operational methods to medical and administrative data in order to understand multiple dimensions of quality of PTSD care within VA. As investigators have gained more skills and experience in retrospective data analysis, new projects have been created to understand and compare the effectiveness of evidence-based treatments (EBTs) for PTSD in routine clinical practice.

VA's National PTSD Brain Bank

Dr. Matthew Friedman, Senior Advisor to the National Center, continued to coordinate the operations of VA's first [National PTSD Brain Bank](#). The PTSD Brain Bank supports the Presidential Executive Order of August 2012 on deployment health by enabling VA to lead the nation in unique research that will facilitate deeper understanding of the causes and consequences of PTSD, as well as furthering assessment and treatment techniques.

Enrollment of potential postmortem donors began in May 2015 with the launch of the PTSD Brain Bank website. Initially, the Brain Bank was a five-part consortium; it has subsequently grown to seven parts, with facilities at six VA Medical Centers (Miami, Florida; Durham, North Carolina; Boston, Massachusetts; San Antonio, Texas; West Haven, Connecticut; and White River Junction, Vermont) and the Uniformed Services University of the Health Sciences (USUHS). The PTSD Brain Bank currently has 168 brains, including 56 PTSD brains, and has received commitments of more than 100 additional brains by the end of 2018. Currently, 64 prospective donors (called *antemortem donors*) have volunteered to be followed over their lifetimes.

Pacific Islands Division

The Pacific Islands Division in Honolulu, Hawaii, was created to advance posttraumatic stress disorder (PTSD) work in the Pacific Rim; to focus on improving access to care by increasing understanding of cultural attitudes and the bases of racial and ethnic disparities in treatment; and to evaluate the use of advanced technology, such as telemedicine, to reach out to Veterans who are otherwise unable to access adequate care.

Treatment Research

Three major projects are aimed at evaluating different methods of delivering PTSD treatment. Investigators are in the dissemination phase of a large trial that examines Veterans' preferences for and the clinical efficacy of three modalities for the provision of Prolonged Exposure (PE): two involving technology and one involving in-home visits to Veterans. A second trial that compares different treatments for in-home delivery of a couples-based intervention for PTSD was recently launched; this study examines the clinical efficacy of Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD, and compares home-based care to traditional office-based care. Lastly, a new trial in collaboration with the Dissemination and Training Division is looking at home-based Skills Training in Affect and Interpersonal Regulation (STAIR) treatment for women Veterans who have experienced military sexual trauma (MST).

Specific Populations

Several ongoing studies examine the prevalence of PTSD, response to treatment, and presence of related mental health comorbidities in ethnic minority populations. The studies

identify unique risk and resilience correlates of PTSD among ethnically and racially diverse Veterans, and the effects of those correlates on Veterans' response to evidence-based PTSD treatments.

In FY 2017, researchers initiated a study using data from the Honolulu Asian-Aging project, looking at the effects of military service combat exposure in particular on late-life dementia, as well as on marital and family structures, mental health, and physical health among Japanese-American men. Another ongoing project examines sociocultural and community influences on mental health decision-making among male and female African American, Latino, and white Veterans who are starting PTSD care in a Department of Veterans Affairs (VA) mental health clinic; the study is looking at social network influences, individual perceptions of mental health issues, provider expectations and experiences, and treatment preferences. Analyses of a longitudinal cohort study in which patient-reported PTSD symptoms and mental health quality of life were evaluated six months after receipt of a PTSD diagnosis were also completed this year; also examined were racial and ethnic disparities in those clinical outcomes.

Women's Health Sciences Division

The Women's Health Sciences Division in Boston, Massachusetts, specializes in the study of women Veterans and non-Veterans, with a particular focus on understanding gender differences in trauma exposure and post-trauma psychopathology.

Biomarkers

Work at the Women's Health Sciences Division includes studies aimed at explaining the basic biological processes underlying posttraumatic stress disorder (PTSD) with particular relevance to women: a study examining the role of neurobiological and psychosocial factors that impact negative pregnancy outcomes among women with PTSD; data analysis on a study of sex hormones and derivatives associated with decreased retention of extinction learning across the menstrual cycle in women with PTSD; a study of GABAergic (gamma-aminobutyric acid-ergic) neuroprotective steroids in men and in women across the menstrual cycle; and a series of studies of the gene-environment interplay in the comorbidity of PTSD and eating disorders.

Another biomarker effort is a study of the role of stress-modulating biological factors in reducing symptoms of withdrawal and negative mood during smoking cessation in trauma-exposed individuals with and without PTSD. The Women's Health Sciences Division is also working on two

studies investigating the role of progressive exercise training to determine whether it affects participants' capacity for releasing shared neurohormones to help reduce or better manage chronic pain (including fibromyalgia) and PTSD symptoms.

Treatment Research

Several intervention studies are examining more efficient treatment formats for Cognitive Processing Therapy (CPT). With support from the [South Texas Research Organizational Network Guiding Studies on Trauma and Resilience \(STRONG STAR\)](#) Consortium, investigators are continuing analysis on data from a recently completed study comparing the relative effectiveness of CPT delivered in an individual format with that delivered in a group format. Also through STRONG STAR, staff are investigating a variable-length CPT protocol testing the efficacy of the intervention when treatment end is determined by patient progress. Another trial will test the efficacy of CPT delivered in an intensive outpatient format with active duty military Servicemembers.

Appendix A: Fiscal Year 2017 Research Narrative

In related studies, Women's Health Sciences Division investigators are working to improve adherence to existing PTSD treatments. A current study is exploring Veteran and provider perspectives on reasons for dropout from both CPT and Prolonged Exposure (PE) to develop an intervention aimed at increasing rates of completion for these treatments.

Other intervention studies focused on traumatized populations include an open trial to test the effectiveness of a therapist-assisted self-management intervention intended to increase self-efficacy and facilitate greater community engagement following a successful course of PTSD treatment. Analyses are ongoing on two trials examining therapist fidelity and client variables as contributors to changes in PTSD across administrations of CPT, and the role of sleep improvement in aiding recovery from PTSD and depression among survivors of interpersonal violence. Another ongoing intervention examines the effectiveness and fit of a transdiagnostic treatment, the Unified Protocol (UP), for trauma-exposed Veterans with co-occurring diagnoses.

The Women's Health Sciences Division is also focused on intervention research among those who have not necessarily been diagnosed with PTSD, including the development of a national network of peer-facilitated psychoeducation and support groups for women Veterans who want to improve their well-being. Additionally, filming has begun on a brief mindfulness-based training video that will be used to assist Servicemembers coping with post-deployment intrusive thoughts.

Gender Differences

The Women's Health Sciences Division continues its major focus on understanding gender differences in stress, trauma, and related psychiatric outcomes. The Longitudinal Investigation of Gender, Health, and Trauma (LIGHT) study is a national survey of Veterans that is just getting underway, focusing on the impact of trauma and community violence on mental, physical, and reproductive health. The [Veterans Metric Initiative \(TVMI\)](#) is a large-scale longitudinal study—supported through a public-private partnership among Department of Veterans Affairs (VA), DoD, academia, and industry—that is investigating the reintegration experiences and program use of male and female post-9/11 Veterans.

Investigators also continue to analyze data from a study of the effects of deployment stressors and resulting mental health conditions on the occupational and family quality of life over time of female and male post-9/11 Veterans. In a separate large sample of Veterans who had deployed to in Iraq and Afghanistan, investigators recently conducted a

gender-stratified examination of suicidal ideation risk models, and found critical gender differences in pathways to suicidal ideation among this cohort.

Work on gender differences also extends to important non-Veteran samples including community members and law enforcement officers exposed to community violence. One prospective study examines gender differences in positive and negative health outcomes within the context of socioeconomic status, racial identity, and prior trauma history. In another series of studies, investigators are establishing a population trauma cohort using the Danish national health and social registries, with a projected sample size of 70,000. Gender differences in longitudinal psychopathology and resilience will be examined, using latent class analyses and machine-learning methodologies.

The health of older women Veterans is another area of focus. One study is examining the impact of military and other lifetime stress exposures and mental health results, with a focus on effects of PTSD on later life health and functioning in Vietnam-era women Veterans. In collaboration with investigators in the Behavioral Science Division, a follow-up study of female and male Vietnam-era Veterans is examining predictors of mortality, as well as changes in physical and mental health-related well-being over time.

Military Sexual Trauma and Intimate Partner Violence

Exposure to interpersonal violence is a key issue of study at the Women's Health Sciences Division. Research specifically related to military sexual trauma (MST) includes two studies: a qualitative investigation aimed at identifying unique factors associated with sexual trauma that occur within a military context, and a mixed-methods investigation of Veterans' experiences with and preferences for the universal MST screening program at the Veterans Health Administration (VHA).

The Women's Health Sciences Division is also studying intimate partner violence (IPV), another important issue among female Veterans. Investigators are examining best practices for IPV identification, assessment, treatment, and the targeting of health services within the VHA context. One study will refine and evaluate the effectiveness of a patient-centered brief counseling intervention for women who experience IPV. This study incorporates hybrid methodology to inform expansion of the intervention throughout VA. A new pilot study is identifying best clinical practices for IPV screening programs within VA primary care settings, with the ultimate goal of disseminating these practices to all VA primary care clinics.

Appendix B: Fiscal Year 2017 Funding

VA Cooperative Studies Program (CSP)

| Principal Investigator | Research Title | Years | Current Funding | Total Funding |
|--------------------------------|--|-----------|-----------------|---------------|
| Stein & Gelernter (Site PI) | CSP #575B: Genomics of Posttraumatic Stress Disorder | 2014-2017 | \$245,156 | \$570,783 |
| Schnurr, Chard, & Ruzek | CSP #591: Comparative Effectiveness Research in Veterans with PTSD | 2013-2018 | \$1,809,752 | \$9,048,760 |

Other VA Sources

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|---------------------------------|---|----------------|-----------|-----------------|---------------|
| Averill | Intrinsic Functional Connectivity and Cognition in Posttraumatic Stress Disorder | VISN 1 CDA | 2016-2018 | \$124,032 | \$249,304 |
| Babson | The Impact of CBT-I on Cannabis Cessation Outcomes | HSR&D | 2014-2019 | \$198,233 | \$991,167 |
| Bernardy | Measuring the Impact of the Use of Academic Detailing to Improve PTSD Treatment | ORH | 2017-2018 | \$284,000 | \$284,000 |
| Bovin & Schnurr | Validation of the PTSD Primary Care Screen | HSR&D | 2017-2019 | \$205,925 | \$461,933 |
| Cloitre | webSTAIR Program | ORH | 2016-2021 | \$1,336,740 | \$12,088,620 |
| Gelernter | The Genetics of Anxiety Disorders | BLR&D | 2013-2017 | \$74,833 | \$648,960 |
| Hamblen | CBT for PTSD in Veterans with Co-occurring Substance Use Disorders | CSR&D | 2012-2018 | \$89,165 | \$892,314 |
| Hamilton & Kimerling (Co-PI) | Enhancing the Mental and Physical Health of Women through Engagement and Retention (EMPOWER) | QUERI | 2015-2020 | \$830,000 | \$4,150,000 |
| Hayes | Neuroimaging Genetics of Mild TBI | RR&D | 2015-2017 | \$42,000 | \$198,000 |
| Heinz | Cognitive Remediation for Alcohol Use Disorder and PTSD | RR&D | 2014-2019 | \$191,703 | \$986,195 |
| Iverson | Intimate Partner Violence Screening Programs in VHA: Informing Scale-Up and Spread of Best Practices | HSR&D | 2017-2018 | \$10,388 | \$96,523 |
| Iverson | Intimate Partner Violence, Health, and Healthcare Use Among Women Veterans | HSR&D | 2011-2017 | \$179,920 | \$736,888 |
| Iverson | Recovering from Intimate Partner Violence Through Strengths and Empowerment (RISE): Tailoring and Evaluating a Patient-Centered Counseling Intervention | HSR&D | 2018-2021 | \$0 | \$853,362 |
| Kachadourian | Mindfulness Treatment for Anger in Veterans with PTSD | CSR&D CDA-2 | 2017-2022 | \$129,304 | \$732,428 |
| Kachadourian | Using EMA to Assess Aggression Perpetration in Veterans with PTSD and Chronic Pain | PRIME | 2017-2018 | \$3,609 | \$3,609 |
| Keane | CAP-Administrative Core* | VA/DoD | 2016-2020 | \$288,205 | \$1,231,923 |
| Kanwal & Kimerling (Co-I) | Care for Women Veterans with Hepatitis C Virus Infection | HSR&D | 2014-2017 | \$220,000 | \$661,100 |

Appendix B: Fiscal Year 2017 Funding

(Other VA Sources Continued)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|---|---|----------------|-----------|-----------------|---------------|
| Kehle-Forbes | Dropout from Evidence-Based Therapy for PTSD: Reasons and Potential Interventions | HSR&D | 2015-2018 | \$258,679 | \$799,130 |
| Kehle-Forbes | Pilot Test of a Self-Management Program for Completers of Trauma-Focused Therapy | RR&D | 2018-2020 | \$0 | \$196,495 |
| Knight | LED Light Therapy To Improve Cognitive-Psychosocial Function in TBI-PTSD Veterans | RR&D | 2015-2018 | \$66,562 | \$199,976 |
| Kuhn | An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach | HSR&D | 2017-2020 | \$275,000 | \$1,100,000 |
| Krystal | CAP-Neuroimaging Core* | VA/DoD | 2016-2020 | \$80,000 | \$240,000 |
| Krystal & Abdallah | CAP-Ketamine for Antidepressant-Resistant PTSD: A Translational Neuroscience, Biomarker-Informed Clinical Trial* | VA/DoD | 2016-2020 | \$488,000 | \$1,588,594 |
| Landes & Rosen (Site PI) | Risk Stratified Enhancements to Clinical Care: Targeting Care for Patients Identified through Predictive Modeling as being at High Risk for Suicide | HSR&D | 2016-2020 | \$247,895 | \$1,222,926 |
| Logue | Genetic and Epigenetic Biomarkers of PTSD | BLR&D | 2017-2020 | \$177,540 | \$610,600 |
| McGlinchey & Rasmusson (Site PI) | VA Center of Excellence: Translational Research Center for TBI and Stress Disorders | RR&D | 2014-2019 | \$1,000,000 | \$5,000,000 |
| Miller | Magnetic Resonance Spectroscopy and Genetic Analysis of Oxidative Stress in OEF/OIF Veterans with PTSD and TBI | CSR&D | 2018-2021 | \$0 | \$600,000 |
| Morland | An Integrative Technology Approach to Home-based Conjoint Therapy for PTSD | RR&D | 2016-2020 | \$351,353 | \$1,038,000 |
| Niles & Nori | Novel Interventions for Gulf War Veterans' Illnesses | CSR&D | 2016-2021 | \$333,740 | \$1,664,578 |
| Norman | Integrated Alcohol Disorder and PTSD Treatment | CSR&D | 2012-2017 | \$149,648 | \$730,922 |
| Norman | Topiramate and Prolonged Exposure for Alcohol Use Disorder and PTSD | RR&D | 2018-2022 | \$0 | \$927,733 |
| Oslin & Gelernter (Site PI) | PRIME Care (PRrecision medicine In MEntal health Care) | HSR&D | 2017-2022 | \$75,701 | \$1,619,407 |
| Peterson & Keane | Consortium to Alleviate PTSD (CAP) | VA/DoD | 2013-2020 | \$5,545,118 | \$21,000,000 |
| Pless Kaiser | Improving Psychosocial Functioning in Older Veterans with PTSD | RR&D | 2017-2021 | \$156,509 | \$809,149 |
| Scioli-Salter | Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD | RR&D | 2013-2018 | \$196,351 | \$953,342 |
| Scioli-Salter | Neurobiological and Psychological Benefits of Fibromyalgia and PTSD | RR&D | 2017-2019 | \$63,275 | \$199,904 |
| Shiner | Improving Care for PTSD | HSR&D | 2014-2019 | \$212,635 | \$1,292,446 |
| Shiner | Patient Safety Center of Inquiry: Prevention of Suicide | NCPS | 2015-2018 | \$113,000 | \$421,500 |
| Sippel | PTSD and Affective Functioning: A Test of the Potentially Normalizing Effects of Oxytocin | VISN 1 CDA | 2016-2017 | \$22,940 | \$100,106 |
| Sloan | Group CBT for Chronic PTSD: A Randomized Clinical Trial | CSR&D | 2012-2017 | \$235,707 | \$1,187,129 |
| Thompson-Hollands | An Adjunctive Family Intervention for Individual PTSD Treatment | CSR&D CDA-2 | 2017-2021 | \$181,373 | \$743,010 |
| Vogt & Smith | Work and Family Functioning in Women Veterans: Implications for VA Service Use | HSR&D | 2013-2017 | \$84,803 | \$743,433 |
| Wolf | PTSD-Related Accelerated Aging in DNA Methylation and Risk for Metabolic Syndrome | CSR&D | 2016-2020 | \$145,268 | \$600,000 |

Appendix B: Fiscal Year 2017 Funding

(Other VA Sources Continued)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|---------------------------------|--|----------------|-----------|-----------------|---------------|
| Zulman & Kimerling (Site PI) | Making Connections: Tablet-Enabled Telehealth to Enhance Veterans' Access and Care | QUERI | 2016-2018 | \$425,964 | \$550,669 |

BLR&D Biomedical Laboratory Research & Development Service; CAP Consortium to Alleviate PTSD; CDA Career Development Award; CSR&D Clinical Science Research and Development Service; HSR&D Health Services Research and Development Service; NCPS National Center for Patient Safety; ORH Office of Rural Health; PRIME Pain Research, Informatics, Multimorbidities, and Education; QUERI Quality Enhancement Research Initiative; RR&D Rehabilitation Research and Development Service; VISN Veterans Integrated Service Network

*Sub-award within the total \$21 million CAP award.

National Institutes of Health (NIH)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|----------------------------------|--|----------------|-----------|-----------------|---------------|
| Abdallah | Examining the Effect of Ketamine On Glutamate/ Glutamine Cycling | NIMH | 2013-2018 | \$168,080 | \$912,630 |
| Abdallah | Glial and Synaptic Functions in Major Depression | NIMH | 2017-2022 | \$311,527 | \$2,493,229 |
| Adams | Enhancement of Extinction Learning Using Transcranial Direct Current Stimulation | NIMH K | 2017-2022 | \$159,730 | \$940,801 |
| Agarwal & Gelernter (Site PI) | Psychiatric Genomics Consortium: Finding Actionable Variation | NIH | 2016-2021 | \$184,653 | \$932,488 |
| Anticevic | Classification of Neuropsychiatric Conditions via Connectivity and Machine Learning | NIMH | 2014-2017 | \$50,000 | \$400,000 |
| Carlson | Development of a Risk Factor Screen for Mental Health Problems after Sudden Illness or Injury | NIMHD | 2017-2021 | \$0 | \$2,566,642 |
| Cloitre | The Implementation of an Evidence-Based PTSD Treatment in Public Sector Settings | NIMH | 2011-2017 | \$0 | \$4,557,445 |
| Clouston & Pietrzak | A Life Course Approach to Integrating Trauma and Cognitive Aging: A Cohort of 9/11 Responders | NIAAA | 2015-2020 | \$407,239 | \$2,865,325 |
| Cosgrove | Imaging Genetics in Tobacco Smokers | NIDA | 2012-2017 | \$126,822 | \$587,140 |
| Cosgrove | Imaging Molecular Mechanisms of Tobacco Smoking Withdrawal | NIDA | 2016-2020 | \$447,737 | \$2,238,685 |
| Cosgrove | Tobacco Smoking, Genes, and Nicotinic Receptors | NIDA | 2009-2017 | \$365,578 | \$2,924,624 |
| Cosgrove & Pietrzak | Imaging Microglial Activation in PTSD Using PET | NIMH | 2017-2022 | \$499,999 | \$825,495 |
| Driesen & Krystal | Assessing the Relationship Between Cortical Oxidative Metabolism and Working Deficits Under NMDA Receptor Blockade | NIMH | 2017-2019 | \$153,125 | \$251,125 |
| Duman | Role of GABA Interneurons in Rapid Antidepressant Actions of NMDA Receptor Blockade | NIMH | 2017-2022 | \$510,206 | \$2,340,351 |
| Duman | Synaptic Mechanisms Underlying the Rapid Antidepressant Actions of Scopolamine | NIMH | 2014-2019 | \$431,989 | \$2,164,744 |
| Esterlis | Glutamate Neurotransmission in Bipolar Depression and Mania | NIMH | 2017-2019 | \$150,000 | \$460,625 |
| Esterlis | PET-fMRI Study of Glutamate and Frontal Function in Bi- and Uni-polar Depression | NIMH | 2015-2020 | \$496,729 | \$2,146,470 |
| Esterlis | Role of Neuroinflammation in the Pathophysiology of Bipolar Depression | NIMH | 2017-2019 | \$149,866 | \$460,625 |
| Gelernter | Genetics of Opioid Dependence | NIDA | 2013-2018 | \$983,501 | \$4,651,496 |
| Gradus | Characterizing Trauma Outcomes: From Pre-trauma Risk to Post-trauma Sequelae | NIMH | 2017-2021 | \$319,091 | \$1,303,518 |

Appendix B: Fiscal Year 2017 Funding

(National Institutes of Health Continued)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|-----------------------------------|--|----------------|-----------|-----------------|---------------|
| Gradus | Risk Profiles for Suicidal Behavior in the General Population | NIMH | 2016-2020 | \$296,515 | \$1,375,793 |
| Gutner | Effectiveness of a Unified Transdiagnostic Treatment in Routine Clinical Care | NIMH | 2014-2019 | \$177,977 | \$889,721 |
| Gutner | Modular Transdiagnostic Treatment in Routine Care | CTSI | 2016-2017 | \$0 | \$20,000 |
| Han & Gelernter | Fine Mapping a Gene Sub-Network Underlying Alcohol Dependence | NIAAA | 2014-2018 | \$34,193 | \$350,914 |
| Harpaz-Rotem | Fear Learning and Reconsolidation After Trauma Exposure: A Computational Approach | NIMH | 2014-2019 | \$436,890 | \$1,830,328 |
| Keane | Postdoctoral Training in PTSD | NIMH | 2016-2020 | \$250,534 | \$1,021,231 |
| Lee & Heinz | Mobile Cognitive Control Training for the Treatment of Alcohol Use Disorder and PTSD | NIAAA | 2017-2018 | \$224,702 | \$224,702 |
| Levy | Medical Decision-Making Under Uncertainty in Older Adults-Behavior and fMRI | NIA | 2015-2018 | \$150,000 | \$275,000 |
| Levy & Pietrzak | Culture-gene Relationship: A Novel Model of Aging Cognitive Health | NIA | 2017-2021 | \$418,750 | \$1,675,000 |
| McKee & Cosgrove | Translational Center to Develop Gender Sensitive Treatments for Tobacco Smoking | NIDA | 2012-2018 | \$0 | \$3,742,805 |
| Morey & Logue (Site PI) | Trauma and Genomics Modulate Brain Structure across Common Psychiatric Disorders | NIMH | 2017-2021 | \$5,308 | \$291,960 |
| Morris & Cosgrove | Imaging Sex Differences in Smoking-Induced Dopamine Release via Novel PET Methods | NIDA | 2015-2020 | \$439,638 | \$2,198,190 |
| Nilni | PTSD-Related Neurobiological Mediators of Negative Pregnancy Outcomes | NICHD K | 2017-2021 | \$153,933 | \$615,735 |
| Ralevski | Effects of Allopregnanolone on Stress-Induced Craving | NIAAA | 2017-2019 | \$155,444 | \$343,613 |
| Sanacora | New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders | NIMH | 2013-2017 | \$147,013 | \$448,443 |
| Sloan | Written Exposure Therapy for PTSD: A Randomized Noninferiority Trial | NIMH | 2012-2017 | \$190,000 | \$1,149,000 |
| Smith | Health Mechanisms and Outcomes in an Epidemiological Cohort of Vietnam Era Women Veterans | NIA | 2016-2018 | \$69,476 | \$137,381 |
| Smith & Logue | The Impact of Traumatic Stress on the Methylome: Implications for PTSD | NIMH | 2016-2020 | \$559,082 | \$2,479,996 |
| Taft | Trauma-Focused Partner Violence Intervention | NIH; BU SoM | 2017-2017 | \$20,000 | \$20,000 |
| Wiltsey Stirman | Leveraging Routine Clinical Materials and Mobile Technology to Assess CBT Quality | NIMH | 2017-2021 | \$696,817 | \$2,744,506 |
| Wiltsey Stirman & Monson | Improving and Sustaining CPT for PTSD in Mental Health Systems | NIMH | 2016-2019 | \$584,763 | \$1,615,257 |
| Wolf | Administrative Supplement to Traumatic Stress and Accelerated Aging in DNA Methylation | NIA | 2017-2018 | \$52,545 | \$52,545 |
| Wolf | Traumatic Stress and Accelerated Aging in DNA Methylation | NIA | 2016-2018 | \$63,000 | \$126,000 |
| Zimmerman | Participatory System Dynamics for Evidence-based Addiction and Mental Healthcare | NIDA | 2016-2018 | \$221,005 | \$397,000 |

BU SoM Boston University School of Medicine; CTSI Clinical and Translational Science Institute; K Career Development Award; NIA National Institute on Aging; NIAAA National Institute on Alcohol Abuse and Alcoholism; NICHD National Institute of Child Health and Human Development; NIDA National Institute on Drug Abuse; NIH National Institutes of Health ; NIMH National Institute of Mental Health; NIMHD National Institute on Minority Health and Health Disparities

Department of Defense (DoD)

| Principal Investigator | Research Title | Years | Current Funding | Total Funding |
|-------------------------------|---|-----------|-----------------|---------------|
| Keane & Marx | Project VALOR: Trajectories of Change in PTSD in Combat-Exposed Veterans | 2012-2017 | \$0 | \$3,295,994 |
| Marx & Nock | New Approaches to the Measurement of Suicide-Related Cognition | 2014-2017 | \$0 | \$207,000 |
| McLean | Web-PE: Internet-Delivered Prolonged Exposure Therapy for PTSD | 2014-2018 | \$495,000 | \$1,979,473 |
| Morland | In-Home Exposure Therapy for Veterans with PTSD | 2012-2017 | \$304,122 | \$2,499,998 |
| Norman | Trauma Informed Guilt Reduction (TriGR) Intervention | 2015-2019 | \$491,798 | \$1,989,870 |
| Ruzek | PTSD Practitioner Registry | 2014-2017 | \$384,903 | \$3,847,219 |
| Ruzek | Randomized Controlled Trial of CBT Training for PTSD Providers | 2012-2017 | \$0 | \$2,464,704 |
| Shiner | Comparative Effectiveness of Psychotropic Medications for PTSD in Clinical Practice | 2017-2020 | \$11,516 | \$1,543,904 |
| Sloan | Brief Treatment for PTSD: Enhancing Treatment Engagement and Retention | 2015-2018 | \$842,431 | \$2,268,872 |
| Taft | Strength at Home Couples Program to Prevent Military Partner Violence | 2015-2019 | \$169,545 | \$708,905 |
| Wachen & Resick | Variable Length Cognitive Processing Therapy for Combat-Related PTSD | 2013-2017 | \$0 | \$1,218,426 |
| White & Mackintosh | Brain Injury and Military Service as Factors for Alzheimer's Disease and Other Conditions | 2015-2018 | \$372,948 | \$1,491,790 |
| Woodward | Can a Canine Companion Modify Cardiac Autonomic Reactivity and Tone in PTSD | 2014-2018 | \$227,583 | \$910,335 |

Other Non-VA Sources

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|------------------------|--|---|-----------|-----------------|---------------|
| Abdallah | Glial and Glutamatergic Deficits In Posttraumatic Stress Disorder | Brain & Behavior Research Foundation | 2015-2017 | \$0 | \$65,000 |
| Adams | Use of Transcranial Direct Current Stimulation to Enhance Consolidation of Therapeutic Learning in Obsessive-Compulsive Disorder | International Obsessive-Compulsive Disorder Foundation | 2017-2018 | \$48,646 | \$48,646 |
| Anticevic | Characterizing the Neuronal Mechanisms Behind Cognitive and Motivational Deficits in Psychiatric Disorders | Blackthron Therapeutics | 2016-2018 | \$1,000,000 | \$2,000,000 |
| Averill | Brain Connectivity Networks and Predictors of Rapid Improvement in Suicidal Ideation Among Veterans | American Foundation for Suicide Prevention | 2018-2020 | \$0 | \$90,000 |
| Averill | Connectivity Networks Underlying Ketamine-Induced Improvements in Suicidal Ideation | Robert E. Leet and Clara Guthrie Patterson Trust for Mentored Clinical Research Award | 2017-2019 | \$45,000 | \$45,000 |
| Averill | Intrinsic Connectivity Networks and Cognitive Impairment in PTSD | Brain & Behavior Research Foundation | 2016-2018 | \$34,993 | \$69,993 |
| Cosgrove | Imaging Glucocorticoid and Neuronal Dysfunction in PTSD | Brain & Behavior Research Foundation | 2017-2018 | \$99,998 | \$99,998 |

Appendix B: Fiscal Year 2017 Funding

(Other Non-VA Sources Continued)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|---------------------------------|---|--|-----------|-----------------|---------------|
| Cosgrove | The Dopamine Signature of Cannabis: Imaging Sex Differences | Naratil Pioneer Award | 2017-2018 | \$50,000 | \$50,000 |
| Duman | Antidepressant Actions of a mTORC1 Activator | Navitor Pharmaceuticals | 2016-2017 | \$272,244 | \$383,229 |
| Duman | Behavioral Actions of GLYX-13 in Rodent Models of Cognitive Flexibility | Allergan | 2016-2018 | \$82,230 | \$82,230 |
| Duman | Cellular Mechanisms Underlying the Antidepressant Actions of GLYX013 | Allergan | 2016-2018 | \$246,960 | \$246,960 |
| Duman | Identification and Characterization of Novel Drug Targets for Depression | Tashio Pharmaceuticals | 2016-2019 | \$200,000 | \$600,000 |
| Esterlis | In Vivo and Postmortem Study of Synaptic Plasticity | Nancy Taylor Foundation | 2015-2018 | \$156,038 | \$500,661 |
| Feder & Pietrzak | A Randomized Controlled Trial of Internet CBT for PTSD in WTC Responders | CDC/NIOSH | 2016-2019 | \$499,912 | \$1,499,736 |
| Feder & Pietrzak | Biomarkers of Psychological Risk and Resilience in World Trade Center Responders | CDC/NIOSH | 2012-2018 | \$995,911 | \$3,873,351 |
| Feder & Pietrzak | Neuroimaging of Resilience in World Trade Center Responders: A Focus on Emotional Processing, Reward and Social Cognition | CDC/NIOSH | 2017-2021 | \$599,086 | \$2,398,856 |
| Galovski & Street | Women Veterans Network (WoVeN) | Wal-Mart Foundation | 2017-2018 | \$250,341 | \$469,392 |
| Harpaz-Rotem | Combining Neurobiology and New Learning: Ketamine and Prolonged Exposure: A Potential Rapid Treatment for PTSD | Brain & Behavior Research Foundation | 2016-2017 | \$50,000 | \$100,000 |
| Kelmendi | Role of MDMA on Amygdala and Prefrontal Cortex on PTSD | Brain & Behavior Research Foundation | 2016-2018 | \$35,000 | \$70,000 |
| Krystal & Abdallah | Examining the Impact of Rapamycin on Ketamine's Antidepressant Effects | Pfeiffer Foundation | 2015-2018 | \$167,000 | \$500,000 |
| Krystal & Sanacora | Discovering a New Class of Antidepressants | Gustavus and Louise Pfeiffer Research Foundation | 2014-2017 | \$167,000 | \$500,000 |
| Marx | Mining Biological Cues from PTSD Interview Recordings | Mitre Corporation | 2017-2017 | \$500,000 | \$500,000 |
| McCaslin | A Pilot Study of Digital Cognitive Behavioral Therapy for Veterans with Insomnia and Comorbid Psychopathology | Big Health, Inc | 2017-2019 | \$26,959 | \$26,959 |
| McCaslin | Evaluation of the Community Provider Toolkit and Military Culture Training | OGP/Office of Executive Council | 2016-2017 | \$100,000 | \$200,000 |
| Monson & Wiltsey Stirman | Improving and Sustaining Clinician Use of CPT | Canadian Institutes of Health Research | 2014-2018 | \$182,000 | \$728,215 |
| Petrakis | Effects of Progesterone on Stress-Induced Craving in PTSD and AUD | Brain & Behavior Research Foundation | 2016-2018 | \$99,390 | \$99,390 |
| Sanacora | Exploring the Role of Glial Mediated Glutamate Clearance in Stress Sensitivity and Resiliency | Brain & Behavior Research Foundation | 2015-2018 | \$0 | \$99,819 |
| Sanacora | Utility of NMR as a Translatable Biomarker for the Regulation of Glutamate Neurotransmission Behavioral Effects of Compounds that Influence Glutamate Release | Merck, Sharp, and Dohme | 2016-2017 | \$71,599 | \$119,211 |
| Sareen & Pietrzak | Defining the Longitudinal Course, Outcomes, and Treatment Needs of Vulnerable Canadians with Posttraumatic Stress Disorder | Canadian Institutes of Health Research | 2015-2022 | \$340,868 | \$2,386,073 |
| Taft | Implementation of VA Rollout of Strength at Home | Bob Woodruff Foundation | 2016-2017 | \$72,717 | \$137,100 |

Appendix B: Fiscal Year 2017 Funding

(Other Non-VA Sources Continued)

| Principal Investigator | Research Title | Funding Source | Years | Current Funding | Total Funding |
|------------------------|---|--|-----------|-----------------|---------------|
| Vogt | The Veterans Metrics Initiative: Linking Program Components to Post-Military Well-Being | Consortium of Public and Private Funding, including VA HSR&D | 2015-2020 | \$1,341,242 | \$5,914,960 |
| Walser | Compassion and PTSD | Mind and Life 1440 Award | 2014-2017 | \$0 | \$14,000 |
| Wolf | The Utility of MMPI-2 RF in Informing VA Pain Clinic Care | University of Minnesota Press, Test Division | 2016-2018 | \$0 | \$24,000 |

CDC Centers for Disease Control; NIOSH National Institute for Occupational Safety and Health; OGP Office of Government-wide Policy; PCORi Patient-Centered Outcomes Research Institute

Pending Research Projects

| Principal Investigator | Research Title | Funding Source | Years | Total Funding |
|------------------------------------|--|--|-----------|---------------|
| Carlson | Pilot Study of Standalone and Peer Supported Online Problem Solving Program in Veterans with Untreated Mental Health Problems | VA HSR&D | 2017-2018 | \$100,000 |
| Cloitre | Connecting Women to Care: Home-based Psychotherapy for Women with MST Living in Rural Areas | VA HSR&D | 2017-2021 | \$1,094,820 |
| Galovski & Kehle-Forbes | Balancing Flexibility and Fidelity: Integrating a Case Formulation Approach with Cognitive Processing Therapy for PTSD to Improve Treatment Outcomes for Veterans | VA HSR&D | 2018-2022 | \$1,099,343 |
| Grubaugh & Hamblen | A Randomized Controlled Trial of AboutFace: A Novel Video Storytelling Resource to Improve Access, Engagement, and Utilization of Mental Health Treatment among Veterans with PTSD | VA HSR&D | 2018-2021 | \$987,800 |
| Hayes | Fear Generalization and Hippocampal Subfields in PTSD | Brain and Behavior Research Foundation | 2018-2020 | \$70,000 |
| Hayes | Neuroimaging and Molecular Markers of AD and Neurodegenerative Disease after Concussion | NIA | 2018-2023 | \$1,872,239 |
| Kimerling | Development of a Patient-Reported Measure to Assess Healthcare Engagement | VA HSR&D | 2017-2020 | \$1,082,363 |
| Krystal | CSP 2016: Adaptive Clinical Trial for Insomnia in Veterans with PTSD (ACTIVE-PTSD) | VA CSP | TBD | TBD |
| McLean & Rosen | Targeted Strategies to Accelerate Evidence-Based Psychotherapies Implementation in Military Settings | DoD | 2017-2021 | \$8,265,060 |
| Pineles | An Electrophysiological Predictor of SSRI Response in Veterans with PTSD | VA CSR&D | 2018-2022 | \$599,531 |
| Pineles | Neurobiological Predictors of Response to SSRIs | NIH NIMH | 2018-2022 | \$2,140,422 |
| Ross & Woodward | Lucid Dreaming in Veterans with PTSD | VA CSR&D | 2018-2020 | \$538,000 |
| Shiner | Patient Safety Center of Inquiry: Prevention of Suicide (Renewal) | VA NCPS | 2018-2021 | \$858,835 |
| Wachen | Massed Cognitive Processing Therapy for Combat-Related PTSD | DoD | 2017-2020 | \$3,262,817 |

CSP Cooperative Studies Program; CSR&D Clinical Science Research and Development Service; DoD Department of Defense; HSR&D Health Services Research and Development Service; NCPS National Center for Patient Safety; NIA National Institute on Aging; NIH National Institutes of Health; NIMH National Institute of Mental Health; VA Veterans Affairs

Appendix C:

Fiscal Year 2017 Publications

1. **Abdallah, C.** (2017). What's the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise? *Biological Psychiatry*, *81*, e61-e63. doi:10.1016/j.biopsych.2017.01.002
2. **Abdallah, C., & Geha, P.** (2017). Chronic pain and chronic stress: Two sides of the same coin? *Chronic Stress*, *1*. doi:10.1177/2470547017704763
3. **Abdallah, C., Averill, L., & Krystal, J. H.** (2017). A new journal: Addressing the behavioral and biological effects of chronic stress. *Chronic Stress*, *1*. doi:10.1177/2470547016683296
4. **Abdallah, C., Averill, L.,** Collins, K. A., **Geha, P.,** Schwartz, J., **Averill, C. L.,** DeWilde, K. E., Wong, E., **Anticevic, A.,** Tang, C. Y., Iosifescu, D. V., Charney, D. S., & Murrough, J. (2017). Ketamine treatment and global brain connectivity in major depression. *Neuropsychopharmacology*, *42*, 1210-1219. doi:10.1038/npp.2016.186
5. **Abdallah, C.,** Hannestad, J., Mason, G., Holmes, S., **DellaGioia, N., Sanacora, G.,** Jiang, L., Matuskey, D., **Satodiya, R.,** Gasparini, F., Lin, X., Javitch, J., Planeta, B., Nabulsi, N., Carson, R., & **Esterlis, I.** (2017). Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: A multimodal imaging study. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *2*, 449-456. doi:10.1016/j.bpsc.2017.03.019
6. **Abdallah, C.,** Jackowski, A., Salas, R., **Gupta, S.,** Sato, J. R., Mao, X., Coplan, J. D., Shungu, D. C., & Mathew, S. J. (2017). The nucleus accumbens and ketamine treatment in major depressive disorder. *Neuropsychopharmacology*, *42*, 1739-1746. doi:10.1038/npp.2017.49
7. **Abdallah, C., Southwick, S. M., & Krystal, J. H.** (2017). Neurobiology of posttraumatic stress disorder (PTSD): A path from novel pathophysiology to innovative therapeutics. *Neuroscience Letters*, *649*, 130-132. doi:10.1016/j.neulet.2017.04.046
8. **Abdallah, C., Wrocklage, K. M., Averill, C. L., Akiki, T., Schweinsburg, B., Roy, A., Martini, B., Southwick, S. M., Krystal, J. H., & Scott, J. C.** (2017). Anterior hippocampal dysconnectivity in posttraumatic stress disorder: A dimensional and multimodal approach. *Translational Psychiatry*, *7*, e1045. doi:10.1038/tp.2017.12
9. Adkins, A., Hack, L., Bigdeli, T., Williamson, V., McMichael, G., Mamdani, M., ... **Gelernter, J.,** ... & Riley, B. (2017). Genomewide association study of alcohol dependence identifies risk loci altering ethanol-response behaviors in model organisms. *Alcoholism: Clinical and Experimental Research*, *41*, 911-928. doi:10.1111/acer.13362
10. **Akiki, T., Averill, C. L., & Abdallah, C.** (2017). A network-based neurobiological model of PTSD: Evidence from structural and functional neuroimaging studies. *Current Psychiatry Reports*, *19*, 81. doi:10.1007/s11920-017-0840-4
11. **Akiki, T., Averill, C. L., Wrocklage, K. M., Schweinsburg, B., Scott, J. C., Martini, B., Averill, L., Southwick, S. M., Krystal, J. H., & Abdallah, C.** (2017). The association of PTSD symptom severity with localized hippocampus and amygdala abnormalities. *Chronic Stress*, *1*. doi:10.1177/2470547017724069
12. **Amoroso, T., & Iverson, K. M.** (2017). Acknowledging the risk for traumatic brain injury in women veterans. *Journal of Nervous and Mental Disease*, *205*, 318-323. doi:10.1097/NMD.0000000000000621
13. Armour, C., Fried, E., Deserno, M., Tsai, J., & **Pietrzak, R. H.** (2017). A network analysis of DSM-5 posttraumatic stress disorder symptoms and correlates in U.S. military veterans. *Journal of Anxiety Disorders*, *45*, 49-59. doi:10.1016/j.janxdis.2016.11.008
14. Asnaani, A., & **McLean, C. P.** (2017). Ethics in exposure therapy. In A. Wenzel (Ed.), *Sage encyclopedia of abnormal and clinical psychology* (pp. 1391-1394). New York, NY: Sage. doi:10.4135/9781483365817.n556
15. **Averill, L., Abdallah, C., Pietrzak, R. H., Averill, C. L., Southwick, S. M., Krystal, J. H., & Harpaz-Rotem, I.** (2017). Combat exposure severity is associated with reduced cortical thickness in combat veterans: A preliminary report. *Chronic Stress*, *1*. doi:10.1177/2470547017724714
16. **Averill, L.,** Murrough, J. W., & **Abdallah, C.** (2016). Ketamine's mechanisms of rapid antidepressant activity: Evidence gleaned from clinical studies. In S. J. Mathew & C. A. Zarate (Eds.), *Ketamine for treatment-resistant depression: The first decade of progress* (pp. 99-121). Cham, Switzerland: Springer. doi:10.1007/978-3-319-42925-0_7
17. **Averill, L., Purohit, P., Averill, C. L.,** Boesl, M., **Krystal, J. H., & Abdallah, C.** (2017). Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. *Neuroscience Letters*, *10*, 147-155. doi:10.1016/j.neulet.2016.11.064
18. **Babson, K. A.,** Sottile, J., & **Morabito, D. M.** (2017). Cannabis, cannabinoids, and sleep: A review of the literature. *Current Psychiatry Reports*, *19*, 23. doi:10.1007/s11920-017-0775-9
19. **Babson, K. A., Woodward, S. H.,** Schaer, M., Sephton, S. E., & **Kaloupek, D. G.** (2017). Salivary cortisol and regional brain volumes among veterans with and without posttraumatic stress disorder. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *2*, 372-379. doi:10.1016/j.bpsc.2016.11.007
20. Banasr, M., Lepack, A., Fee, C., Duric, V., Maldonado-Aviles, J., DiLeone, R., Sibille, E., **Duman, R., & Sanacora, G.** (2017). Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression. *Chronic Stress*, *1*. doi:10.1177/2470547017720459

Appendix C: Fiscal Year 2017 Publications

21. **Banducci, A. N.**, Connolly, K., Vujanovic, A. A., Alvarez, J., & **Bonn-Miller, M.** (2017). The impact of changes in distress tolerance on PTSD symptom severity post-treatment among veterans in residential trauma treatment. *Journal of Anxiety Disorders, 47*, 99-105. doi:10.1016/j.janxdis.2017.01.004
22. Batchelder, A., Ehlinger, P., Boroughs, M., **Shipherd, J. C.**, Safren, S., Ironson, G., & O'Cleirigh, C. (2017). Psychological and behavioral moderators of the relationship between trauma severity and HIV transmission risk behavior among MSM with a history of childhood sexual abuse. *Journal of Behavioral Medicine, 40*, 794-802. doi:10.1007/s10865-017-9848-9
23. Berke, D., **Macdonald, A.**, Poole, G., Portnoy, G., McSheffrey, S., **Creech, S. K.**, & **Taft, C. T.** (2017). Optimizing trauma-informed intervention for intimate partner violence in veterans: The role of alexithymia. *Behaviour Research and Therapy, 97*, 222-229. doi:10.1016/j.brat.2017.08.007
24. **Bernardy, N. C.**, & **Friedman, M. J.** (2017). Pharmacological management of posttraumatic stress disorder. *Current Opinion in Psychology, 14*, 116-121. doi:10.1016/j.copsyc.2017.01.003
25. **Bernardy, N. C.**, & **Friedman, M. J.** (2017). Psychopharmacological treatment of traumatization in adults. In S. Gold (Ed.), *APA handbook of trauma psychology: Trauma practice* (pp. 363-388). Washington, DC: American Psychological Association Press.
26. Blosnich, J., Marsiglio, M., Dichter, M., Gao, S., Gordon, A. J., **Shipherd, J. C.**, Kauth, M. R., Brown, G., & Fine, M. (2017). Impact of social determinants of health on medical conditions among transgender veterans. *American Journal of Preventive Medicine, 52*, 491-498. doi:10.1016/j.amepre.2016.12.019
27. **Boden, M. T.**, **Heinz, A. J.**, & Kashdan, T. B. (2017). Pleasure as an overlooked target of substance use disorder research and treatment. *Current Drug Abuse Reviews, 9*, 113-125. doi:10.2174/1874473710666170308163310
28. Bosch, J., Weaver, T. L., Neylan, T. C., Herbst, E., & **McCaslin, S. E.** (2017). Impact of engagement in exercise on sleep quality among veterans with posttraumatic stress disorder symptoms. *Military Medicine, 182*, e1745-e1750. doi:10.7205/MILMED-D-16-00385
29. Bountress, K., Danielson, C., Williamson, V., Vladimirov, V., **Gelernter, J.**, Ruggiero, K., & Amstadter, A. (2017). Genetic and psychosocial predictors of alcohol use trajectories among disaster-exposed adolescents. *The American Journal on Addictions, 26*, 623-631. doi:10.1111/ajad.12575
30. Boutron, I., Altman, D. G., Moher, D., Schulz, K. F., Ravaud, P., & CONSORT NPT group incl. **Schnurr, P. P.** (2017). CONSORT statement for randomized trials of nonpharmacologic treatments: A 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. *Annals of Internal Medicine, 167*, 40-47. doi:10.7326/M17-0046
31. **Bovin, M. J.**, **Marx, B. P.**, Weathers, F. W., **Gallagher, M. W.**, Rodriguez, P., **Schnurr, P. P.**, & **Keane, T. M.** (2016). Psychometric properties of the PTSD Checklist for DSM-5 (PCL-5) in veterans. *Psychological Assessment, 28*, 1379-1391. doi:10.1037/pas0000254
32. **Bovin, M. J.**, **Wolf, E. J.**, & **Resick, P. A.** (2017). Longitudinal associations between posttraumatic stress disorder severity and personality disorder features among female rape survivors. *Frontiers in Psychiatry. doi:10.3389/fpsy.2017.00006*
33. Brignone, E., Gundlapalli, A., Blais, R., **Kimerling, R.**, Barrett, T., Nelson, R., Carter, M., Samore, M., & Fargo, J. (2017). Increased health care utilization and costs among veterans with a positive screen for military sexual trauma. *Medical Care, 55*, S70-S77. doi:10.1097/MLR.0000000000000767
34. Brucia, E., Cordova, M. J., & **Ruzek, J. I.** (2017). Critical incident interventions: Crisis response and debriefing. In C. Mitchell & E. Dorian (Eds.), *Police psychology and its growing impact on modern law enforcement* (pp. 119-142). Hershey, PA: IGI Global.
35. Bukowski, L. A., Blosnich, J. R., **Shipherd, J. C.**, Kauth, M. R., Brown, G. R., & Gordon, A. J. (2017). Exploring rural disparities in medical diagnoses among veterans with transgender-related diagnoses utilizing Veterans Health Administration Care. *Medical Care, 55*, S97-S103. doi:10.1097/MLR.0000000000000745
36. Bunnell, B., Davidson, T., **Hamblen, J. L.**, Cook, D., Grubaugh, A., Lozano, B., Tuerk, P., & Ruggiero, K. (2017). Protocol for the evaluation of a digital storytelling approach to address stigma and improve readiness to seek services among veterans. *Pilot and Feasibility Studies, 3*, 7. doi:10.1186/s40814-017-0121-3
37. Carroll, T. D., Currier, J. M., McCormick, W. H., & **Drescher, K.** (2017). Adverse childhood experiences and risk for suicidal behavior in male Iraq and Afghanistan veterans seeking PTSD treatment. *Psychological Trauma: Theory, Research, Practice, and Policy, 9*, 583-586. doi:10.1037/tra0000250
38. Chekroud, A. M., Gueorguieva, R., Krumholz, H. M., Trivedi, M. H., **Krystal, J. H.**, & **McCarthy, E.** (2017). Reevaluating the efficacy and predictability of antidepressant treatments: A symptom clustering approach. *JAMA Psychiatry, 74*, 370-378. doi:10.1001/jamapsychiatry.2017.0025
39. Chekroud, A. M., Loho, H., & **Krystal, J. H.** (2017). Mental illness and mental health. *Lancet Psychiatry, 4*, 276-277. doi:10.1016/S2215-0366(17)30088-3
40. Chen, J. A., Olin, C. C., **Wiltsey-Stirman, S.**, & Kaysen, D. (2017). The role of context in the implementation of trauma-focused treatments: Effectiveness research and implementation in higher and lower income settings. *Current Opinion in Psychology, 14*, 61-66. doi:10.1016/j.copsyc.2016.11.007
41. Chowdhury, G., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., **Duman, R.**, Rothman, D., Behar, K., & **Sanacora, G.** (2017). Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. *Molecular Psychiatry, 22*, 120-126. doi:10.1038/mp.2016.34
42. Claycomb Erwin, M., Charak, R., Durham, T., Armour, C., Lv, X., **Southwick, S. M.**, Elhai, J., & **Pietrzak, R. H.** (2017). The 7-factor hybrid model of DSM-5 PTSD symptoms and alcohol consumption and consequences in a national sample of trauma-exposed veterans. *Journal of Anxiety Disorders, 51*, 14-21. doi:10.1016/j.janxdis.2017.08.001
43. **Cloitre, M.**, & Beck, J. (2017). Introduction for the special issue: The long-term effects of childhood adversity and trauma. *Clinical Psychology: Science and Practice, 24*, 107-110. doi:10.1111/cpsp.12199
44. Colvonen, P., Glassman, L. H., Crocker, L. D., Buttner, M., Orff, H., Schiehsler, D. M., **Norman, S. B.**, & Afari, N. (2017). Pretreatment biomarkers predicting PTSD psychotherapy outcomes: A systematic review. *Neuroscience and Biobehavioral Reviews, 75*, 140-156. doi:10.1016/j.neubiorev.2017.01.027

Appendix C: Fiscal Year 2017 Publications

45. **Cook, J., Simiola, V., Hamblen, J. L., Bernardy, N. C., & Schnurr, P. P.** (2017). The influence of patient readiness on implementation of evidence-based PTSD treatments in Veterans Affairs residential programs. *Psychological Trauma: Theory, Research, Practice, and Policy*, *9*(Suppl. 1), 51-58. doi:10.1037/tra0000162
46. Coplan, J. D., **Gopinath, S., Abdallah, C.**, Margolis, J., Chen, W., Scharf, B. A., Rosenblum, L. A., Batuman, O. A., & Smith, E. L. (2017). Effects of acute confinement stress-induced hypothalamic-pituitary adrenal axis activation and concomitant peripheral and central transforming growth factor- β 1 measures in nonhuman primates. *Chronic Stress*, *1*. doi:10.1177/2470547016688693
47. Creech, S. K., **Macdonald, A.**, Benzer, J., Poole, G., Murphy, C., & **Taft, C. T.** (2017). PTSD symptoms predict outcome in trauma-informed treatment of intimate partner aggression. *Journal of Consulting and Clinical Psychology*, *85*, 966-974. doi:10.1037/ccp0000228
48. Cronce, J., Bedard-Gilligan, M., **Zimmerman, L. E.**, Hodge, K., & Kaysen, D. (2017). Alcohol and binge eating as mediators between posttraumatic stress disorder symptom severity and body mass index. *Obesity*, *25*, 801-806. doi:10.1002/oby.21809
49. Currier, J. M., **Drescher, K.**, Nieuwsma, J., & McCormick, W. H. (2017). Theodicies and professional quality of life in a nationally representative sample of chaplains in the Veterans Health Administration. *Journal of Prevention & Intervention in the Community*, *45*, 286-296. doi:10.1080/10852352.2016.1197748
50. Dalenberg, C. J., Straus, E., & **Carlson, E. B.** (2017). Defining trauma. In S. Gold (Ed.), *APA handbook of trauma psychology: Foundations in knowledge* (pp. 15-33). Washington, DC: American Psychological Association Press.
51. **Dardis, C.**, & Gidycz, C. (2017). The frequency and perceived impact of engaging in in-person and cyber unwanted pursuit after relationship break-up among college men and women. *Sex Roles*, *76*, 56-72. doi:10.1007/s11199-016-0667-1
52. **Dardis, C., Amoroso, T., & Iverson, K. M.** (2017). Intimate partner stalking: Contributions to PTSD symptomatology among a national sample of women veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, *9*(Suppl. 1), 67-73. doi:10.1037/tra0000171
53. **Dardis, C., Shipherd, J. C., & Iverson, K. M.** (2017). Intimate partner violence among women veterans by sexual orientation. *Women & Health*, *57*, 775-791. doi:10.1080/03630242.2016.1202884
54. Davis, M. T., Holmes, S., **Pietrzak, R. H.**, & **Esterlis, I.** (2017). Neurobiology of chronic stress related psychiatric disorders: Evidence from molecular studies. *Chronic Stress*, *1*. doi:10.1177/2470547017710916
55. Davis, M., DellaGioia, N., Matuskey, D., Harel, B., Maruff, P., **Pietrzak, R. H.**, & **Esterlis, I.** (2017). Preliminary evidence concerning the pattern and magnitude of cognitive dysfunction in major depressive disorder using Cogstate measures. *Journal of Affective Disorders*, *218*, 82-85. doi:10.1016/j.jad.2017.04.064
56. DeLorenzo, C., Gallezot, J. D., Gardus, J., Yang, J., Planeta, B., Nabulsi, N., Ogden, R. T., Labaree, D. C., Huang, Y. H., Mann, J. J., Gasparini, F., Lin, X., Javitch, J. A., Parsey, R. V., Carson, R. E., & **Esterlis, I.** (2017). In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11 C]ABP688 and [18 F]FPEB. *Journal of Cerebral Blood Flow and Metabolism*, *37*, 2716-2727. doi:10.1177/0271678X16673646
57. Dichter, M. E., Haywood, T. N., Butler, A. E., Bellamy, S. L., & **Iverson, K. M.** (2017). IPV screening in Veterans Health Administration: Demographic and military service characteristics. *American Journal of Preventive Medicine*, *52*, 761-768. doi:10.1016/j.amepre.2017.01.003
58. Do, C., Shearer, A., Suzuki, M., Terry, M., **Gelernter, J.**, Grealley, J., & Tycko, B. (2017). Genetic-epigenetic interactions in cis: A major focus in the post-GWAS era. *Genome Biology*, *18*, 120. doi:10.1186/s13059-017-1250-y
59. Duncan, L., Yilmaz, Z., Gaspar, H., Walters, R., Goldstein, J., ... **Mitchell, K. S.**, ... & Bulik, C. (2017). Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. *American Journal of Psychiatry*, *174*, 850-858. doi:10.1176/appi.ajp.2017.16121402
60. **Dutra, S.**, & **Wolf, E. J.** (2017). Perspectives on the conceptualization of the dissociative subtype of PTSD and implications for treatment. *Current Opinion in Psychology*, *14*, 35-39. doi:10.1016/j.copsy.2016.10.003
61. **Edwards, K. S.**, Rosen, R., Smith, L., **Garvert, D.**, **Graham, B. C.**, Hoyman, L., Humphrey, S., & **Ruzek, J. I.** (2017). Group telephone consultation after online self-administered training: Acceptability and feasibility. *Training and Education in Professional Psychology*, *11*, 198-206. doi:10.1037/tep0000153
62. **Eftekhari, A., Landes, S. J.**, Bailey, K. M., Shin, H. J., & **Ruzek, J. I.** (2017). Evidence-based treatments for PTSD: Clinical considerations for PTSD and comorbid suicidality. In B. Bongar, G. Sullivan, & L. James (Eds.), *Handbook of military and veteran suicide: Assessment, treatment, and prevention* (pp. 131-146). New York, NY: Oxford University Press.
63. **Engel-Rebitzer, E., Bovin, M. J., Black, S. K.**, Rosen, R., **Keane, T. M.**, & **Marx, B. P.** (2016). A longitudinal examination of peritraumatic emotional responses and their association with posttraumatic stress disorder and major depressive disorder among veterans. *Journal of Trauma & Dissociation*, *18*, 679-692. doi:10.1080/15299732.2016.1267683
64. Feder, A., **Mota, N.**, Salim, R., Rodriguez, J., Singh, R., Schaffer, J., Schechter, C., Cancelmo, L., Bromet, E., Katz, C., Reissman, D., Ozbay, F., Kotov, R., Crane, M., Harrison, D., Herbert, R., Levin, S., Luft, B., Moline, J., Stellman, J., Udasin, I., Landrigan, P., Zvolensky, M., Yehuda, R., **Southwick, S. M.**, & **Pietrzak, R. H.** (2016). Risk, coping and PTSD symptom trajectories in World Trade Center responders. *Journal of Psychiatric Research*, *82*, 68-79. doi:10.1016/j.jpsychires.2016.07.003
65. Finley, E. P., Noël, P. H., Mader, M., Haro, E., **Bernardy, N. C.**, **Rosen, C. S.**, Bollinger, M. J., Garcia, H., **Sherrieb, K.**, & Pugh, M. J. (2017). Community clinicians and the Veterans Choice Program for PTSD care: Understanding provider interest during early implementation. *Medical Care*, *55*, S61-S70. doi:10.1097/MLR.0000000000000668
66. Fonda, J. R., Fredman, L., Brogly, S. B., McGlinchey, R. E., Milberg, W. B., & **Gradus, J. L.** (2017). Traumatic brain injury and attempted suicide among veterans of the wars in Iraq and Afghanistan. *American Journal of Epidemiology*, *186*, 220-226. doi:10.1093/aje/kwx044
67. Fortenbaugh, F., Corbo, V., Poole, V., McGlinchey, R., Milberg, W., **Salat, D.**, DeGutis, J., & Esterman, M. (2017). Interpersonal early-life trauma alters amygdala connectivity and sustained attention performance. *Brain and Behavior*, *7*, e00684. doi:10.1002/brb3.684

Appendix C: Fiscal Year 2017 Publications

68. **Fox, A. B., Smith, B. N., & Vogt, D.** (2016). The relationship between anticipated stigma and work functioning for individuals with depression. *Journal of Clinical and Social Psychology, 35*, 883-897. doi:10.1521/jscp.2016.35.10.883
69. **Friedman, M. J., & Bernardy, N. C.** (2017). Considering future pharmacotherapy for PTSD. *Neuroscience Letters, 649*, 181-185. doi:10.1016/j.neulet.2016.11.048
70. **Friedman, M. J., Huber, B., Brady, C., Ursano, R., Benedek, D., Kowall, N., & McKee, A.** (2017). VA's National PTSD Brain Bank: A national resource for research. *Current Psychiatry Reports, 19*, 73. doi:10.1007/s11920-017-0822-6
71. **Friedman, M. J., Kilpatrick, D. G., & Schnurr, P. P.** (2016). Changes to the definition of posttraumatic stress disorder in the DSM-5-reply. *JAMA Psychiatry, 73*, 1203. doi:10.1001/jamapsychiatry.2016.2401
72. Frota Ribeiro, C., **Sanacora, G., & Ostroff, R.** (2017). Reply to: Ketamine and psychosis history: Antidepressant efficacy and psychotomimetic effects postinfusion. *Biological Psychiatry, 82*, e35-e36. doi:10.1016/j.biopsych.2017.01.012
73. **Galovski, T. E., Harik, J. M., Blain, L., Farmer, C., Turner, D., & Houle, T.** (2016). Identifying patterns and predictors of PTSD and depressive symptom change during Cognitive Processing Therapy. *Cognitive Therapy and Research, 40*, 617-626. doi:10.1007/s10608-016-9770-4
74. Goldenberg, M. N., & **Krystal, J. H.** (2017). Undergraduate neuroscience majors: A missed opportunity for psychiatry workforce development. *Academic Psychiatry, 41*, 239-242. doi:10.1007/s40596-017-0670-z
75. **Gradus, J. L.** (2017). Prevalence and prognosis of stress disorders: A review of the epidemiologic literature. *Clinical Epidemiology, 9*, 251-260. doi:10.2147/CLEPS106250
76. **Gradus, J. L., Farkas, D. K., Svensson, E., Ehrenstein, V., Lash, T. L., & Sørensen, H. T.** (2017). Posttraumatic stress disorder and gastrointestinal disorders in the Danish population. *Epidemiology, 28*, 354-360. doi:10.1097/EDE.0000000000000622
77. **Gradus, J. L., Leatherman, S., Myers, L. G., Ferguson, R., & Miller, M.** (2017). Gender differences in substance abuse, PTSD and intentional self-harm among Veterans Health Administration patients. *Drug and Alcohol Dependence, 171*, 66-69. doi:10.1016/j.drugalcdep.2016.11.012
78. **Green, J. D., Annunziata, A., Kleiman, S., Bovin, M. J., Harwell, A. M., Fox, A. B., Black, S. K., Schnurr, P. P., Holowka, D. W., Rosen, R. C., Keane, T. M., & Marx, B. P.** (2017). Examining the diagnostic utility of the DSM-5 PTSD symptoms among male and female returning veterans. *Depression and Anxiety, 34*, 752-760. doi:10.1002/da.22667
79. **Green, J. D., Black, S. K., Marx, B. P., & Keane, T. M.** (2017). Behavioral, cognitive, biological, and neurocognitive conceptualizations of posttraumatic stress disorder. In S. Gold (Ed.), *APA handbook of trauma psychology: Foundations in knowledge* (pp. 407-428). Washington, DC: American Psychological Association Press.
80. **Green, J. D., Marx, B. P., & Keane, T. M.** (2017). Empirically supported conceptualizations and treatments of posttraumatic stress disorder. In D. McKay, J. Abramowitz, & E. Storch (Eds.), *Treatments for psychological problems and syndromes* (pp. 115-135). New York, NY: John Wiley.
81. **Greenbaum, M. A., Neylan, T. C., & Rosen, C. S.** (2017). Symptom presentation and prescription of sleep medications for veterans with posttraumatic stress disorder. *Journal of Nervous and Mental Disease, 205*, 112-118. doi:10.1097/NMD.0000000000000657
82. Greene, T., Gelkopf, M., Grinapol, S., Werbeloff, N., **Carlson, E. B., & Lapid, L.** (2017). Trajectories of traumatic stress symptoms during conflict: A latent class growth analysis. *Journal of Affective Disorders, 220*, 24-30. doi:10.1016/j.jad.2017.05.036
83. Groff, E., **Ruzek, J. I., Bongar, B., & Cordova, M.** (2016). Social constraints, loss-related factors, depression, and posttraumatic stress in a treatment-seeking suicide bereaved sample. *Psychological Trauma: Theory, Research, Practice, and Policy, 8*, 657-660. doi:10.1037/tra0000128
84. Grubb, M., Tymula, A., Gilaie-Dotan, S., Glimcher, P., & **Levy, I.** (2016). Neuroanatomy accounts for age-related changes in risk preferences. *Nature Communications, 7*, 13822. doi:10.1038/ncomms13822
85. Grubbs, K., Fortney, J., Kimbrell, T., Pyne, J. M., Hudson, T. J., Robinson, D., Moore, W. M., Custer, P., Schneider, R., & **Schnurr, P. P.** (2017). Usual care for rural veterans with posttraumatic stress disorder. *Journal of Rural Health, 33*, 290-296. doi:10.1111/jrh.12230
86. Gudiño, O. G., Landolt, M. A., **Cloitre, M., & Schnyder, U.** (2017). STAIR Narrative Therapy for adolescents. In M. A. Landolt, M. Cloitre, and U. Schnyder (Eds.), *Evidence-based treatments for trauma related disorders in children and adolescent* (pp. 251-271). Gewerbestrasse, Switzerland: Springer. doi:10.1007/978-3-319-46138-0_12
87. Gueorguieva, R., Chekroud, A. M., & **Krystal, J. H.** (2017). Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: An individual patient-level data meta-analysis. *Lancet Psychiatry, 4*, 230-237. doi:10.1016/S2215-0366(17)30038-X
88. **Gutner, C. A., Galovski, T. E., Bovin, M. J., & Schnurr, P. P.** (2016). Emergence of transdiagnostic treatments for PTSD and posttraumatic distress. *Current Psychiatry Reports, 18*, 95. doi:10.1007/s11920-016-0734-x
89. **Gutner, C. A., Suvak, M., Sloan, D. M., & Resick, P. A.** (2016). Does timing matter? Examining the impact of session timing on outcome. *Journal of Consulting and Clinical Psychology, 84*, 1108-1115. doi:10.1037/ccp0000120
90. **Haller, M., Colvonen, P., Davis, B., Trim, R. S., Bogner, R., & Norman, S. B.** (2016). Examining pretreatment differences between veterans in residential versus outpatient treatment for alcohol use disorder and comorbid combat-related PTSD. *Journal of Dual Diagnosis, 12*, 282-289. doi:10.1080/15504263.2016.1256516
91. **Haller, M., Myers, U., McKnight, A., Angkaw, A., & Norman, S. B.** (2016). Predicting engagement in psychotherapy, pharmacotherapy, or both psychotherapy and pharmacotherapy among returning veterans seeking PTSD treatment. *Psychological Services, 13*, 341-348. doi:10.1037/ser0000093
92. **Hamblen, J. L., Norris, F. H., Symon, K. A., & Bow, T. E.** (2017). Cognitive behavioral therapy for postdisaster distress: A promising transdiagnostic approach to treating disaster survivors. *Psychological Trauma: Theory, Research, Practice and Policy, 9*, 130-136. doi:10.1037/tra0000221

Appendix C: Fiscal Year 2017 Publications

93. **Harik, J. M., Matteo, R., Hermann, B. A., & Hamblen, J. L.** (2017). What people with PTSD symptoms do (and don't) know about PTSD: A national survey. *Depression and Anxiety, 34*, 374–382. doi:10.1002/da.22558
94. Harmer, C. J., **Duman, R.**, & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. *Lancet Psychiatry, 4*, 409–418. doi:10.1016/S2215-0366(17)30015-9
95. Haug, N. A., Padula, C., Sottile, J. E., Vandrey, R., **Heinz, A. J.**, & **Bonn-Miller, M.** (2017). Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. *Addictive Behaviors, 72*, 14–20. doi:10.1016/j.addbeh.2017.03.006
96. **Hayes, J. P., Logue, M. W., Reagan, A., Salat, D., Wolf, E. J., Samimi Sadeh, N.**, Spielberg, J. M., **Sperbeck, E., Hayes, S.**, McGlinchey, R. E., Milberg, W. P., Verfaellie, M., & **Miller, M. W.** (2017). COMT VAL158MET moderates the association between PTSD symptoms severity and hippocampal volume. *Journal of Psychiatry and Neuroscience, 42*, 95–102. doi:10.1503/jpn.150339
97. **Hayes, J. P., Logue, M. W., Samimi Sadeh, N.**, Spielberg, J., Verfaellie, M., **Hayes, S., Reagan, A., Salat, D., Wolf, E. J.**, McGlinchey, R., Milberg, W., Stone, A., Schichman, S., & **Miller, M. W.** (2017). Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease. *Brain, 140*, 813–825. doi:10.1093/brain/aww344
98. **Hayes, S., Hayes, J. P.**, Williams, V., Liu, H., & Verfaellie, M. (2017). fMRI activity during associative encoding is correlated with cardiorespiratory fitness and source memory performance in older adults. *Cortex, 91*, 208–220. doi:10.1016/j.cortex.2017.01.002
99. Herbst, E., **McCaslin, S. E.**, & Kalapatapu, R. K. (2017). Use of stimulants and performance enhancers during and after trauma exposure in a combat veteran: A possible risk factor for posttraumatic stress symptoms. *American Journal of Psychiatry, 174*, 95–99. doi:10.1176/appi.ajp.2016.16010014
100. **Hermann, B. A.**, Meyer, E. C., **Schnurr, P. P.**, Batten, S. V., & **Walsler, R. D.** (2016). Acceptance and Commitment Therapy for co-occurring PTSD and substance use: A manual development study. *Journal of Contextual Behavioral Science, 5*, 225–234. doi:10.1016/j.jcbs.2016.07.001
101. Hicks, T. A., Thomas, S. P., Wilson, S. M., Calhoun, P., **Kuhn, E. R.**, & Beckham, J. (2017). A preliminary investigation of a relapse prevention mobile application to maintain smoking abstinence among individuals with posttraumatic stress disorder. *Journal of Dual Diagnosis, 13*, 15–20. doi:10.1080/15504263.2016.1267828
102. Hillmer, A., Li, S., Zheng, M., Scheunemann, M., Lin, S., Nabulsi, N., Holden, D., Pracitto, R., Labaree, D., Ropchan, J., Teodoro, R., Deuther-Conrad, W., **Esterlis, I., Cosgrove, K.**, Brust, P., Carson, R., & Huang, Y. (2017). PET imaging of α_7 nicotinic acetylcholine receptors: A comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. *European Journal of Nuclear Medicine and Molecular Imaging, 24*, 3621–3628. doi:10.1007/s00259-017-3621-8
103. Holmes, S., **Esterlis, I.**, Mazure, C., Lim, Y., Ames, D., Rainey-Smith, S., Martins, R., Salvado, O., Dore, V., Villemagne, V., Rowe, C., Laws, S., Masters, C., Maruff, P., & **Pietrzak, R. H.** (2016). β -Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. *American Journal of Geriatric Psychiatry, 24*, 1191–1195. doi:10.1016/j.jagp.2016.08.007
104. Horn, S., **Pietrzak, R. H.**, Schechter, C., Bromet, E., Katz, C., Reissman, D., Kotov, R., Crane, M., Harrison, D., Herbert, R., Luft, B., Moline, J., Stellman, J., Udasin, I., Landrigan, P., Zvolensky, M., **Southwick, S. M.**, & Feder, A. (2016). Latent typologies of posttraumatic stress disorder in World Trade Center responders. *Journal of Psychiatric Research, 83*, 151–159. doi:10.1016/j.jpsychires.2016.08.018
105. Hundt, N. E., **Harik, J. M.**, Barrera, T. L., Cully, J., & Stanley, M. A. (2016). Treatment decision-making for PTSD: The impact of patient and therapist characteristics. *Psychological Trauma: Theory, Research, Practice, and Policy, 8*, 728–735. doi:10.1037/tra0000102
106. Hyland, P., Murphy, J., Shevlin, M., Vallières, F., McElroy, E., Elklit, A., Christoffersen, M., & **Cloitre, M.** (2017). Variation in post-traumatic response: The role of trauma type in predicting ICD-11 PTSD and CPTSD symptoms. *Social Psychiatry and Psychiatric Epidemiology, 52*, 727–736. doi:10.1007/s00127-017-1350-8
107. Hyland, P., Shevlin, M., Brewin, C., **Cloitre, M.**, Downes, A., Jumbe, S., Karatzias, T., Bisson, J., & Roberts, N. (2017). Validation of post-traumatic stress disorder (PTSD) and complex PTSD using the International Trauma Questionnaire. *Acta Psychiatrica Scandinavica, 136*, 313–322. doi:10.1111/acps.12771
108. Hyland, P., Shevlin, M., Elklit, A., Murphy, J., Vallières, F., **Garvert, D.**, & **Cloitre, M.** (2017). An assessment of the construct validity of the ICD-11 proposal for complex posttraumatic stress disorder. *Psychological Trauma: Theory, Research, Practice, and Policy, 9*, 1–9. doi:10.1037/tra0000114
109. Ide, J. S., Zhornitsky, S., Hu, S., Zhang, S., **Krystal, J. H.**, & Li, C. R. (2017). Sex differences in the interacting roles of impulsivity and positive alcohol expectancy in problem drinking: A structural brain imaging study. *NeuroImage Clinical, 14*, 750–759. doi:10.1016/j.nicl.2017.03.015
110. Isaacs, K., **Mota, N.**, Tsai, J., **Harpaz-Rotem, I., Cook, J.**, Kirwin, P., **Krystal, J. H., Southwick, S. M., & Pietrzak, R. H.** (2017). Psychological resilience in U.S. military veterans: A 2-year, nationally representative prospective cohort study. *Journal of Psychiatric Research, 84*, 301–309. doi:10.1016/j.jpsychires.2016.10.017
111. **Iverson, K. M., Dardis, C.**, & Pogoda, T. (2017). Traumatic brain injury and PTSD symptoms as a consequence of intimate partner violence. *Comprehensive Psychiatry, 74*, 80–87. doi:10.1016/j.comppsy.2017.01.007
112. **Iverson, K. M., Vogt, D., Maskin, R., & Smith, B. N.** (2017). Intimate partner violence victimization and associated implications for health and functioning among male and female post-9/11 veterans. *Medical Care, 55*, S78–S84. doi:10.1097/MLR.0000000000000741
113. **Jain, S., McLean, C. P.**, Adler, E., & **Rosen, C. S.** (2016). Peer support and outcome for veterans with posttraumatic stress disorder (PTSD) in a residential rehabilitation program. *Community Mental Health Journal, 52*, 1089–1092. doi:10.1007/s10597-015-9982-1
114. Jensen, K. P., Smith, A. H., Herman, A. I., Farrer, L. A., Kranzler, H. R., Sofuoglu, M., & **Gelernter, J.** (2016). A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke. *Molecular Psychiatry, 22*, 242–249. doi:10.1038/mp.2016.43

Appendix C: Fiscal Year 2017 Publications

115. Justice, A., McGinnis, K., Tate, J., Xu, K., Becker, W., Zhao, H., **Gelernter, J.**, & Kranzler, H. (2017). Validating harmful alcohol use as a phenotype for genetic discovery using phosphatidylethanol and a polymorphism in ADH1B. *Alcoholism: Clinical and Experimental Research*, *41*, 998-1003. doi:10.1111/acer.13373
116. Kalkstein, S., Scott, J. C., Biester, R., Brownlow, J. A., **Harpaz-Rotem, I.**, & Gur, R. (2017). Comparison of blast-exposed OEF/OIF veterans with and without a history of TBI symptoms on a brief computerized neuropsychological battery. *Journal Applied Neuropsychology: Adult*, *24*, 92-97. doi:10.1080/23279095.2015.1119693
117. Karatzias, T., Shevlin, M., Fyvie, C., Hyland, P., Efthymiadou, E., Wilson, D., Roberts, N., Bisson, J. I., Brewin, C. R., & **Cloitre, M.** (2017). Evidence of distinct profiles of posttraumatic stress disorder (PTSD) and complex posttraumatic stress disorder (CPTSD) based on the new ICD-11 Trauma Questionnaire (ICD-TQ). *Journal of Affective Disorders*, *207*, 181-187. doi:10.1016/j.jad.2016.09.032
118. **Kearns, J. C., Gorman, K. R., Bovin, M. J., Green, J. D., Rosen, R., Keane, T. M., & Marx, B. P.** (2016). The effect of military sexual assault, combat exposure, postbattle experiences, and general harassment on the development of PTSD and MDD in female OEF/OIF veterans. *Translational Issues in Psychological Science*, *2*, 418-428. doi:10.1037/tps0000098
119. **Kehle-Forbes, S.**, Campbell, E., Taylor, B., Scholten, J., & Sayers, S. (2017). Does co-occurring traumatic brain injury affect VHA outpatient health service utilization and associated costs among veterans with posttraumatic stress disorder? An examination based on VHA administrative data. *Journal of Head Trauma Rehabilitation*, *32*, e16-e23. doi:10.1097/HTR.0000000000000227
120. **Kehle-Forbes, S.**, Harwood, E., **Spoont, M.**, Sayer, N., Gerould, H., & Murdoch, M. (2017). Experiences with VHA care: A qualitative study of U.S. women veterans with self-reported trauma histories. *BMC Women's Health*, *17*, 38. doi:10.1186/s12905-017-0395-x
121. **Kelmendi, B., Adams, T., Yarnell, S., Southwick, S. M., Abdallah, C., & Krystal, J. H.** (2016). PTSD: From neurobiology to pharmacological treatments. *European Journal of Psychotraumatology*, *7*, 31858. doi:10.3402/ejpt.v7.31858
122. **Kimerling, R.** (2017). No mission too difficult: Responding to military sexual assault. *American Journal of Public Health*, *107*, 642-644. doi:10.2105/AJPH.2017.303731
123. Kirkpatrick, S., Goldberg, L., Yazdani, N., Babbs, R., Wu, J., Reed, E., Jenkins, D., Bolgioni, A., Landaverde, K., Luttik, K., **Mitchell, K. S.**, Kumar, V., Johnson, W., Mulligan, M., Cottone, P., & Bryant, C. (2016). Cytoplasmic FMR1-interacting protein 2 is a major genetic factor underlying binge eating. *Biological Psychiatry*, *81*, 757-769. doi:10.1016/j.biopsych.2016.10.021
124. Kors, E., Bijen, K., Knipschild, R., Koopmans, H., Kroeze, K., van Leeuwen, D., Gudino, O., & **Cloitre, M.** (2017). *Training in affectieve en interpersoonlijke regulatievaardigheden voor meervoudig getraumatiseerde adolescenten-protocol*. Houten, Netherlands: Springer.
125. **Krystal, J. H.** (2017). The neuroscience of psychiatry. In B. J. Sadock, V. Sadock, & P. Ruiz (Eds.), *Kaplan and Sadock's comprehensive textbook of psychiatry*, (10th ed.). New York, NY: Lippincott Williams & Wilkins.
126. **Krystal, J. H., Abdallah, C., Averill, L., Kelmendi, B., Harpaz-Rotem, I., Sanacora, G., Southwick, S. M., & Duman, R.** (2017). Synaptic loss and the pathophysiology of PTSD: Implications for ketamine as a prototype novel therapeutic. *Current Psychiatry Reports*, *19*, 74. doi:10.1007/s11920-017-0829-z
127. **Krystal, J. H., Anticevic, A., Murray, J. D., Glahn, D. C., Driesen, N. R., Yang, G., & et, A.** (2016). Clinical heterogeneity arising from categorical and dimensional features of the neurobiology of psychiatric diagnoses: Insights from neuroimaging and computational neuroscience. In A. D. Redish & J. A. Gordon (Eds.), *Computational psychiatry: New perspectives on mental illness* (pp. 295-317). Cambridge, MA: MIT Press.
128. **Krystal, J. H., Davis, L., Neylan, T., A. Raskind, M., Schnurr, P. P., Stein, M., Vessicchio, J., Shiner, B., Gleason, T., & Huang, G.** (2017). It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD psychopharmacology working group. *Biological Psychiatry*, *17*, 31362-31368. doi:10.1016/j.biopsych.2017.03.007
129. **Krystal, J. H., Petrakis, I., O'Malley, S., Krishnan-Sarin, S., Pearlson, G., & Yoon, G.** (2017). NMDA glutamate receptor antagonism and the heritable risk for alcoholism: New insights from a study of nitrous oxide. *International Journal of Neuropsychopharmacology*, *20*, 351-353. doi:10.1093/ijnp/pyw118
130. **Kuhn, E. R., & Hugo, E.** (2017). Technology-based blended learning to facilitate psychiatry resident training in Prolonged Exposure (PE) therapy for PTSD. *Academic Psychiatry*, *41*, 121-124. doi:10.1007/s40596-016-0648-2
131. **Kuhn, E. R., Kanuri, N., Hoffman, J. E., Garvert, D., Ruzek, J. I., & Taylor, C. B.** (2017). A randomized controlled trial of a smartphone app for posttraumatic stress disorder symptoms. *Journal of Consulting and Clinical Psychology*, *85*, 267-273. doi:10.1037/ccp0000163
132. **LaMotte, A. D., Taft, C. T., Weatherill, R. P., & Eckhardt, C. I.** (2017). Social skills deficits as a mediator between PTSD symptoms and intimate partner aggression in returning veterans. *Journal of Family Psychology*, *31*, 105-110. doi:10.1037/fam0000215
133. **LaMotte, A. D., Taft, C. T., Weatherill, R. P., Casement, M., Creech, S. K., Milberg, W., Fortier, C., & McGlinchey, R.** (2017). Sleep problems and physical pain as moderators of the relationship between PTSD symptoms and aggression in returning veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, *9*, 113-116. doi:10.1037/tra0000178
134. Landolt, M. A., **Cloitre, M.**, & Schnyder, U. (2017). *Evidence-based treatments for trauma related disorders in children and adolescents*. Gewerbestrasse, Switzerland: Springer. doi:10.1007/978-3-319-46138-0
135. Landolt, M. A., **Cloitre, M.**, & Schnyder, U. (2017). How to treat children and adolescents with trauma-related disorders. In M. A. Landolt, **M. Cloitre**, & U. Schnyder (Eds.), *Evidence-based treatments for trauma related disorders in children and adolescents* (pp. 507-517). Gewerbestrasse, Switzerland: Springer. doi:10.1007/978-3-319-46138-0_24
136. Landolt, M. A., **Cloitre, M.**, & Schnyder, U. (2017). Introduction. In M. A. Landolt, **M. Cloitre**, & U. Schnyder (Eds.), *Evidence-based treatments for trauma related disorders in children and adolescents* (pp. 1-3). Gewerbestrasse, Switzerland: Springer.

Appendix C: Fiscal Year 2017 Publications

137. Lang, A. J., **Schnurr, P. P.**, Jain, S., He, F., **Walsler, R. D.**, Bolton, E., Benedek, D. M., **Norman, S. B.**, Sylvers, P., Flashman, L., Strauss, J., Raman, R., & Chard, K. M. (2017). Randomized controlled trial of Acceptance and Commitment Therapy for distress and impairment in OEF/OIF/OND veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, *9*(Suppl. 1), 74-84. doi:10.1037/tra0000127
138. Langdon, K., Rubin, A., Brief, D., Enggasser, J., Roy, M., Solhan, M., **Helmuth, E.**, Rosenbloom, D., & **Keane, T. M.** (2017). Sexual traumatic event exposure, posttraumatic stress symptomatology, and alcohol misuse among women: A critical review of the empirical literature. *Clinical Psychology: Science and Practice*, *24*, 5-22. doi:10.1111/cpsp.12167
139. Lau, A., Barnett, M. L., Stadnick, N., Saifan, D., Regan, J., **Wiltsey-Stirman, S.**, Roesch, S., & Brookman-Frazee, L. (2017). Therapist report of adaptations to delivery of evidence-based practices within a system driven reform of publicly-funded children's mental health services. *Journal of Consulting and Clinical Psychology*, *85*, 664-671. doi:10.1037/ccp0000215
140. Lee, C. M., Cronce, J. M., Baldwin, S., Fairlie, A., Atkins, D. C., Patrick, M. E., **Zimmerman, L. E.**, Larimer, M., & Leigh, B. C. (2017). Psychometric analysis and validity of the daily alcohol-related consequences and evaluations measure for young adults. *Psychological Assessment*, *29*, 253-263. doi:10.1037/pas0000320
141. Lee, C., Patrick, M., Geisner, I., Mastroleo, N., Mittmann, A., & **Zimmerman, L. E.** (2017). Individual, interpersonal, and contextual factors associated with discrepancies between intended and actual spring break drinking. *Addictive Behaviors*, *69*, 42-47. doi:10.1016/j.addbeh.2017.01.006
142. **Lee, D. J.**, Weathers, F. W., **Sloan, D. M.**, Davis, M., & Domino, J. L. (2017). Development and preliminary psychometric examination of the Semi-Structured Emotion Regulation Interview. *Journal of Personality Assessment*, *99*, 56-66. doi:10.1080/000223891.2016.1215992
143. Lepack, A., Bang, E., Lee, B., Dwyer, J., & **Duman, R.** (2016). Rapid acting antidepressants stimulate ERK signaling and BDNF release in primary neuronal cultures. *Neuropharmacology*, *111*, 242-252. doi:10.1016/j.neuropharm.2016.09.011
144. **Levy, I.** (2017). Neuroanatomical substrates for risk behavior. *The Neuroscientist*, *23*, 275-286. doi:10.1177/1073858416672414
145. **Levy, I.** (2017). The behavioral economics of anxiety. *Biological Psychiatry*, *81*, 974-976. doi:10.1016/j.biopsych.2017.04.007
146. Liu, R., **Duman, R.**, Kato, T., Hare, B., Lopresto, D., Bang, E., Burgdorf, J., Moskal, J., Taylor, J., Aghajanian, G., & **Duman, R.** (2017). GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine. *Neuropsychopharmacology*, *42*, 1231-1242. doi:10.1038/npp.2016.202
147. **Loflin, M. J.**, **Babson, K. A.**, & **Bonn-Miller, M.** (2017). Cannabinoids as therapeutic for PTSD. *Current Opinion in Psychology*, *14*, 78-83. doi:10.1016/j.copsyc.2016.12.001
148. **Loflin, M. J.**, Earleywine, M., & **Bonn-Miller, M.** (2017). Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. *Addictive Behaviors*, *68*, 18-23. doi:10.1016/j.addbeh.2017.01.008
149. Lusk, J., **Samimi Sadeh, N.**, **Wolf, E. J.**, & **Miller, M. W.** (2017). Reckless self-destructive behavior and PTSD in veterans: The mediating role of new adverse events. *Journal of Traumatic Stress*, *30*, 270-278. doi:10.1002/jts.22182
150. Manhapra, A., **Petrakis, I.**, & **Rosenheck, R. A.** (2017). Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. *The American Journal on Addictions*, *26*, 572-580. doi:10.1111/ajad.12553
151. Manikandan, S., **Nillni, Y. I.**, Zvolensky, M. J., Rohan, K. J., Carkeek, K. R., & Leyro, T. M. (2016). The role of emotion regulation in the experience of menstrual symptoms and perceived control over anxiety-related events across the menstrual cycle. *Archives of Women's Mental Health*, *19*, 1109-1117. doi:10.1007/s00737-016-0661-1
152. Manseau, M., Rajparia, A., Joseph, A., Azarchi, S., Goff, D., **Satodiya, R.**, & Lewis, C. (2017). Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. *Substance Use & Misuse*, *52*, 822-825. doi:10.1080/10826084.2016.1263663
153. **Mansfield, A. J.**, **Greenbaum, M. A.**, Schaper, K. M., **Banducci, A. N.**, & **Rosen, C. S.** (2017). PTSD care among veterans with and without co-occurring substance use disorders. *Psychiatric Services*, *68*, 632-635. doi:10.1176/appi.ps.201600128
154. **Marx, B. P.**, **Engel-Rebitzer, E.**, **Bovin, M. J.**, **Parker-Guilbert, K.**, **Moshier, S. J.**, **Barretto, K. M.**, Szafranski, D., **Gallagher, M. W.**, Holowka, D. W., Rosen, R. C., & **Keane, T. M.** (2017). The influence of veteran race and psychometric testing on Veterans Affairs posttraumatic stress disorder (PTSD) disability exam outcomes. *Psychological Assessment*, *29*, 710-719. doi:10.1037/pas0000378
155. Mason, G. F., **Krystal, J. H.**, & **Sanacora, G.** (2017). Nuclear magnetic resonance imaging and spectroscopy: Basic principles and recent findings in neuropsychiatric disorders. In B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), *Kaplan and Sadock's comprehensive textbook of psychiatry* (10th ed., pp. 259-284). Philadelphia, PA: Lippincott Williams & Wilkins.
156. Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., ... **Gutner, C. A.**, ... & Thuras, P. (2017). D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders. *JAMA Psychiatry*, *75*, 501-510. doi:10.1001/jamapsychiatry.2016.3955
157. **McCaslin, S. E.** (2016). A common mission: Ensuring optimal behavioral health care for veterans and their families. *The California Psychologist*, *49*, 20-25. Retrieved from <http://www.cpapsych.org/?page=CPv49n4>
158. McCormick, W. H., Carroll, T. D., Slagel, B. A., **Drescher, K.**, Nieuwsma, J., & Currier, J. M. (2017). Professional quality of life and changes in spirituality among VHA chaplains: A mixed methods investigation. *Journal of Healthcare Chaplaincy*, *23*, 113-129. doi:10.1080/08854726.2017.1295675
159. **McLean, C. P.**, Gay, N. G., Metzger, D. A., Foa, E. B., & Penn Mental Health AIDS Research Center (2017). Psychiatric symptoms and barriers to care in HIV-infected individuals who are lost to care. *Journal of the International Association of Providers of AIDS Care*, *16*, 423-429. doi:10.1177/2325957417711254
160. Meis, L., Erbes, C., Kramer, M., Arbisi, P., **Kehle-Forbes, S.**, DeGarmo, D., Shallcross, S., & Polusny, M. (2017). Using reinforcement sensitivity to understand longitudinal links between PTSD and relationship adjustment. *Journal of Family Psychology*, *31*, 71-81. doi:10.1037/fam0000195

Appendix C: Fiscal Year 2017 Publications

161. Meredith, L. S., Azhar, G., Okunogbe, A., Canelo, I., Darling, J., & **Street, A. E.** (2017). Primary care providers with more experience and stronger self-efficacy beliefs regarding women veterans screen more frequently for interpersonal violence. *Women's Health Issues, 27*, 586-591. doi:10.1016/j.whi.2017.06.003
162. Meshberg-Cohen, S., **Kachadourian, L.**, Black, A. C., & Rosen, M. I. (2017). Relationship between substance use and attitudes towards seeking professional psychological help among veterans filing PTSD claims. *Addictive Behaviors, 74*, 9-12. doi:10.1016/j.addbeh.2017.05.024
163. Miles, S., **Harik, J. M.**, Hundt, N. E., Mignogna, J., Pastorek, N., Thompson, K. E., Freshour, J., Yu, H., & Cully, J. (2017). Delivery of mental health treatment to combat veterans with psychiatric diagnoses and TBI histories. *PLOS ONE, 12*, e0184265. doi:10.1371/journal.pone.0184265
164. **Miller, D. R., Hayes, J. P., Lafleche, G., Salat, D.,** & Verfaellie, M. (2016). White matter abnormalities are associated with overall cognitive status in blast-related mTBI. *Brain Imaging and Behavior, 37*, 220-229. doi:10.1007/s11682-016-9593-7
165. **Miller, D. R., Hayes, S., Hayes, J. P., Spielberg, J., Lafleche, G.,** & Verfaellie, M. (2017). Default mode network subsystems are differentially disrupted in posttraumatic stress disorder. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2*, 363-371. doi:10.1016/j.bpsc.2016.12.006
166. **Miller, D. R., Logue, M. W., Wolf, E. J., Maniates, H., Robinson, M. E., Hayes, J. P., Stone, A., Schichman, S., McGlinchey, R. E., Milberg, W. P., & Miller, M. W.** (2017). Posttraumatic stress disorder symptom severity is associated with reduced default mode network connectivity in individuals with elevated genetic risk for psychopathology. *Depression and Anxiety, 34*, 632-640. doi:10.1002/da.22633
167. **Mitchell, K. S., Wolf, E. J., Bovin, M. J., Lee, L., Green, J. D., Rosen, R., Keane, T. M., & Marx, B. P.** (2017). Network models of DSM-5 posttraumatic stress disorder: Implications for ICD-11. *Journal of Abnormal Psychology, 126*, 355-365. doi:10.1037/abn0000252
168. Monin, J. K., **Mota, N., Pachankis, J., & Pietrzak, R. H.** (2017). Older age associated with mental health resiliency in sexual minority U.S. veterans. *American Journal of Geriatric Psychiatry, 25*, 81-90. doi:10.1016/j.jagp.2016.09.006
169. Montalvo-Ortiz, J., Bordner, K., Carlyle, B., **Gelernter, J., Simen, A., & Kaufman, J.** (2016). The role of genes involved in stress, neural plasticity, and brain circuitry in depressive phenotypes: Convergent findings in a mouse model of neglect. *Behavioural Brain Research, 315*, 71-74. doi:10.1016/j.bbr.2016.08.010
170. Moore, R., Kaufmann, C., Rooney, A., Moore, D., Marder, S. R., Granholm, E., Woods, S., Swendsen, J., Heaton, R., **Scott, J. C.,** & Depp, C. (2017). Feasibility and acceptability of ecological momentary assessment of daily functioning among older adults with HIV. *The American Journal of Geriatric Psychiatry, 25*, 829-840. doi:10.1016/j.jagp.2016.11.019
171. **Morland, L. A., Greene, C. J., Rosen, C. S., Kuhn, E. R., Hoffman, J., & Sloan, D. M.** (2017). Telehealth and eHealth interventions for posttraumatic stress disorder. *Current Opinion in Psychology, 14*, 102-108. doi:10.1016/j.copsy.2016.12.003
172. Mukamal, K. J., Clowry, C. M., Murray, M. M., Hendriks, H. F., Rimm, E. B., Sink, K. M., Adebamowo, C. A., Dragsted, L. O., Lapinski, P. S., Lazo, M., & **Krystal, J. H.** (2016). Moderate alcohol consumption and chronic disease: The case for a long-term trial. *Alcoholism: Clinical and Experimental Research, 40*, 2283-2291. doi:10.1111/acer.13231
173. Murdoch, M., **Kehle-Forbes, S.,** & Partin, M. (2017). Changes in affect after completing a mailed survey about trauma: Two pre- and post-test studies in former disability applicants for posttraumatic stress disorder. *BMC Medical Research Methodology, 17*, 1-9. doi:10.1186/s12874-017-0357-x
174. Murdoch, M., **Spoont, M., Kehle-Forbes, S., Harwood, E. A., Sayer, N. A., Clothier, B. A., & Bangertter, A. K.** (2017). Persistent serious mental illness and outcomes among former applicants for VA PTSD disability benefits: Symptoms, functioning, and employment. *Journal of Traumatic Stress, 30*, 36-44. doi:10.1002/jts.22162
175. Nickerson, A., **Cloitre, M., Bryant, R., Schnyder, U., Morina, N., & Schick, M.** (2017). Response to the letter to the editor regarding 'The factor structure of complex posttraumatic stress disorder in traumatized refugees'. *European Journal of Psychotraumatology, 8*. doi:10.1080/20008198.2017.1308200
176. **Niles, B. L., Mori, D., Polizzi, C., Pless Kaiser, A., Ledoux, A., & Wang, C.** (2016). Feasibility, qualitative findings and satisfaction of a brief Tai Chi mind-body programme for veterans with post-traumatic stress symptoms. *BMJ Open, 6*. doi:10.1136/bmjopen-2016-012464
177. **Nilini, Y. I., Pineles, S. L., Rohan, K. J., Zvolensky, M. J., & Rasmussen, A. M.** (2017). The influence of menstrual cycle on reactivity to a CO2 challenge among women with and without premenstrual symptoms. *Cognitive Behaviour Therapy, 46*, 239-249. doi:10.1080/16506073.2016.1236286
178. Nixon, R., & **Sloan, D. M.** (2017). Treating PTSD: Innovations and understanding processes of change [Special Series]. *Behavior Therapy, 48*, 143-146. doi:10.1016/j.beth.2016.06.003
179. **Norman, S. B., & Hamblen, J. L.** (2017). Promising directions for treating comorbid PTSD and substance use disorder. *Alcoholism: Clinical and Experimental Research, 41*, 708-710. doi:10.1111/acer.13349
180. **Onoye, J. M., Spoont, M., Whealin, J., Pole, N., Mackintosh, M. A., Spira, J. L., & Morland, L. A.** (2017). Improving assessment of race, ethnicity, and culture to further veteran PTSD research. *Psychological Trauma: Theory, Research, Practice, and Policy, 9*, 222-229. doi:10.1037/tra0000181
181. Orazem, R., Frazier, P., **Schnurr, P. P., Oleson, H., Carlson, K., Litz, B., & Sayer, N.** (2016). Identity adjustment among Afghanistan and Iraq War veterans with reintegration difficulty. *Psychological Trauma: Theory, Research, Practice, and Policy, 9*(Suppl. 1), 4-11. doi:10.1037/tra0000225
182. Pantalone, D. W., Valentine, S. E., & **Shipherd, J. C.** (2017). Working with survivors of trauma in the sexual minority and transgender/gender nonconforming populations. In K. DeBord, T. Perez, A. Fischer, & K. Bieschke (Eds.), *The handbook of sexual orientation and gender diversity in counseling and psychotherapy* (pp. 183-211). Washington, DC: American Psychological Association Press. doi:10.1037/15959-008
183. **Pietrzak, R. H., Pitts, B., Harpaz-Rotem, I., Southwick, S. M., & Whealin, J.** (2017). Factors protecting against the development of suicidal ideation in military veterans. *World Psychiatry, 16*, 326-327. doi:10.1002/wps.20467

Appendix C: Fiscal Year 2017 Publications

184. **Pietrzak, R. H.,** Zhu, Y., Slade, M., Qi, Q., **Krystal, J. H., Southwick, S. M.,** & Levy, B. R. (2016). Association between negative age stereotypes and accelerated cellular aging: Evidence from two cohorts of older adults. *Journal of American Geriatrics Society, 64*, e228-e230. doi:10.1111/jgs.14452
185. **Pineles, S. L., Arditte Hall, K., & Rasmusson, A. M.** (2017). Gender and PTSD: Different pathways to a similar phenotype. *Current Opinion in Psychology, 14*, 44-48. doi:10.1016/j.copsyc.2016.11.002
186. Pittenger, C., Gruner, P., **Adams, T., & Kelmendi, B.** (2017). The dynamics of obsessive-compulsive disorder: A heuristic framework. In C. Pittenger (Ed.), *Obsessive-compulsive disorder: Phenomenology, pathophysiology, and treatment* (pp. 669-882). New York, NY: Oxford University Press.
187. **Pless Kaiser, A.,** Kabat, D., **Spiro, A., Davison, E.,** & Stellman, J. (2017). Women at war: The crucible of Vietnam. *SSM - Population Health, 3*, 236-244. doi:10.1016/j.ssmph.2017.01.003
188. **Pless Kaiser, A.,** Wang, J., **Davison, E.,** Park, C. L., & Stellman, J. M. (2017). Stressful and positive experiences of women who served in Vietnam. *Journal of Women & Aging, 29*, 26-38. doi:10.1080/08952841.2015.1019812
189. Polimanti, R., Chen, C., Ursano, R., Heeringa, S., Jain, S., Kessler, R., Nock, M., Smoller, J., Sun, X., **Gelernter, J.,** & Stein, M. (2017). Cross-phenotype polygenic risk score analysis of persistent post-concussive symptoms in U.S. Army Soldiers with deployment-acquired traumatic brain injury. *Journal of Neurotrauma, 34*, 781-789. doi:10.1089/neu.2016.4550
190. Polimanti, R., Kranzler, H., & **Gelernter, J.** (2016). Phenome-wide association study for alcohol and nicotine risk alleles in 26394 women. *Neuropsychopharmacology, 41*, 2688-2696. doi:10.1038/npp.2016.72
191. Polimanti, R., Meda, S. A., Pearson, G. D., Zhao, H., Sherva, R., Farrer, L. A., Kranzler, H. R., & **Gelernter, J.** (2017). S100A10 identified in a genome-wide gene x cannabis dependence interaction analysis of risky sexual behaviours. *Journal of Psychiatry Neuroscience, 42*, 252-261. doi:10.1503/jpn.160189
192. Polimanti, R., Wang, Q., Meda, S., Patel, K., Pearson, G., Zhao, H., Farrer, L., Kranzler, H., & **Gelernter, J.** (2016). The interplay between risky sexual behaviors and alcohol dependence: Genome-wide association and neuroimaging support for LHPP as a risk gene. *Neuropsychopharmacology, 42*, 598-605. doi:10.1038/npp.2016.153
193. Possemato, K., **Kuhn, E. R.,** Johnson, E., Hoffman, J., & Brooks, E. (2017). Development and refinement of a clinician intervention to facilitate primary care patient use of the PTSD Coach app. *Translational Behavioral Medicine, 7*, 116-126. doi:10.1007/s13142-016-0393-9
194. Powers, A., Mathys, C., & **Corlett, P.** (2017). Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. *Science, 357*, 596-600. doi:10.1126/science.aan3458
195. **Prins, A., Bovin, M. J.,** Smolenski, D. J., **Marx, B. P., Kimerling, R.,** Jenkins-Guarnieri, M. A., **Kaloupek, D. G., Schnurr, P. P., Pless Kaiser, A., Leyva, Y. E., & Tiet, Q. Q.** (2016). The Primary Care PTSD screen for DSM-5 (PC-PTSD-5): Development and evaluation within a veteran primary care sample. *Journal of General Internal Medicine, 31*, 1206-1211. doi:10.1007/s11606-016-3703-5
196. Pyne, J. M., Constans, J., Wiederhold, M. D., Gibson, D. P., Kimbrell, T., Kramer, T. L., Pitcock, J. A., Han, X., Williams, D. K., Chartrand, D., Gevirtz, R. N., **Spira, J. L.,** Wiederhold, B. K., McCraty, R., & McCune, T. R. (2016). Heart rate variability: Pre-deployment predictor of post-deployment PTSD symptoms. *Biological Psychology, 121*, 91-98. doi:10.1016/j.biopsycho.2016.10.008
197. Raffa, S., Maciejewski, M., **Zimmerman, L. E.,** Damschroder, L., Estabrooks, P., Ackermann, R., Tsai, A., Histon, T., & Goldstein, M. (2017). A system-level approach to overweight and obesity in the Veterans Health Administration. *Journal of General Internal Medicine, 32*, 79-82. doi:10.1007/s11606-016-3948-z
198. **Rasmusson, A. M.** (2017). The gut peptide neuropeptide Y and post-traumatic stress disorder. *Current Opinion in Endocrinology, Diabetes, and Obesity, 24*, 3-8. doi:10.1097/MED.0000000000000301
199. **Rasmusson, A. M.,** Marx, C., **Pineles, S. L.,** Locci, A., **Scioli-Salter, E. R., Nillni, Y. I.,** Liang, J., & Pinna, G. (2017). Neuroactive steroids and PTSD treatment. *Neuroscience Letters, 649*, 156-163. doi:10.1016/j.neulet.2017.01.054
200. Ratanatharathorn, A., Boks, M., Maihofer, A., Aiello, A., Amstadter, A., Ashley-Koch, A., Baker, D. G., Beckham, J., Bromet, E., Dennis, M., Garrett, M., Geuze, E., Guffanti, G., Hauser, M., Kilaru, V., Kimbrel, N. A., Koenen, K., Kuan, P., **Logue, M. W.,** Luft, B., **Miller, M. W.,** Mitchell, C., Nugent, N., Ressler, K., Rutten, B., Stein, M., Vermetten, E., Vinkers, C., Youssef, N., Uddin, M., Nievergelt, C., & Smith, A. (2017). Epigenome-wide association of PTSD from heterogeneous cohorts with a common multi-site analysis pipeline. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 174*, 619-630. doi:10.1002/ajmg.b.32568
201. Resick, P. A., **Wachen, J. S.,** Dondanville, K. A., Pruiksma, K. E., Yarvis, J. S., Mintz, J., Peterson, A. L., & STRONG STAR Consortium (2017). Effect of group vs. individual Cognitive Processing Therapy in active-duty military seeking treatment for posttraumatic stress disorder: A randomized clinical trial. *JAMA Psychiatry, 74*, 28-36. doi:10.1001/jamapsychiatry.2016.2729
202. Riblet, N., **Shiner, B.,** Mills, P., Rusch, B., Hemphill, R., & Watts, B. (2017). Systematic and organizational issues implicated in post-hospitalization suicides of medically hospitalized patients: A study of root-cause analysis reports. *General Hospital Psychiatry, 46*, 68-73. doi:10.1016/j.genhosppsych.2017.03.009
203. Riblet, N., **Shiner, B.,** Watts, B., Mills, P., Rusch, B., & Hemphill, R. (2017). Death by suicide within 1 week of hospital discharge. *The Journal of Nervous and Mental Disease, 205*, 436-442. doi:10.1097/NMD.0000000000000687
204. Riblet, N., **Shiner, B.,** Young-Xu, Y., & Watts, B. (2017). Strategies to prevent death by suicide: meta-analysis of randomised controlled trials. *The British Journal of Psychiatry, 210*, 396-402. doi:10.1192/bjpp.116.187799
205. Rosellini, A., **Street, A. E.,** Ursano, R., Chiu, W., Heeringa, S., Monahan, J., Naifeh, J., Petukhova, M., Reis, B., Sampson, N., Bliese, P., Stein, M., Zaslavsky, A., & Kessler, R. (2017). Sexual assault victimization and mental health treatment, suicide attempts, and career outcomes among women in the U.S. Army. *American Journal of Public Health, 107*, 732-739. doi:10.2105/AJPH.2017.303693

Appendix C: Fiscal Year 2017 Publications

206. **Rosen, C. S., Azevedo, K. J., Tiet, Q. Q.,** Greene, C. J., Wood, A. E., Calhoun, P., Bowe, T., Capehart, B. P., Crawford, E., **Greenbaum, M. A.,** Harris, A. H. S., Hertzberg, M., Lindley, S. E., **Smith, B. N., & Schnurr, P. P.** (2017). An RCT of effects of telephone care management on treatment adherence and clinical outcomes among veterans with PTSD. *Psychiatric Services, 68*, 151-158. doi:10.1176/appi.ps.201600069
207. **Rosen, C. S., Eftekhari, A., Crowley, J. J., Smith, B. N., Kuhn, E. R., Trent, L., Martin, N. B., Tran, C. T., & Ruzek, J. I.** (2017). Maintenance and reach of exposure psychotherapy for posttraumatic stress disorder 18 months after training. *Journal of Traumatic Stress, 30*, 63-70. doi:10.1002/jts.22153
208. **Rosen, C. S.,** Matthieu, M. M., **Wiltsey-Stirman, S., Cook, J., Landes, S. J., Bernardy, N. C.,** Chard, K. M., **Crowley, J. J., Eftekhari, A.,** Finley, E. P., **Hamblen, J. L., Harik, J. M., Kehle-Forbes, S.,** Meis, L. A., Osei-Bonsu, P. E., **Rodriguez, A.,** Ruggiero, K. J., **Ruzek, J. I., Smith, B. N., Trent, L., & Watts, B. V.** (2016). A review of studies on the system-wide implementation of evidence-based psychotherapies for posttraumatic stress disorder in the Veterans Health Administration. *Administration and Policy in Mental Health and Mental Health Services Research, 43*, 957-977. doi:10.1007/s10488-016-0755-0
209. Rosen, R. C., **Ruzek, J. I., & Karlin, B. E.** (2017). Evidence-based training in the era of evidence-based practice: Challenges and opportunities for training of PTSD providers. *Behaviour Research and Therapy, 88*, 37-48. doi:10.1016/j.brat.2016.07.009
210. Rungnirundorn, T., Verachai, V., **Gelernter, J.,** Malison, R., & Kalayasiri, R. (2017). Sex differences in methamphetamine use and dependence in a Thai treatment center. *Journal of Addiction Medicine, 11*, 19-27. doi:10.1097/ADM.0000000000000262
211. **Ruzek, J. I., & Yeager, C. M.** (2017). Internet and phone technologies: Addressing the mental health of trauma survivors in less resourced communities. *Global Mental Health, 4*. doi:10.1017/gmh.2017.11
212. **Ruzek, J. I., Eftekhari, A., Crowley, J. J., Kuhn, E. R.,** Karlin, B. E., & **Rosen, C. S.** (2017). Post-training beliefs, intentions, and use of Prolonged Exposure therapy by clinicians in the Veterans Health Administration. *Administration and Policy in Mental Health and Mental Health Services Research, 44*, 123-132. doi:10.1007/s10488-015-0689-y
213. **Sanacora, G.,** Heimer, H., Hartman, D., Mathew, S., Frye, M., Nemeroff, C., & Beale, R. (2017). Balancing the promise and risks of ketamine treatment for mood disorders. *Neuropsychopharmacology, 42*, 1179-1181. doi:10.1038/npp.2016.193
214. Sauer-Zavala, S., **Gutner, C. A.,** Farchione, T. J., Boettcher, H. T., Bullis, J. R., & Barlow, D. H. (2017). Current definitions of "transdiagnostic" in treatment development: A search for consensus. *Behavior Therapy, 48*, 128-138. doi:10.1016/j.beth.2016.09.004
215. **Schnurr, P. P.** (2017). Focusing on trauma-focused psychotherapy for posttraumatic stress disorder. *Current Opinion in Psychology, 14*, 56-60. doi:10.1016/j.copsyc.2016.11.005
216. **Schnurr, P. P.** (2017). Physical health and health services utilization. In S. Gold (Ed.), *APA handbook of trauma psychology: Foundations in knowledge* (pp. 349-370). Washington, DC: American Psychological Association Press.
217. Sharma, V., Marin, D., Koenig, H., Feder, A., Iacoviello, B., **Southwick, S. M., & Pietrzak, R. H.** (2017). Religion, spirituality, and mental health of U.S. military veterans: Results from the National Health and Resilience in Veterans Study. *Journal of Affective Disorders, 217*, 197-204. doi:10.1016/j.jad.2017.03.071
218. Shaw, J. G., Asch, S. M., Katon, J. G., Shaw, K. A., **Kimerling, R.,** Frayne, S. M., & Phibbs, C. S. (2017). Post-traumatic stress disorder and antepartum complications: A novel risk factor for gestational diabetes and preeclampsia. *Paediatric and Perinatal Epidemiology, 31*, 185-194. doi:10.1111/ppe.12349
219. Shevlin, M., Hyland, P., Karatzias, T., Fyvie, C., Roberts, N., Bisson, J. I., Brewin, C. R., & **Cloitre, M.** (2017). Alternative models of disorders of traumatic stress based on the new ICD-11 proposals. *Acta Psychiatrica Scandinavica, 135*, 419-428. doi:10.1111/acps.12695
220. **Shiner, B.,** Westgate, C. L., **Bernardy, N. C., Schnurr, P. P., & Watts, B. V.** (2017). Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. *Journal of Dual Diagnosis, 13*, 201-212. doi:10.1080/015504263.2017.1325033
221. **Shiner, B.,** Westgate, C., **Bernardy, N. C., Schnurr, P. P., & Watts, B. V.** (2017). Anticonvulsant medication use in veterans with posttraumatic stress disorder. *Journal of Clinical Psychiatry, 78*, e545-e552. doi:10.4088/JCP.16m11031
222. **Shiner, B.,** Westgate, C., **Harik, J. M.,** Watts, B. V., & **Schnurr, P. P.** (2017). Effect of patient-therapist gender match on psychotherapy retention among United States veterans with posttraumatic stress disorder. *Administration and Policy in Mental Health and Mental Health Services Research, 44*, 642-650. doi:10.1007/s10488-016-0761-2
223. **Sippel, L. M.,** Allington, C., **Pietrzak, R. H., Harpaz-Rotem, I.,** Mayes, L., & Olf, M. (2017). Oxytocin and stress-related disorders: Neurobiological mechanisms and treatment opportunities. *Chronic Stress, 1*. doi:10.1177/2470547016687996
224. Slifstein, M., **Krystal, J. H., & Abi-Dargham, A.** (2017). Radiotracer imaging with positron emission tomography and single photon emission computed tomography: Fundamental principles, methodology, and role in neuropsychiatric research. In B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), *Kaplan & Sadock's comprehensive textbook of psychiatry* (10th ed., pp. 285-303). Philadelphia, PA: Lippincott Williams & Wilkins.
225. **Sloan, D. M., & Marx, B. P.** (2017). On the implementation of Written Exposure Therapy (WET) with veterans diagnosed with PTSD. *Pragmatic Case Studies in Psychotherapy, 13*, 154-164. doi:10.14713/pcsp.v13i2.2005
226. **Sloan, D. M.,** Beck, J. G., & **Sawyer, A. T.** (2017). Trauma-focused group therapy. In S. Gold (Ed.), *APA handbook of trauma psychology: Trauma practice* (pp. 467-482). Washington, DC: American Psychological Association Press.
227. Smith, A. H., Jensen, K. P., Li, J., Nunez, Y., Farrer, L. A., Hakonarson, H., Cook-Sather, S. D., Kranzler, H. R., & **Gelernter, J.** (2017). Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. *Molecular Psychiatry, 22*, 346-352. doi:10.1038/mp.2016.257
228. **Smith, B. N., Taverna, E., Fox, A. B., Schnurr, P. P., Matteo, R., & Vogt, D.** (2017). The role of PTSD, depression, and alcohol misuse symptom severity in linking deployment stressor exposure and post-military work and family outcomes in male and female veterans. *Clinical Psychological Science, 5*, 664-682. doi:10.1177/2167702617705672

Appendix C: Fiscal Year 2017 Publications

229. **Smith, B. N.,** Wang, J. M., Vaughn-Coaxum, R. A., Di Leone, B.A.L., & **Vogt, D.** (2017). The role of postdeployment social factors in linking deployment experiences and current PTSD symptomatology among male and female veterans. *Anxiety, Stress, & Coping, 30*, 39-51. doi:10.1080/10615806.2016.1188201
230. **Smith, N., Doran, J., Sippel, L. M., & Harpaz-Rotem, I.** (2017). Fear extinction and memory reconsolidation as critical components in behavioral treatment for posttraumatic stress disorder and potential augmentation of these processes. *Neuroscience Letters, 649*, 170-175. doi:10.1016/j.neulet.2017.01.006
231. Sonis, J., **Suvak, M., & Schnurr, P. P.** (2017). Empirical study of trauma: Methodological and statistical considerations. In S. Gold (Ed.), *APA handbook of trauma psychology: Foundations in knowledge* (pp. 35-61). Washington, DC: American Psychological Association Press.
232. **Southwick, S. M., Satodiya, R., & Pietrzak, R. H.** (2016). Disaster mental health and positive psychology: An afterword to the special issue. *Journal of Clinical Psychology, 72*, 1364-1368. doi:10.1002/jclp.22418
233. Spielberg, J., **Samimi Sadeh, N.,** Leritz, E., McGlinchey, R., Milberg, W., **Hayes, J. P., & Salat, D.** (2017). Higher serum cholesterol is associated with intensified age-related neural network decoupling and cognitive decline in early- to mid-life. *Human Brain Mapping, 38*, 3249-3261. doi:10.1002/hbm.23587
234. **Spoont, M.,** Nelson, D., van Ryn, M., & Alegria, M. (2017). Racial and ethnic variation in perceptions of VA mental health providers are associated with treatment retention among veterans with PTSD. *Medical Care, 55*, S33-S42. doi:10.1097/MLR.0000000000000755
235. **Spoont, M.,** Sayer, N., **Kehle-Forbes, S.,** Meis, L., & Nelson, D. (2017). A prospective study of racial and ethnic variation in VA psychotherapy services for PTSD. *Psychiatric Services, 63*, 231-237. doi:10.1176/appi.ps.201600086
236. Stein, M. B., Campbell-Sills, L., **Gelernter, J.,** He, F., Heeringa, S. G., Nock, M. J., Sampson, N. A., Sun, X., Jain, S., & Kessler, R. C. (2017). Alcohol misuse and co-occurring mental disorders among new soldiers in the U.S. Army. *Alcoholism: Clinical and Experimental Research, 41*, 139-148. doi:10.1111/acer.13269
237. Stein, M., Chen, C., Jain, S., Jensen, K., He, F., Heeringa, S., Kessler, R., Maihofer, A., Nock, M., Ripke, S., Sun, X., Thomas, M., Ursano, R., Smoller, J., & **Gelernter, J.** (2017). Genetic risk variants for social anxiety. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 174*, 120-131. doi:10.1002/ajmg.b.32520
238. Steine, I., Winje, D., **Krystal, J. H.,** Bjorvatn, B., Milde, A., Grønli, J., Nordhus, I., & Pallesen, S. (2017). Cumulative childhood maltreatment and its dose-response relation with adult symptomatology: Findings in a sample of adult survivors of sexual abuse. *Child Abuse & Neglect, 65*, 99-111. doi:10.1016/j.chiabu.2017.01.008
239. Steine, I., Zayats, T., Stansberg, C., Pallesen, S., Mrdalj, J., Håvik, B., Soule, J., Haavik, J., Milde, A., Skrede, S., Murison, R., **Krystal, J. H., & Grønli, J.** (2016). Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims. *Translational Psychiatry, 6*, e977. doi:10.1038/tp.2016.248
240. Sterneke, L., Serpi, T., **Spiro, A., Kimerling, R.,** Kilbourne, A., Cypel, Y., Frayne, S., Furey, J., Huang, G., Reinhard, M., & Magruder, K. (2017). Assessment of a revised Wartime Experiences Scale for Vietnam-era women: The Health of Vietnam-Era Women's Study (HealthViEWS). *Women's Health Issues, 27*, 471-477. doi:10.1016/j.whi.2017.03.006
241. **Street, A. E.,** Rosellini, A. J., Ursano, R. J., Heeringa, S. G., Hill, E. D., Monahan, J., Naifeh, J., Petukhova, M. V., Reis, B. Y., Sampson, N. A., Bliese, P. D., Stein, M. B., Zaslavsky, A. M., & Kessler, R. C. (2016). Developing a risk model to target high-risk preventive interventions for sexual assault victimization among female U.S. Army soldiers. *Clinical Psychological Science, 4*, 939-956. doi:10.1177/2167702616639532
242. Sumner, J. A., Duncan, L. E., **Wolf, E. J.,** Amstadter, A. B., Baker, D. G., Beckham, J., Gelaye, B., Hemmings, S., Kimbrel, N. A., **Logue, M. W.,** Michopoulos, V., **Mitchell, K. S.,** Nievergelt, C., Rothbaum, A., Seedat, S., Shinzaki, G., & Vermetten, E. (2017). Letter to the editor: Posttraumatic stress disorder has genetic overlap with cardiometabolic traits. *Psychological Medicine, 47*, 2036-2039. doi:10.1017/S0033291717000733
243. Szafranski, D., **Smith, B. N.,** Gros, D., & **Resick, P.** (2017). High rates of PTSD treatment dropout: A possible red herring? *Journal of Anxiety Disorders, 47*, 91-98. doi:10.1016/j.janxdis.2017.01.002
244. **Taft, C. T.,** Creech, S. K., & Murphy, C. (2017). Anger and aggression in PTSD. *Current Opinion in Psychology, 14*, 67-71. doi:10.1016/j.copsyc.2016.11.008
245. **Taft, C. T.,** Creech, S. K., **Gallagher, M. W., Macdonald, A.,** Murphy, C., & Monson, C. (2016). Strength at Home couples program to prevent military partner violence: A randomized controlled trial. *Journal of Consulting and Clinical Psychology, 84*, 935-945. doi:10.1037/ccp0000129
246. Taylor, M., **Petrakis, I., & Ralevski, E.** (2017). Treatment of alcohol use disorder and co-occurring PTSD. *The American Journal of Drug and Alcohol Abuse, 43*, 391-401. doi:10.1080/00952990.2016.1263641
247. Thapa, M., **Petrakis, I., & Ralevski, E.** (2017). A comparison of antidepressants with/without naltrexone on sexual side effects. *Journal of Dual Diagnosis, 13*, 230-235. doi:10.1080/15504263.2017.1326650
248. Thomas, M., **Harpaz-Rotem, I.,** Tsai, J., **Southwick, S. M., & Pietrzak, R. H.** (2017). Mental and physical health conditions in U.S. combat veterans: Results from the National Health and Resilience in Veterans Study. *Primary Care Companion for CNS Disorders, 19*. doi:10.4088/PCC.17m02118
249. **Thompson-Hollands, J., Jun, J. J., & Sloan, D. M.** (2017). The association between peritraumatic dissociation and PTSD symptoms: The mediating role of negative beliefs about the self. *Journal of Traumatic Stress, 30*, 190-194. doi:10.1002/jts.22179
250. Totah, N., Akil, H., Huys, Q. J. M., **Krystal, J. H., MacDonald, A.,** Maia, T. V., Malenka, R. C., & Pauli, W. M. (2016). Complexity and heterogeneity in psychiatric disorders: Opportunities for computational psychiatry. In A. D. Redish & J. A. Gordon (Eds.), *Computational psychiatry: New perspectives on mental illness* (pp. 33-60). Cambridge, MA: MIT Press.
251. Tsai, J., **Harpaz-Rotem, I., Pietrzak, R. H., & Southwick, S. M.** (2017). Trauma resiliency and posttraumatic growth. In S. Gold (Ed.), *APA handbook of trauma psychology: Trauma practice* (pp. 89-113). Washington, DC: American Psychological Association. doi:10.1037/0000020-005

Appendix C: Fiscal Year 2017 Publications

252. Tsai, J., Hoff, R., & **Harpaz-Rotem, I.** (2017). One-year incidence and predictors of homelessness among 300,000 U.S. veterans referred to specialty mental health care. *Psychological Service, 14*, 203-207. doi:10.1037/ser0000083
253. Tsai, J., **Pietrzak, R. H., Cook, J., Hoff, R., Harpaz-Rotem, I., & Smith, N.** (2017). Differential predictive value of PTSD symptom clusters for mental health care among Iraq and Afghanistan veterans following PTSD diagnosis. *Psychiatry Research, 256*, 32-39. doi:10.1016/j.psychres.2017.06.005
254. **Vasterling, J. J., Aslan, M., Proctor, S., Ko, J., Marx, B. P., Jakupcak, M., Schnurr, P. P., Gleason, T., Huang, G., & Concato, J.** (2016). Longitudinal examination of posttraumatic stress disorder as a long-term outcome of Iraq War deployment. *American Journal of Epidemiology, 184*, 796-805. doi:10.1093/aje/kww151
255. **Vogt, D., Erbes, C., & Polusny, M.** (2017). Role of social context in posttraumatic stress disorder (PTSD). *Current Opinion in Psychology, 14*, 138-142. doi:10.1016/j.copsyc.2017.01.006
256. **Vogt, D., Smith, B. N., Fox, A. B., Amoroso, T., Taverna, E., & Schnurr, P. P.** (2017). Consequences of PTSD for the work and family quality of life of female and male U.S. Afghanistan and Iraq War veterans. *Social Psychiatry and Psychiatric Epidemiology, 52*, 341-352. doi:10.1007/s00127-016-1321-5
257. Vujanovic, A., & **Schnurr, P. P.** (2017). Editorial overview: Advances in science and practice in traumatic stress. *Current Opinion in Psychology, 14*, iv-viii. doi:10.1016/j.copsyc.2017.03.004
258. **Wachen, J. S.** (2017). Cognitive Processing Therapy. In A. Wenzel (Ed.), *SAGE encyclopedia of abnormal and clinical psychology* (p. 760-763). Thousand Oaks, CA: Sage.
259. **Wachen, J. S., Dondanville, K. A., Macdonald, A., & Resick, P. A.** (2017). Cognitive therapy. In S. Gold (Ed.), *APA handbook of trauma psychology: Trauma practice* (pp. 143-168). Washington, DC: American Psychological Association Press.
260. **Walser, R. D., Sears, K., Chartier, M., & Karlin, B.** (2016). *Acceptance and Commitment Therapy (ACT) for depressed veterans: Therapist manual*. Washington, DC: U.S. Department of Veterans Affairs.
261. **Watkins, L. E., Harpaz-Rotem, I., Sippel, L. M., Krystal, J. H., Southwick, S. M., & Pietrzak, R. H.** (2016). Hostility and telomere shortening among U.S. military veterans: Results from the National Health and Resilience in Veterans Study. *Psychoneuroendocrinology, 74*, 251-257. doi:10.1016/j.psychneuen.2016.09.006
262. **Watkins, L. E., Sippel, L. M., Pietrzak, R. H., Hoff, R., & Harpaz-Rotem, I.** (2017). Co-occurring aggression and suicide attempt among veterans entering residential treatment for PTSD: The role of PTSD symptom clusters and alcohol misuse. *Journal of Psychiatric Research, 87*, 8-14. doi:10.1016/j.jpsychires.2016.12.009
263. **Watson, P., & Hamblen, J. L.** (2017). Natural disasters/ community trauma. In S. Gold (Ed.), *APA handbook of trauma psychology: Foundations in knowledge* (pp. 87-98). Washington, DC: American Psychological Association Press.
264. Webber, T. S., Liverant, G. I., **Jun, J. J., Lee, D. J., Dutra, S., Cohen, D., Pizzagalli, D. A., & Sloan, D. M.** (2016). Punishment learning in veterans with posttraumatic stress disorder. *Journal of Traumatic Stress, 29*, 374-378. doi:10.1002/jts.22109
265. Wilkinson, S., Toprak, M., Turner, M., Levine, S., Katz, R., & **Sanacora, G.** (2017). A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. *American Journal of Psychiatry, 174*, 695-696. doi:10.1176/appi.ajp.2017.17020239
266. Wilkinson, S., Wright, D., Fasula, M., Fenton, L., Griep, M., Ostroff, R., & **Sanacora, G.** (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. *Psychotherapy and Psychosomatics, 86*, 162-167. doi:10.1159/000457960
267. Williams, V., **Hayes, J. P., Forman, D., Salat, D., Sperling, R., Verfaellie, M., & Hayes, S.** (2017). Cardiorespiratory fitness is differentially associated with cortical thickness in young and older adults. *NeuroImage, 146*, 1084-1092. doi:10.1016/j.neuroimage.2016.10.033
268. **Wiltsey-Stirman, S., Finley, E., Shields, N., Cook, J., Haine-Schlagel, R., Burgess, J., Dimeff, L., Koerner, K., Suvak, M., Gutner, C. A., Gagnon, D., Masina, T., Beristianos, M., Mallard, K. N., Ramirez, V., & Monson, C.** (2017). Improving and sustaining delivery of CPT for PTSD in mental health systems: A cluster randomized trial. *Implementation Science, 12*, 32-42. doi:10.1186/s13012-017-0544-5
269. **Wiltsey-Stirman, S., Pontoski, K., Creed, T., Xhezo, R., Hurford, M., Evans, A. C., Beck, A. T., & Crits-Christoph, P.** (2017). A non-randomized comparison of strategies for consultation in a community-academic training program to implement an evidence-based psychotherapy. *Administration and Policy in Mental Health Services and Mental Health Services Research, 44*, 55-66. doi:10.1007/s10488-015-0700-7
270. Wisco, B., **Marx, B. P., Miller, M. W., Wolf, E. J., Krystal, J. H., Southwick, S. M., & Pietrzak, R. H.** (2017). A comparison of ICD-11 and DSM criteria for posttraumatic stress disorder in two national samples of U.S. military veterans. *Journal of Affective Disorders, 223*, 17-19. doi:10.1016/j.jad.2017.07.006
271. Wisco, B., **Marx, B. P., Miller, M. W., Wolf, E. J., Mota, N., Krystal, J. H., Southwick, S. M., & Pietrzak, R. H.** (2016). Probable posttraumatic stress disorder in the U.S. veteran population according to DSM-5: Results from the National Health and Resilience in Veterans Study. *The Journal of Clinical Psychiatry, 77*, 1503-1510. doi:10.4088/JCP.15m10188
272. Wohleb, E. S., Gerhard, D., Thomas, A., & **Duman, R.** (2017). Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. *Current Neuropharmacology, 15*, 11-20. Retrieved from <http://europepmc.org/abstract/med/26955968>
273. **Wolf, E. J.** (2016). PTSD and accelerated aging. *PTSD Research Quarterly, 27*(3).
274. **Wolf, E. J., Mitchell, K. S., Samimi Sadeh, N., Hein, C., Fuhrman, I., Pietrzak, R. H., & Miller, M. W.** (2017). The Dissociative Subtype of PTSD Scale (DSPS): Initial evaluation in a national sample of trauma-exposed veterans. *Assessment, 24*, 503-516. doi:10.1177/1073191115615212
275. Wood, A., **Prins, A., Bush, N., Hsia, J., Bourn, L., Earley, M., Walser, R. D., & Ruzek, J. I.** (2017). Reduction of burnout in mental health care providers using the Provider Resilience mobile application. *Community Mental Health Journal, 53*, 452-459. doi:10.1007/s10597-016-0076-5

Appendix C: Fiscal Year 2017 Publications

276. **Woodward, S. H.**, Michell, G., & Santerre, C. (2017). The psychophysiology of PTSD nightmares. In E. Vermetten, A. Germain, & T. C. Neylan (Eds.), *Sleep and combat-related posttraumatic stress disorder* (pp. 420-445). Cambridge, UK: Cambridge University Press.
277. **Wrocklage, K. M., Averill, L., Scott, J. C., Averill, C. L., Schweinsburg, B., Trejo, M., Roy, A., Weisser, V., Kelly, C., Martini, B., Harpaz-Rotem, I., Southwick, S. M., Krystal, J. H., & Abdallah, C.** (2017). Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD. *European Neuropsychopharmacology*, *27*, 515-525. doi:10.1016/j.euroneuro.2017.02.010
278. Yehuda, R., Spiegel, D., **Southwick, S. M.**, Davis, L., Neylan, T., & **Krystal, J. H.** (2016). What I have changed my mind about and why. *European Journal of Psychotraumatology*, *7*. doi:10.3402/ejpt.v7.33768
279. Zandberg, L., & **McLean, C. P.** (2017). Exposure therapy. In A. Wenzel (Ed.), *Sage encyclopedia of abnormal and clinical psychology* (pp. 1386-1389). New York, NY: Sage. doi:10.4135/9781483365817.n555
280. Zang, Y., Gallagher, T., **McLean, C. P.**, Tannahill, H. S., Yarvis, J. S., Foa, E. B., & STRONG STAR Consortium (2017). The impact of social support, unit cohesion, and trait resilience on PTSD in treatment-seeking military personnel with PTSD: The role of posttraumatic cognitions. *Journal of Psychiatric Research*, *86*, 18-25. doi:10.1016/j.jpsychires.2016.11.005
281. **Zimmerman, L. E., Lounsbury, D., Rosen, C. S., Kimerling, R., Trafton, J., & Lindley, S.** (2016). Participatory system dynamics modeling: Increasing stakeholder engagement and precision to improve implementation planning in systems. *Administration and Policy in Mental Health and Mental Health Services Research*, *43*, 834-849. doi:10.1007/s10488-016-0754-1
282. Zisman-Ilani, Y., Barnett, E., **Harik, J. M.**, Pavlo, A., & O'Connell, M. (2017). Expanding the concept of shared decision making for mental health: Systematic search and scoping review of interventions. *Mental Health Review Journal*, *22*, 191-213. doi:10.1108/MHRJ-01-2017-0002

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

1. **Abdallah, C., Averill, C. L.,** Salas, R., **Averill, L.,** Baldwin, P., **Krystal, J. H.,** Mathew, S., & Mathalon, D. (2017). Prefrontal connectivity and glutamate transmission: Relevance to depression pathophysiology and ketamine treatment. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. Advance online publication. doi:10.1016/j.bpsc.2017.04.006
2. **Abdallah, C., Averill, L., Krystal, J. H., Southwick, S. M.,** & Arnsten A.F.T. (in press). Glutamate and norepinephrine interaction: Relevance to higher cognitive operations and psychopathology. *Behavioral and Brain Sciences*.
3. Allard, C. B., **Norman, S. B.,** Thorp, S. R., Browne, K. C., & Stein, M. B. (2016). Mid-treatment reduction in trauma-related guilt predicts PTSD and functioning following cognitive trauma therapy for survivors of intimate partner violence. *Journal of Interpersonal Violence*. Advance online publication. doi:10.1177/0886260516636068
4. Andersen, A., **Pietrzak, R. H.,** Kranzler, H., Ma, L., Zhou, H., Liu, X., Kramer, J., Kuperman, S., Edenberg, H., Nurnberger, J., Rice, J., Tischfield, J., Goate, A., Foroud, T., Meyers, J., Porjesz, B., Dick, D., Hesselbrock, V., Boerwinkle, E., **Southwick, S. M., Krystal, J. H.,** Weissman, M., Levinson, D., Potash, J., **Gelernter, J.,** & Han, S. (2017). Polygenic scores for major depressive disorder and risk of alcohol dependence. *JAMA Psychiatry*. Advance online publication. doi:10.1001/jamapsychiatry.2017.2269
5. **Arditte Hall, K.,** Bartlett, B., **Iverson, K. M., & Mitchell, K. S.** (2017). Eating disorder symptoms in female veterans: The role of childhood, adult, and military trauma exposure. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000301
6. **Arditte Hall, K.,** Bartlett, B., **Iverson, K. M., & Mitchell, K. S.** (2017). Military-related trauma is associated with eating disorder symptoms in male veterans. *International Journal of Eating Disorders*. Advance online publication. doi:10.1002/eat.22782
7. **Banducci, A. N., Bonn-Miller, M.,** Timko, C., & **Rosen, C. S.** (in press). Associations between residential treatment length, PTSD, and outpatient healthcare utilization among veterans. *Psychological Services*.
8. Baumann, A., Cabassa, L., & **Wiltsey-Stirman, S.** (in press). Adaptation in implementation science. In R. C. Brownsen, G. A. Golditz, & E. K. Proctor (Eds.), *Dissemination and implementation research in health: Translating science to practice: Second edition*. New York, NY: Oxford University Press.
9. Beagley, M. C., Peterson, Z. D., Strasshofer, D. R., & **Galovski, T. E.** (in press). Sex differences in PTSD and depression in police officers following exposure to violence in Ferguson: The moderating effect of empathy. *Policing: An International Journal of Police Strategies & Management*.
10. Bedard-Gilligan, M., Duax, J., Stines, L., Jaeger, J., **Eftekhari, A.,** Feeny, N., & Zoellner, L. (in press). Characteristics of individuals seeking treatment in a PTSD treatment trial: An investigation of depression, trauma history and severity. *Journal of Clinical Psychology*.
11. **Bell, M. E., Dardis, C., Vento, S., & Street, A. E.** (2017). Victims of sexual harassment and assault in the military: Understanding risks and promoting recovery. *Military Psychology*. Advance online publication. doi:10.1037/mil0000144
12. Bomyea, J., Lang, A. J., & **Schnurr, P. P.** (in press). TBI and treatment response in a randomized trial of Acceptance and Commitment Therapy. *Journal of Head Trauma Rehabilitation*.
13. **Bovin, M. J., Black, S. K.,** Rodriguez, P., **Lunney, C., Kleiman, S.,** Weathers, F. W., **Schnurr, P. P., Spira, J. L., Keane, T. M., & Marx, B. P.** (in press). Development and validation of a measure of PTSD-related functional impairment: The Inventory of Psychosocial Functioning. *Psychological Services*.
14. Brewin, C., **Cloitre, M.,** Hyland, P., Shevlin, M., Maercker, A., Bryant, R., Humayun, A., Jones, L., Kagee, A., Rousseau, C., Somasundaram, D., Suzuki, Y., Wessely, S., van Ommeren, M., & Reed, G. (2017). A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. *Clinical Psychology Review*. Advance online publication. doi:10.1016/j.cpr.2017.09.001
15. Brief, D., Solhan, M., Rybin, D., Enggasser, J., Rubin, A., Roy, M., **Helmuth, E.,** Schreiner, A., **Heilman, M.,** Vittorio, L., Rosenbloom, D., & **Keane, T. M.** (2017). Web-based alcohol intervention for veterans: PTSD, combat exposure, and alcohol outcomes. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000281
16. Buchholz, L. J., **Feingold, Z., & Galovski, T. E.** (in press). Etiology and phenomenology of posttraumatic stress disorder. In B. Olatunji (Ed.), *Handbook of anxiety and related disorders*. Cambridge, UK: Cambridge University Press.
17. Byrne, S., **Krystal, J. H.,** Rosenheck, R., Vessicchio, J., & **Pietrzak, R. H.** (2017). Correlates of nonimprovement to pharmacotherapy for chronic, antidepressant-resistant, military service-related posttraumatic stress disorder: Insights from the Veterans Affairs Cooperative Study No. 504. *Journal of Clinical Psychopharmacology*. Advance online publication. doi:10.1097/JCP.0000000000000777
18. **Carlson, E. B.,** Palmieri, P., & Spain, D. A. (in press). Development and preliminary performance of brief risk factor measures to predict posttraumatic psychological disorder after trauma exposure. *General Hospital Psychiatry*.
19. **Carlson, E. B.,** Waelde, L. C., Palmieri, P. A., **Macia, K. S.,** Smith, S. R., & McDade-Montez, E. (2016). Development and validation of the Dissociative Symptoms Scale. *Assessment*. Advance online publication. doi:10.1177/1073191116645904

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

20. Chang, C., Kaczurkin, A. N., **McLean, C. P.**, & Foa, E. B. (2017). Emotion regulation is associated with PTSD and depression among female adolescent survivors of childhood sexual abuse. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000306
21. **Cloitre, M., Garvert, D., & Weiss, B. J.** (in press). Depression as a moderator of STAIR Narrative Therapy for Women with PTSD related to childhood abuse. *European Journal of Psychotraumatology*.
22. **Cook, J.**, & Ross, R. J. (in press). Cognitive-behavioral treatment for posttraumatic nightmares: An investigation of predictors of dropout and outcome. *Psychological Trauma: Theory, Research, Practice & Policy*.
23. Creech, S. K., **Macdonald, A., & Taft, C. T.** (in press). Use and experience of recent intimate partner violence among women veterans who deployed to Iraq and Afghanistan. *Partner Abuse*.
24. Currier, J. M., Farnsworth, J. K., & **Drescher, K.** (in press). Moral injury and resilience in the military. In K. H. Thomas (Ed.), *Bulletproofing the psyche: Preventing mental health problems in our military and veterans*. Santa Barbara, CA: Praeger.
25. **Dardis, C.**, & Gidycz, C. (2017). Reconciliation or retaliation? An integrative model of postrelationship in-person and cyber unwanted pursuit perpetration among undergraduate men and women. *Psychology of Violence*. Advance online publication. doi:10.1037/vio0000102
26. **Dardis, C., Vento, S., Gradus, J. L., & Street, A. E.** (in press). Labeling of deployment sexual harassment experiences among male and female veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*.
27. Dichter, M. E., Butler, A., Bellamy, S., Medvedeva, E., Roberts, C. B., & **Iverson, K. M.** (in press). Disproportionate mental health burden associated with past-year intimate partner violence among women receiving care in the Veterans Health Administration. *Journal of Traumatic Stress*.
28. **Doran, J., Pietrzak, R. H., Hoff, R., & Harpaz-Rotem, I.** (2017). Psychotherapy utilization and retention in a national sample of veterans with PTSD. *Journal of Clinical Psychology*. Advance online publication. doi:10.1002/jclp.22445
29. Duncan, L. E., Ratanatharathorn, A., Aiello, A. E., Almli, L. M., Amstadter, A. B., Ashley-Koch, A., ... **Gelernter, J., ... Logue, M. W., ... Miller, M. W., ... & Koenen, K. C.** (2017). Largest GWAS of PTSD (N=20,070) yields genetic overlap with schizophrenia and sex differences in heritability. *Molecular Psychiatry*. Advance online publication. doi:10.1038/mp.2017.77
30. Edwards, K., & **Dardis, C.** (2016). Disclosure recipients' social reactions to victims' disclosures of intimate partner violence. *Journal of Interpersonal Violence*. Advance online publication. doi:10.1177/0886260516681155
31. Ellis, A., Simiola, V., Brown, L., Courtois, C., & **Cook, J.** (2017). The role of evidence-based therapy relationships on treatment outcome for adults with trauma: A systematic review. *Journal of Trauma & Dissociation*. Advance online publication. doi:10.1080/15299732.2017.1329771
32. Ellison, M. L., Belanger, L. K., **Niles, B. L.**, Evans, L., & Bauer, M. S. (2016). Explication and definition of mental health recovery: A systematic review. *Administration and Policy in Mental Health and Mental Health Services Research*. Advance online publication. doi:10.1007/s10488-016-0767-9
33. **Esterlis, I., DellaGioia, N., Pietrzak, R. H.**, Matuskey, D., Nabulsi, N., **Abdallah, C.**, Yang, J., Pittenger, C., **Sanacora, G., Krystal, J. H.**, Parsey, R., Carson, R., & DeLorenzo, C. (2017). Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: An [11C]ABP688 and PET imaging study in depression. *Molecular Psychiatry*. Advance online publication. doi:10.1038/mp.2017.58
34. Farnsworth, J., **Drescher, K.**, Evans, W., & **Walser, R. D.** (2017). A functional approach to understanding and treating military-related moral injury. *Journal of Contextual Behavioral Science*. Advance online publication. doi:10.1016/j.jcbs.2017.07.003
35. **Feingold, Z., Fox-Galalis, A. B., & Galovski, T. E.** (in press). Effectiveness of evidence-based psychotherapy for posttraumatic distress within a jail diversion program. *Psychological Services*.
36. Finley, E. P., Noël, P. H., Lee, S., Haro, E., Garcia, H., **Rosen, C. S., Bernardy, N. C.**, Pugh, M. J., & Pugh, J. A. (2017). Psychotherapy practices for veterans with PTSD among community-based providers in Texas. *Psychological Services*. Advance online publication. doi:10.1037/ser0000143
37. Foa, E. B., **McLean, C. P.**, Zandberg, L. J., Zang, Y., Asnaani, A., Benhamou, K., Rosenfield, D., Campbell, H., Francis, J., Hanson, B. S., Lillard, I. J., Patterson, T. J., Scott, V., Weber, C., Wise, J. E., Zamora, C., Mintz, J., Young-McCaughan, S., Peterson, A. L., & STRONG STAR Consortium (2017). The implementation of Prolonged Exposure: Design of a multisite study evaluating the usefulness of workshop with and without consultation. *Contemporary Clinical Trials*. Advance online publication. doi:10.1016/j.cct.2017.07.018
38. **Fox, A. B.**, Earnshaw, V. A., **Taverna, E.**, & **Vogt, D.** (in press). Conceptualizing and measuring mental illness stigma: The mental illness stigma framework and critical review of measures. *Stigma and Health*.
39. Franklin, T. C., Wohleb, E. S., & **Duman, R.** (in press). Role of immune cells in the brain during physiological and pathological conditions. *Psychiatric Annals*.
40. Gelpkopf, M., Lapid, L., Grinapol, S., Werbeloff, N., **Carlson, E. B.**, & Greene, T. (in press). Peritraumatic reaction courses during war in individuals with serious mental illness: Gender, mental health status, and exposure. *Psychiatry: Interpersonal and Biological Processes*.
41. Gerber, M. R., **King, M. W., Iverson, K. M., Pineles, S. L., & Haskell, S. G.** (in press). Association between mental health burden and coronary artery disease in U.S. women veterans over 45: A national cross-sectional study. *Journal of Women's Health*.
42. Ghosal, S., Hare, B., & **Duman, R.** (2017). Prefrontal cortex GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression. *Current Opinion in Behavioral Sciences*. Advance online publication. doi:10.1016/j.cobeha.2016.09.012
43. Girgenti, M. J., Ghosal, S., Lopresto, D., Taylor, J. R., & **Duman, R.** (2017). Ketamine accelerates fear extinction via mTORC1 signaling. *Neurobiology of Disease*. Advance online publication. doi:10.1016/j.nbd.2016.12.026
44. Gobin, R., **Mackintosh, M. A.**, Willis, E., Allard, C. B., Kloezeman, K., & **Morland, L. A.** (2017). Predictors of differential PTSD treatment outcomes between veteran and civilian women after Cognitive Processing Therapy. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000266

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

45. Goldstein, K. M., **Vogt, D.**, Hamilton, A., Frayne, S., Gierisch, J., Blakeney, J., Sadler, A., Carney, D., DiLeone, B., **Fox-Galalis, A.**, Klap, R., Yee, E., Romodan, Y., Strehlow, H., Yosef, J., & Yano, E. (in press). Practice-based research networks add value to evidence-based quality improvement. *Healthcare: The Journal of Delivery Science and Innovation*.
46. **Gradus, J. L., King, M. W.**, Galatzer-Levy, I., & **Street, A. E.** (2017). Gender differences in machine learning models of trauma and suicidal ideation in veterans of the Iraq and Afghanistan wars. *Journal of Traumatic Stress*. Advance online publication. doi:10.1002/jts.22210
47. **Green, J. D., Annunziata, A., & Marx, B. P.** (in press). Acceptance and Commitment Therapy for depression and anxiety. In H. Friedman (Ed.), *Encyclopedia of mental health* (2nd ed). Oxford, England: Elsevier.
48. **Green, J. D., Hatgis, C., Kearns, J. C., Nock, M. K., & Marx, B. P.** (in press). The Direct and Indirect Self-Harm Inventory (DISH): A new measure for assessing high-risk and self-harm behaviors among military veterans. *Psychology of Men and Masculinity*.
49. **Harik, J. M., Hamblen, J. L., Norman, S. B., & Schnurr, P. P.** (in press). Evidence-based psychotherapies for adults with PTSD. In D. M. Benedek, R. J. Ursano, F. Stoddard, & M. Milad (Eds.), *Trauma and stressor related disorders*. New York, NY: Oxford University Press.
50. Haroon, E., Miller, A., & **Sanacora, G.** (2017). Inflammation, glutamate and glia: A trio of trouble in mood disorders. *Neuropsychopharmacology*. Advance online publication. doi:10.1038/npp.2016.199
51. **Hayes, J. P., Hayes, S., Miller, D. R., Lafleche, G., Logue, M. W., & Verfaellie, M.** (2017). Automated measurement of hippocampal subfields in PTSD: Evidence for smaller dentate gyrus volume. *Journal of Psychiatric Research*. Advance online publication. doi:10.1016/j.jpsychires.2017.09.007
52. **Hayes, J. P., Reagan, A., Logue, M. W., Hayes, S., Samimi Sadeh, N., Miller, D. R., Verfaellie, M., Wolf, E. J., McGlinchey, R. E., Milberg, W. P., Stone, A., Schichman, S. A., & Miller, M. W.** (2017). BDNF genotype is associated with hippocampal volume in mild traumatic brain injury. *Genes, Brain and Behavior*. Advance online publication. doi:10.1111/gbb.12403
53. **Heinz, A. J., Freeman, M. F., Harpaz-Rotem, I., & Pietrzak, R. H.** (in press). American military veteran entrepreneurs: A comprehensive profile of demographic, service history, and psychosocial characteristics. *Military Psychology*.
54. Herbst, E., Pennington, D., **Kuhn, E. R., McCaslin, S. E., Delucchi, K., Batki, S., Dickter, B., & Carmody, T.** (in press). Mobile technology for treatment augmentation in veteran smokers with PTSD. *American Journal of Preventive Medicine*.
55. Higgins, D., Martin, A., Baker, D. G., **Vasterling, J. J., & Risbrough, V. B.** (2017). The relationship between chronic pain and neurocognitive function. *Clinical Journal of Pain*. Advance online publication. doi:10.1097/AJP.0000000000000536
56. Holmes, S., Girgenti, M., Davis, M., **Pietrzak, R. H., DellaGioia, N., Nabulsi, N., Matuskey, D., Southwick, S. M., Duman, R., Carson, R., Krystal, J. H., & Esterlis, I.** (2017). Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. *Proceedings of the National Academy of Sciences*. Advance online publication. doi:10.1073/pnas.1701749114
57. Hundt, N. E., **Harik, J. M.,** Thompson, K. E., Barrera, T. L., & Reynolds-Miles, S. (2017). Increased utilization of PE and CPT over time: A case example from a large Veterans Affairs PTSD clinic. *Psychological Services*. Advance online publication. doi:10.1037/ser0000138
58. **Iverson, K. M.,** Sayer, N., Meterko, M., Stolzmann, K., Suri, P., Gormley, K., Nealon Seibert, M., Yan, K., & Pogoda, T. K. (2017). Intimate partner violence among female OEF/OIF/OND veterans who were evaluated for traumatic brain injury in the Veterans Health Administration: A preliminary investigation. *Journal of Interpersonal Violence*. Advance online publication. doi:10.1177/0886260517702491
59. Kauth, M. R., & **Shipherd, J. C.** (in press). How to begin: An introduction to the book. In M. R. Kauth & **J. C. Shipherd** (Eds.), *Adult transgender care: An interdisciplinary approach for training mental health professionals*. New York, NY: Routledge.
60. **Kelmendi, B., Adams, T., Southwick, S. M., Abdallah, C., & Krystal, J. H.** (in press). PTSD: An integrated overview and neurobiological rationale for pharmacology. *Clinical Psychology: Science and Practice*.
61. **Khan, C. T., & Woodward, S. H.** (in press). Calibrating actigraphy to improve sleep efficiency estimates. *Journal of Sleep Research*.
62. Kilbourne, A. M., Schumacher, K., Frayne, S. M., Cypel, Y., Barbaresso, M. M., Nord, K. M., Perzhinsky, J., Lai, Z., Prenovost, K., **Spiro, A.,** Gleason, T. C., **Kimerling, R.,** Huang, G. D., Serpi, T. B., & Magruder, K. M. (2017). Physical health conditions among a population-based cohort of Vietnam-era women veterans: Agreement between self-report and medical records. *Journal of Women's Health*. Advance online publication. doi:10.1089/jwh.2016.6069
63. Kilpatrick, D., **Friedman, M. J., & Gilmore, A. K.** (in press). Classification and descriptive psychopathology of posttraumatic stress disorder and other stressor-related disorders. In J. Geddes, G. Doodwin, & N. Andreasen (Eds.), *New Oxford textbook of psychiatry* (3rd ed.). Oxford, England: Oxford University Press.
64. Kim, S., Han, S., Gallan, A. J., & **Hayes, J. P.** (in press). Neurometabolic indicators of mitochondrial dysfunction in repetitive mild traumatic brain injury. *Concussion*.
65. Knaevelsrud, C., Böttche, M., **Pietrzak, R. H.,** Freyberger, H. J., & Kuwert, P. (2017). Efficacy and feasibility of a therapist-guided internet-based intervention for older persons with childhood traumatization: A randomized controlled trial. *American Journal of Geriatric Psychiatry*. Advance online publication. doi:10.1016/j.jagp.2017.02.024
66. Kredlow, M. A., **Pineles, S. L.,** Inslicht, S. S., Marin, M. F., Milad, M. R., Otto, M. W., & Orr, S. P. (in press). Assessment of skin conductance in African American and Non-African American participants in studies of conditioned fear. *Psychophysiology*.
67. **Kuhn, E. R., & McCaslin, S. E.** (in press). Military and veteran students. In N. Roberts (Ed.), *University student mental health*. New York, NY: Springer.
68. **LaMotte, A. D., Taft, C. T., & Weatherill, R. P.** (in press). Mistrust of others as mediators of trauma exposure and use of partner aggression. *Psychological Trauma: Theory, Research, Practice, and Policy*.

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

69. **Landes, S. J., Rodriguez, A., Smith, B. N.,** Matthieu, M., **Trent, L., Kemp, J., & Thompson, C.** (2017). Barriers, facilitators, and benefits of implementation of Dialectical Behavior Therapy in routine care: Results from a national program evaluation survey in the Veterans Health Administration. *Translational Behavioral Medicine*. Advance online publication. doi:10.1007/s13142-017-0465-5
70. **Logue, M. W.,** Smith, A. K., **Wolf, E. J.,** Maniates, H., Stone, A., Schichman, S. A., McGlinchey, R. E., Milberg, W., & **Miller, M. W.** (2017). The correlation of methylation levels measured using Illumina 450K and EPIC BeadChips in blood samples. *Epigenomics*. Advance online publication. doi:10.2217/epi-2017-0078
71. **Logue, M. W.,** van Rooij, S., Dennis, E., **Davis, L., Hayes, J. P.,** Stevens, L., ... **Harpaz-Rotem, I.,** Jahanshad, N., Koopowitz, S., **Levy, I.,** Nawijn, L., O'Connor, L., Olf, M., **Salat, D.,** ... **Wolf, E. J.,** Wang, X., **Wrocklage, K. M., Abdallah, C.,** Bryant, R., Geuze, E., Jovanovic, T., Kaufman, M., **King, L. A., Krystal, J. H.,** ... & Morey, R. (2017). Smaller hippocampal volume in posttraumatic stress disorder: A multi-site ENIGMA-PGC study. *Biological Psychiatry*. Advance online publication. doi:10.1016/j.biopsych.2017.09.006
72. **Mackintosh, M. A.,** Niehaus, J., **Taft, C. T., Marx, B. P.,** Grubbs, K., & **Morland, L. A.** (in press). Using a mobile application in the treatment of dysregulated anger among veterans. *Military Medicine*.
73. Mathew, S., Gueorguieva, R., Brandt, C., Fava, M., & **Sanacora, G.** (2017). A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder. *Neuropsychopharmacology*. Advance online publication. doi:10.1038/npp.2017.106
74. **McCaslin, S. E., Ortigo, K. M., Simon, E. P., & Ruzek, J. I.** (in press). Addressing PTSD in veterans. In N. Roberts (Ed.), *Handbook of veterans mental health*. New York, NY: Springer.
75. **McLean, C. P.,** Zandberg, L., Roache, J. D., Fitzgerald, H., Pruikisma, K. E., Taylor, D. J., Dondanville, K. A., Litz, B. T., Mintz, J., Young-McCaughan, S., Yarvis, J. S., Peterson, A. L., Foa, E. B., & STRONG STAR Consortium (2017). Caffeine use in military personnel with PTSD: Prevalence and impact on sleep. *Behavioral Sleep Medicine*. Advance online publication. doi:10.1080/15402002.2017.1326920
76. Medici, C. R., **Gradus, J. L.,** Pedersen, L., Sørensen, H. T., Østergaard, S. D., & Christiansen, C. F. (in press). No impact of preadmission anti-inflammatory drug use on risk of depression and anxiety after critical illness. *Critical Care Medicine*.
77. Meyer, E. C., Konecky, B., Kimbrel, N. A., **Marx, B. P.,** Schumm, J., Penk, W. E., Gulliver, S. B., & Morissette, S. B. (in press). Gender differences in associations between DSM-5 posttraumatic stress disorder symptom clusters and functional impairment in war veterans. *Psychological Services*.
78. **Miller, K. E.,** Brownlow, J. A., **Woodward, S. H.,** & Gehrman, P. R. (2017). Sleep and dreaming in posttraumatic stress disorder. *Current Psychiatry Reports*. Advance online publication. doi:10.1007/s11920-017-0827-1
79. **Miller, K. E.,** Koffel, E., Kramer, M., Erbes, C., Arbisi, P., & Polusny, M. (2017). At-home partner sleep functioning over the course of military deployment. *Journal of Family Psychology*. Advance online publication. doi:10.1037/fam0000262
80. **Miller, M. W.,** Lin, A. P., **Wolf, E. J., & Miller, D. R.** (2017). Oxidative stress, inflammation and neuroprogression in chronic PTSD. *Harvard Review of Psychiatry*. Advance online publication. doi:10.1097/HRP.0000000000000167
81. **Miller, M. W.,** Maniates, H., **Wolf, E. J., Logue, M. W.,** Schichman, S., Stone, A., Milberg, W., & McGlinchey, R. (2017). CRP polymorphisms and DNA methylation of the AIM2 gene influence associations between trauma exposure, PTSD, and C-reactive protein. *Brain, Behavior, and Immunity*. Advance online publication. doi:10.1016/j.bbi.2017.08.022
82. **Moshier, S. J., Parker-Guilbert, K., Marx, B. P., & Keane, T. M.** (in press). Posttraumatic stress disorder. In J. Hunsley & E. Mash (Eds.), *A guide to assessments that work* (2nd ed.). New York, NY: Oxford University Press.
83. Murrough, J. W., **Abdallah, C.,** & Mathew, S. J. (2017). Targeting glutamate signaling in depression: Progress and prospects. *Nature Reviews Drug Discovery*. Advance online publication. doi:10.1038/nrd.2017.16
84. Naeser, M., Martin, P. I., Ho, M. D., Krengel, M. H., **Knight, J. A.,** Bogdanov, Y., Yee, M. K., Zafonte, R. O., Frazier, J. A., Hamblin, M. R., & Koo, B. B. (in press). Transcranial, red/near-infrared light-emitting diode (LED) therapy for chronic, traumatic brain injury. In M. R. Hamblin, T. Agrawal, & M. de Sousa (Eds.), *Handbook of low-level laser therapy*. Boca Raton, FL: Pan Stanford Publishing.
85. **Niles, B. L.,** Polizzi, C. P., Voelkel, E., Weinstein, E. S., Smidt, K., & Fisher, L. M. (2017). Initiation, dropout, and outcome from evidence-based psychotherapies in a VA PTSD outpatient clinic. *Psychological Services*. Advance online publication. doi:10.1037/ser0000175
86. O'Connor, A., Herbst, E., **McCaslin, S. E.,** Armstrong, K., Leach, B., & Jersky, B. (2017). Supporting veteran transitions to the academic setting: VA on campus. *Community College Journal of Research and Practice*. Advance online publication. doi:10.1080/10668926.2017.1294121
87. **Owen, J. E., Jaworski, B. K., Kuhn, E. R.,** Hoffman, J. E., Schievelbein, L., **Chang, A., & Rosen, C. S.** (2017). Development of a mobile app for family members of veterans with PTSD: Identifying needs and modifiable factors associated with burden, depression, and anxiety. *Journal of Family Studies*. Advance online publication. doi:10.1080/13229400.2017.1377629
88. **Parker-Guilbert, K., Moshier, S. J., Marx, B. P., & Keane, T. M.** (in press). Measures of PTSD symptom severity. In C. R. Nemeroff & C. B. Marmar (Eds.), *Post-Traumatic Stress Disorder*. New York, NY: Oxford.
89. Petrakis, I., Ralevski, E., Gueorguieva, R., O'Malley, S., Arias, A. J., Sevarino, K., Jane, J., O'Brien, E., & **Krystal, J. H.** (2017). Mecamylamine treatment for alcohol dependence: A randomized controlled trial. *Addiction*. Advance online publication. doi:10.1111/add.13943
90. **Pineles, S. L.,** & Orr, S. P. (in press). Psychophysiology of PTSD. In C. B. Nemeroff & C. R. Marmar (Eds.), *Post-traumatic stress disorder*. New York, NY: Oxford University Press.
91. Polimanti, R., Kaufman, J., Zhao, H., Kranzler, H., Ursano, R., Kessler, R., **Gelernter, J.,** & Stein, M. (2017). A genome-wide gene-by-trauma interaction study of alcohol misuse in two independent cohorts identifies PRKG1 as a risk locus. *Molecular Psychiatry*. Advance online publication. doi:10.1038/mp.2017.24

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

92. Powers, A., Fani, N., Carter, S., Cross, D., **Cloitre, M.**, & Bradley, B. (2017). Differential predictors of DSM-5 PTSD and ICD-11 complex PTSD among African American women. *European Journal of Psychotraumatology*. Advance online publication. doi:10.1080/20008198.2017.1338914
93. Pruiksma, K. E., **Wachen, J. S.**, & Resick, P. A. (in press). Psychotherapy interventions. In E. Vermetten, T. Neylan, S. R. Pandi-Perumal, & M. Kramer (Eds.), *Sleep and combat-related post-traumatic stress disorders*. New York, NY: Humana Press.
94. **Rasmusson, A. M.**, Marx, C., **Jain, S.**, Farfel, G. M., Tsai, J., Sun, X., Geraciotti, T. D., Hamner, M. B., Lohr, J. B., Rosse, R., Summerall, L., Naylor, J., Cusin, C., Lang, A. J., Raman, R., & Stein, M. B. (in press). A randomized controlled trial of ganaxolone in posttraumatic stress disorder. *Psychopharmacology*.
95. Reger, G. M., Browne, K., Campellone, T. R., Simons, C., **Kuhn, E. R.**, Fortney, J., Sayre, G. C., & Reisinger, H. S. (in press). Barriers and facilitators to mobile application use during PTSD treatment: Clinician adoption of PE Coach. *Professional Psychology: Research and Practice*.
96. Rosellini, A. J., Monahan, J., **Street, A. E.**, Petukhova, M. V., Sampson, N. A., Benedek, D. M., & Kessler, R. C. (2017). Predicting sexual assault perpetration in the U.S. Army using administrative data. *American Journal of Preventive Medicine*. Advance online publication. doi:10.1016/j.amepre.2017.06.022
97. Rosellini, A., Stein, M., Benedek, D., Bliese, P., Chiu, W., Hwang, I., Monahan, J., Nock, M., Petukhova, M., Sampson, N., **Street, A. E.**, Zaslavsky, A., Ursano, R., & Kessler, R. (2017). Using self-report surveys at the beginning of service to develop multi-outcome risk models for new soldiers in the U.S. Army. *Psychological Medicine*. Advance online publication. doi:10.1017/S003329171700071X
98. **Sanacora, G.**, Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., & Summergrad, P. (2017). Council of research task force on novel biomarkers and treatments. *JAMA Psychiatry*. Advance online publication. doi:10.1001/jamapsychiatry.2017.0080
99. Sayer, N. A., **Rosen, C. S.**, **Bernardy, N. C.**, **Cook, J.**, Orazem, R., Chard, K., Mohr, D., **Kehle-Forbes, S.**, **Eftekhari, A.**, **Crowley, J. J.**, **Ruzek, J. I.**, **Smith, B. N.**, & **Schnurr, P. P.** (2017). Context matters: Team and organizational factors associated with reach of evidence-based psychotherapies for PTSD in the Veterans Health Administration. *Administration and Policy in Mental Health and Mental Health Services Research*. Advance online publication. doi:10.1007/s10488-017-0809-y
100. **Schnurr, P. P.**, Bryant, R., Berliner, L., Kilpatrick, D. G., Rizzo, A. S., & **Ruzek, J. I.** (2017). What I have changed my mind about and why: Public health and technology perspectives in the field of trauma studies. *European Journal of Psychotraumatology*. Advance online publication. doi:10.1080/20008198.2017.1372007
101. Scholten, J., Grimes, J. B., & **Vasterling, J. J.** (in press). Traumatic brain injury clinical practice guidelines and best practices from the TBI State of the Art Conference. *Brain Injury*.
102. Seelig, A. D., Rivera, A. C., Powell, T. M., Williams, E. C., Peterson, A. V., Littman, A. J., Maynard, C., **Street, A. E.**, Bricker, J. B., & Boyko, E. J. (2017). Patterns of smoking and unhealthy alcohol use following sexual trauma among U.S. service members. *Journal of Traumatic Stress*. Advance online publication. doi:10.1002/jts.22214
103. **Shippherd, J. C.**, & Salters-Pedneault, K. (2017). Do acceptance and mindfulness moderate the relationship between maladaptive beliefs and posttraumatic distress? *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000248
104. **Siegel, E.**, **Haller, M.**, Ruifeng, C., Trim, R. S., Tate, S. R., & **Norman, S. B.** (in press). Examining changes in negative mood regulation expectancies, PTSD, depression, and substance use following integrated cognitive-behavioral therapy. *Journal of Substance Abuse*.
105. **Sippel, L. M.**, Han, S., **Watkins, L. E.**, **Harpaz-Rotem, I.**, **Southwick, S. M.**, **Krystal, J. H.**, Olff, M., Sherva, R., Farrer, L., Kranzler, H. R., **Gelernter, J.**, & **Pietrzak, R. H.** (2017). Oxytocin receptor gene polymorphisms, attachment, and PTSD: Results from the National Health and Resilience in Veterans Study. *Journal of Psychiatric Research*. Advance online publication. doi:10.1016/j.jpsychires.2017.07.008
106. **Sippel, L. M.**, **Watkins, L. E.**, **Pietrzak, R. H.**, **Hoff, R.**, & **Harpaz-Rotem, I.** (in press). The unique roles of emotional numbing and arousal symptoms in relation to social connectedness among military veterans in residential treatment for PTSD. *Psychiatry: Interpersonal and Biological Processes*. doi:10.1080/00332747.2017.1395313
107. Smith, S. K., **Kuhn, E. R.**, O'Donnell, J., Koontz, B. F., Nelson, N., Molloy, K., Chang, J., & Hoffman, J. E. (2017). Cancer Distress Coach: Pilot study of a mobile app for managing posttraumatic stress. *Psycho-Oncology*. Advance online publication. doi:10.1002/pon.4363
108. Smith, T. L., **Landes, S. J.**, Lester-Williams, K., Day, K. T., Batdorf, W., Brown, G. K., Trockel, M., **Smith, B. N.**, Chard, K. M., **Healy, E.**, & Weingardt, K. R. (2017). Developing alternative training delivery methods to improve psychotherapy implementation in the U.S. Department of Veterans Affairs. *Training and Education in Professional Psychology*. Advance online publication. doi:10.1037/tep0000156
109. Sofko, C., Currier, J. M., Hill, B. D., & **Drescher, K.** (in press). mTBI severity complicates symptom picture in Iraq/Afghanistan veterans seeking PTSD residential treatment. *Brain Injury*.
110. Stefanovics, E., Potenza, M., & **Pietrzak, R. H.** (2017). Gambling in a national U.S. veteran population: Prevalence, socio-demographics, and psychiatric comorbidities. *Journal of Gambling Studies*. Advance online publication. doi:10.1007/s10899-017-9678-2
111. Stefanovics, E., Rosenheck, R., Jones, K., Huang, G., & **Krystal, J. H.** (2017). Minimal clinically important differences (MCID) in assessing outcomes of post-traumatic stress disorder. *Psychiatric Quarterly*. Advance online publication. doi:10.1007/s11126-017-9522-y
112. Stein, D., **Friedman, M. J.**, McLaughlin, K., Scott, K., & Kessler, R. (in press). DSM-5 and ICD-11 definitions of posttraumatic stress disorder: Investigating "narrow" and "broad" approaches. In K. C. Koene, D. J. Stein, & E. G. Karam (Eds.), *Trauma and posttraumatic stress disorder*. Cambridge: Cambridge University Press.
113. Stein, M., Ware, E., Mitchell, C., Chen, C., Borja, S., Cai, T., Dempsey, C., Fullerton, C., **Gelernter, J.**, Heeringa, S., **Jain, S.**, Kessler, R., Naifeh, J., Nock, M., Ripke, S., Sun, X., Beckham, J., Kimbrel, N. A., Ursano, R., & Smoller, J. (2017). Genomewide association studies of suicide attempts in U.S. soldiers. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. Advance online publication. doi:10.1002/ajmg.b.32594

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

114. Strasshofer, D., Beagley, M. C., Peterson, Z., & **Galovski, T. E.** (2017). Investigating the relationship between posttraumatic stress symptoms and posttraumatic growth following community violence: The role of anger. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000314
115. Straus, L. D., Drummond, S. P., Risbrough, V. B., & **Norman, S. B.** (2017). Sleep disruption, safety learning, and fear extinction in humans: Implications for posttraumatic stress disorder. *Current Topics in Behavioral Neuroscience*. Advance online publication. doi:10.1007/7854_2017_31
116. **Street, A. E.**, Hilbert, A. J., Eliezer, D., Axelrad, S. H., Dyches, K. D., & Galbreath, N. W. (in press). Sexual assault in the military. In E. Weiss & C. Castro (Eds.), *American military life in the 21st century: Social, cultural, economic issues and trends*. Santa Barbara, CA: Praeger/ABC-CLIO.
117. Su, T. P., Chen, M. H., Li, C. T., Lin, W. C., Hong, C. J., Gueorguieva, R., Tu, P. C., Bai, Y. M., Cheng, C. M., & **Krystal, J. H.** (2017). Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. *Neuropsychopharmacology*. Advance online publication. doi:10.1038/npp.2017.94
118. Suri, P., Stolzmann, K., **Iverson, K. M.**, Williams, R., Meterko, M., Yan, K., Gormley, K., & Pogoda, T. (2017). Associations between traumatic brain injury history and future headache severity in veterans: A longitudinal study. *Archives of Physical Medicine and Rehabilitation*. Advance online publication. doi:10.1016/j.apmr.2017.04.008
119. Tamman, A. J. F., **Sippel, L. M.**, Han, S., Neria, Y., **Krystal, J. H.**, **Southwick, S. M.**, **Gelernter, J.**, & **Pietrzak, R. H.** (2017). Attachment style moderates effects of FKBP5 polymorphisms and childhood abuse on posttraumatic stress symptoms: Results from the National Health and Resilience in Veterans Study. *Biological Psychiatry*. Advance online publication. doi:10.1080/15622975.2017.1376114
120. Taylor, B., Hagel Campbell, E., Nugent, S., Bidelspach, D., **Kehle-Forbes, S.**, Scholten, J., Stroupe, K., & Sayer, N. (2017). Three year trends in VHA utilization and costs following traumatic brain injury screening among veterans with mild traumatic brain injury. *Journal of Neurotrauma*. Advance online publication. doi:10.1089/neu.2016.4910
121. Thompson, R. R., Simiola, V., **Schnurr, P. P.**, **Wiltsey Stirman, S.**, & **Cook, J.** (2016). VA residential treatment providers' use of two evidence-based psychotherapies for PTSD: Global endorsement versus specific components. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0000220
122. **Tiet, Q. Q.**, Leyva, Y. E., Moos, R. H., & **Smith, B. N.** (2017). Diagnostic accuracy of a two-item Drug Abuse Screening Test (DAST-2). *Addictive Behaviors*. Advance online publication. doi:10.1016/j.addbeh.2017.06.008
123. Trim, J. G., **Galovski, T. E.**, Wagner, A., & Brewerton, T. (in press). Treating ED-PTSD patients: A synthesis of the literature and new treatment directions. In L. K. Anderson, S. B. Murray, & W. H. Kaye (Eds.), *The Oxford handbook of atypical and complex eating disorders*. New York, NY: Oxford University Press.
124. Tsai, J., & **Pietrzak, R. H.** (2017). Trajectories of posttraumatic growth among U.S. military veterans: A 4-year nationally representative, prospective cohort study. *Acta Psychiatrica Scandinavica*. Advance online publication. doi:10.1111/acps.12800
125. Valentine, S., Woulfe, J., & **Shipherd, J. C.** (in press). An evidence-based approach to conceptualizing trauma responses among transgender and gender non-conforming (TGNC) adults. In J. E. Pachankis & S. A. Safren (Eds.), *Handbook of evidence-based mental health practice with LGBT clients*. New York, NY: Oxford University Press.
126. **Vojvoda, D.**, Stefanovics, E., & Rosenheck, R. A. (in press). Psychotropic medication prescribing in Iraq/Afghanistan veterans and Vietnam era veterans with posttraumatic stress disorder. *Journal of Nervous and Mental Disease*.
127. **Wachen, J. S.**, Dondanville, K. A., & Resick, P. A. (2017). Correcting misperceptions about Cognitive Processing Therapy to treat moral injury: A response to Gray and colleagues. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2017.06.001
128. **Watson, P.** (in press). Acute interventions for trauma-related problems. In R. Ursano, C. Fullerton, L. Weisaeth, & B. Raphael (Eds.), *Textbook of disaster psychiatry* (2nd ed.). New York, NY: Cambridge University Press.
129. Weathers, F., **Bovin, M. J.**, Lee, D., **Sloan, D. M.**, **Schnurr, P. P.**, **Kaloupek, D. G.**, **Keane, T. M.**, & **Marx, B. P.** (2017). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychological Assessment*. Advance online publication. doi:10.1037/pas0000486
130. Wells, S., **Morland, L. A.**, Torres, E., Kloezeman, K., **Mackintosh, M. A.**, & Aarons, G. (2017). The development of a brief version of the Posttraumatic Cognitions Inventory (PTCI-9). *Assessment*. Advance online publication. doi:10.1177/1073191116685401
131. Williams, A. M., **Galovski, T. E.**, & Resick, P. A. (in press). Cognitive Processing Therapy. In B. A. Moore & W. E. Penk (Eds.), *Treating PTSD in Military Personnel: A Clinical Handbook - Second Edition*. New York City, NY: Guilford Press.
132. **Wiltsey Stirman, S.** (in press). The future of practice-based research. In R. T. Codd, III (Ed.), *Practice-based research: A guide for clinicians*. New York, NY: Taylor & Francis/Routledge Press.
133. **Wiltsey Stirman, S.**, Gamarra, J., Calloway, A., Bartlett, B., & **Gutner, C. A.** (in press). The impact of modifications to evidence-based psychotherapy on patient-level outcomes. *Clinical Psychology: Science and Practice*.
134. Wisco, B. E., **Marx, B. P.**, May, C. L., **Martini, B.**, **Krystal, J. H.**, **Southwick, S. M.**, & **Pietrzak, R. H.** (2017). Moral injury in U.S. combat veterans: Results from the National Health and Resilience in Veterans Study. *Depression and Anxiety*. Advance online publication. doi:10.1002/da.22614
135. Wohleb, E. S., & **Duman, R.** (in press). Disruption of mTORC1 signaling contributes to synaptic deficits caused by chronic stress: Reversal by rapid-acting antidepressants. *Neurobiology of Stress*.
136. **Wolf, E. J.**, & Morrison, F. G. (2017). Traumatic stress and accelerated cellular aging: From epigenetics to cardiometabolic disease. *Current Psychiatry Reports*. Advance online publication. doi:10.1007/s11920-017-0823-5
137. **Wolf, E. J.**, **Logue, M. W.**, **Stoop, T.**, Schichman, S. A., Stone, A., **Samimi Sadeh, N.**, **Hayes, J. P.**, & **Miller, M. W.** (2017). Accelerated DNA methylation age: Associations with PTSD and mortality. *Psychosomatic Medicine*. Advance online publication. doi:10.1097/PSY.0000000000000506

Appendix D: Fiscal Year 2017 In Press and Advance Online Publications

138. **Wolf, E. J., Miller, D. R., Logue, M. W.,** Sumner, J., Stoop, T., Leritz, E., **Hayes, J. P.,** Stone, A., Schichman, S., McGlinchey, R., Milberg, W., & **Miller, M. W.** (2017). Contributions of polygenic risk for obesity to PTSD-related metabolic syndrome and cortical thickness. *Brain, Behavior, and Immunity*. Advance online publication. doi:10.1016/j.bbi.2017.06.001
139. **Woodward, S. H., Jamison, A., Gala, S. M.,** & Holmes, T. H. (in press). Canine companionship is associated with modified attentional bias in chronic severe posttraumatic stress disorder. *PLOSOne*.
140. Ziobrowski, H., Sartor, C. E., Tsai, J., & **Pietrzak, R. H.** (2017). Gender differences in mental and physical health conditions in U.S. veterans: Results from the National Health and Resilience in Veterans Study. *Journal of Psychosomatic Research*. Advance online publication. doi:10.1016/j.jpsychores.2017.08.011

Appendix E: Fiscal Year 2017 Scientific Presentations

Academy Health Research Meeting New Orleans, LA June 2017

1. Dichter, M., Butler, A., Haywood, T., Bellamy, S., Medvedeva, E., Roberts, C., & **Iverson, K. M.** *Demographic, clinical, and health services use characteristics of women screening positive for past-year intimate partner violence in the Veterans Health Administration.*
2. Miller, C. J., **Bovin, M. J.**, Burgess, J. F., Lipschitz, J., Zamora, K. A., & Pyne, J. M. *Getting the ball rolling: Rural veterans' experiences initiating mental health care.*
3. Pogoda, T. K., **Iverson, K. M.**, Stolzmann, K. L., Charns, M. P., Gormley, K. E., Seibert, M. N., Suri, P., Yan, K., Sayer, N. A., & Meterko, M. *Predictors of employment status for Iraq and Afghanistan war veterans three years after evaluation for traumatic brain injury.*
4. Shin, M., Gormley, K., Toldeo, N., **Vento, S.**, & **Street, A. E.** *Understanding patient perspectives in screening for military sexual trauma in the Veterans Health Administration: Are veterans satisfied with their experiences?*
5. **Zimmerman, L. E.** *Enhancing implementation science: Applying system models to address complexity.*
6. **Zimmerman, L. E.**, Dollar, K., Lambert-Kerzner, A., Fickel, J., Oliver, K., Mushiana, S., Miller, C., Ritchie, M., & Kirchner, J. E. *Facilitating implementation of clinical innovations virtually: Benefits, challenges, and expert recommendations.*

American College of Neuropsychopharmacology Hollywood, FL December 2016

7. **Abdallah, C.** The impact of ketamine on global brain connectivity in treatment resistant depression. In J. Murrugh (Chair), *Biomarkers of TRD.*
8. **Abdallah, C.**, **Averill, L.**, Collins, K. A., **Geha, P.**, Schwartz, J., **Averill, C. L.**, DeWilde, K. E., Wong, E., **Anticevic, A.**, Tang, C. Y., Iosifescu, D. V., Charney, D. S., & Murrugh, J. *Ketamine treatment and global brain connectivity in major depression.*
9. **Averill, L.**, **Abdallah, C.**, Nicui, M. J., Fenton, L. R., Fasula, M. K., Jiang, L., Rothman, D. L., Mason, G. F., & **Sanacora, G.** *Glutamate neurotransmission and early life stress in major depression.*
10. **Esterlis, I.** *In vivo quantification of synaptic density in depression with 11C-UCB-J PET brain imaging.*
11. **Esterlis, I.** *Prefrontal cortical mGluR5 availability in PTSD: Preliminary findings from an [18F] FPEB PET study.*
12. **Sanacora, G.** *A translational approach to refining molecular therapeutic targets within glutamatergic pathways: Examining the relationship between glutamate cycling and rapid acting antidepressant response.*

Anxiety and Depression Association of America San Francisco, CA April 2017

13. **Adams, T.**, **Kelmendi, B.**, Kichuk, S., George, J., Wasylink, S., Billingslea, E., & Pittenger, C. *Galvanized learning: Augmentation of the therapeutic fear extinction with transcranial direct current stimulation (tDCS).*
14. Chang, C., Kaczurkin, A., **McLean, C. P.**, & Foa, E. *Emotion regulation, depression, and PTSD in adolescent survivors of child sexual abuse.*
15. **Heinz, A. J.**, **Cohen, N. L.**, **Meffert, B.**, Freeman, M. A., **Harpaz-Rotem, I.**, **Southwick, S. M.**, & **Pietrzak, R. H.** *Entrepreneurship is linked to psychological resilience in military veterans: Results from the National Health and Resilience in Veterans Study.*
16. **Klein, A.**, **Bovin, M. J.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** *Associations among dimensions of childhood adversity and adult depressive, anxiety, and PTSD in a sample of OEF/OIF veterans.*
17. **McLean, C. P.**, Zang, Y., Zandberg, L., Bryan, C. J., Gay, N., Yarvis, J., Foa, E. B., & STONG STAR Consortium. *Predictors of suicidal ideation among active duty military personnel with posttraumatic stress disorder.*
18. **Meffert, B.**, **Banducci, A. N.**, Alvarez, J., **Heinz, A. J.**, & Bonn-Miller, M. O. *Changes in distress tolerance across treatment are associated with residential PTSD treatment retention.*
19. **Miller, M. W.** 5-HT2A gene variants moderate the association between PTSD and reduced Default Mode Network connectivity. In **M. W. Miller** (Chair), *Structural and functional connectivity networks in PTSD: Clinical and genetic correlates.*
20. **Moshier, S. J.**, **Klein, A.**, **Kleiman, S.**, **Parker-Guilbert, K.**, **Harwell, A. M.**, Trachtenberg, F., Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** *Treatment satisfaction and early termination in U.S. veterans seeking treatment for PTSD. In A. Asnaani (Chair), From RCTs to the clinic: Predictors, moderators, and other factors influencing naturalistic CBT outcomes for populations with anxiety disorders.*

Appendix E: Fiscal Year 2017 Scientific Presentations

(Anxiety and Depression Association of America Continued)

21. **Wiltsey-Stirman, S.**, Carreno, P., **Mallard, K. N.**, **Beristianos, M.**, Masina, T., & Monson, C. Examining modifications to an evidence-based psychotherapy for PTSD-associations with symptom change. In L. Marques (Chair), *Clinician modifications to evidence-based treatments: The "how, why, and what's next?" of changes to treatment protocols.*
22. **Wolf, E. J.** PTSD-related accelerated DNA methylation age and medical morbidity and mortality. In J. Sumner and **E. Wolf** (Chairs), *Traumatic stress and accelerated aging across the lifespan: Converging evidence from epigenetic, health, and neurocognitive markers.*

Association for Behavioral and Cognitive Therapies New York, NY October 2016

23. Ametaj, A., **Gutner, C. A.**, Idrobo, F., & Barlow, D. H. Implementation data from a trial of the unified protocol with victims of the armed conflict in Colombia. In A. Ametaj (Chair), *Cross-cultural dissemination and implementation of a transdiagnostic intervention: The unified protocol in international settings.*
24. **Black, S. K.**, **Harwell, A. M.**, **Klein, A.**, **Bovin, M. J.**, **Green, J. D.**, **Keane, T. M.**, & **Marx, B. P.** Implications of the recent and upcoming diagnostic changes to posttraumatic stress disorder: A comparison of DSM-5 and ICD-11.
25. Coleman, J. N., Batchelder, A., Boroughs, M. S., **Shipherd, J. C.**, Bedoya, C. A., & O'Leirigh, C. *Dissociation partially mediates the relationship between lifetime PTSD symptoms and sexual risk among men who have sex with men with a history of childhood sexual abuse.*
26. **Gorman, K. R.**, **Klein, A.**, **Kearns, J. C.**, **Parker-Guilbert, K.**, **Bovin, M. J.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** Comparison of PTSD and depression in sexual minority and non-sexual minority female veterans exposed to military sexual assault, combat, and harassment.
27. **Green, J. D.**, **Kearns, J. C.**, **Marx, B. P.**, Nock, M. K., Rosen, R. C., & **Keane, T. M.** Evaluating safety plan effectiveness: Do safety plans tailored to individual veteran characteristics decrease risk? In D. J. Lee (Chair), *Preventing suicide among military and veteran populations.*
28. **Gutner, C. A.**, **Sloan, D. M.**, **Gallagher, M.**, & **Resick, P. A.** Dropout in treatment of PTSD: Examining the role of timing in clinical trials. In C. Cassiello-Robbins (Chair), *Going beyond the basics: Identifying modifiable and clinically useful predictors of attrition from cognitive-behavioral treatment.*
29. **Gutner, C. A.**, **Sloan, D. M.**, **Suvak, M.**, & **Resick, P. A.** Does timing matter? Examining the impact of session timing on outcome. In J. J. Jun (Chair), *Psychotherapy process-oriented assessment to enhance trauma-focused treatment: In-depth clinical exploration of key change processes.*
30. **Gutner, C. A.**, **Vento, S.**, Barlow, D. H., **Sloan, D. M.**, & **Wiltsey Stirman, S.** Patient and stakeholder preferences on transdiagnostic mental health treatment for trauma-exposed veterans. In J. R. Bullis (Chair), *Direct-to-consumer marketing of psychological treatments: Consumer preferences and attitudes toward evidence-based practice.*
31. **Harwell, A. M.**, **Klein, A.**, **Erb, S. E.**, **Green, J. D.**, Holowka, D. W., **Barretto, K. M.**, **Bovin, M. J.**, **Marx, B. P.**, **Keane, T. M.**, & Rosen, R. C. *War-time atrocity exposure and PTSD symptom severity among OEF/OIF veterans: Evaluating the role of gender.*
32. **Heilman, M.**, **Stoop, T.**, & **Wolf, E. J.** Associations between posttraumatic stress disorder, psychiatric comorbidity, and malingering.
33. **Kachadourian, L.**, Black, A. C., & Rosen, M. I. *Factors associated with mental health treatment attendance among veterans applying for service-connected compensation.*
34. **Klein, A.**, **Green, J. D.**, **Gorman, K. R.**, **Bovin, M. J.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** Associations between childhood trauma and the dissociative subtype of PTSD in OEF/OIF veterans.
35. **Maskin, R.**, **Vogt, D.**, **Taverna, E.**, & **Smith, B. N.** Indirect effects of deployment social support on parenting outcomes through PTSD symptomatology.
36. **Norman, S. B.** Discussant for D. Hien (Chair), *Advances in treatments for traumatic stress disorders and addictions using behavioral and pharmacologic approaches in civilian and veteran populations.*
37. **Norman, S. B.** Discussant for A. Asnaani (Chair), *Under the influence: The co-occurrence of substance use disorders with PTSD and potential mechanisms maintaining their comorbidity.*
38. Sauer-Zavala, S., Boswell, J. F., **Gutner, C. A.**, Bentley, K., Boettcher, H., Ametaj, A., & Barlow, D. H. *Dissemination of the unified protocol in routine care: Balancing flexibility within fidelity.*
39. **Sloan, D. M.** Alliance across group treatment for PTSD: Modeling change with respect to individual and group characteristics. In J. J. Jun (Chair), *Predictors of PTSD treatment outcome.*
40. **Sloan, D. M.** *Emotional acceptance and suppression: Effects on self-reported affect and physiological responding among veterans with depression.*
41. **Sloan, D. M.** *The impact of fear of depressed mood on physiological responding in veterans with unipolar depression.*
42. **Sloan, D. M.** *Predictors of suicidal ideation among individuals with PTSD: Differences across veteran and community samples.*

Association for Psychological Science Boston, MA May 2017

43. **Arditte Hall, K.**, Rosebrock, L. E., **Pineles, S. L.**, Rando, A., & Liverant, G. I. The interaction of rumination and emotion regulation on sadness following negative autobiographical memory recall in veterans with depression. In S. L. Connolly & E. J. Hamlat (Chairs), *Memory biases, rumination, and depression: Underlying mechanisms and novel interventions.*
44. **Berlingeri, A.**, & **Knight, J. A.** *Vast PTSD diagnostic heterogeneity reflected by unique clinical symptom patterns on the CAPS and PCL-C.*
45. **Levy, I.** *Neuroanatomy accounts for age-related changes in risk preference: Understanding uncertainty.*

Appendix E: Fiscal Year 2017 Scientific Presentations

(Association for Psychological Science Continued)

46. **Maskin, R., Vogt, D., Iverson, K. M., & Smith, B. N.** *Indirect effects of warfare exposure and perceived threat on alcohol problems through PTSD symptom clusters.*
47. **Pedersen, S., Bovin, M. J., Klein, A., Jackson, C. E., Green, J. D., Harwell, A. M., Rosen, R. C., Keane, T. M., & Marx, B. P.** *The influence of veteran gender on applying for and receiving TBI-related service connection.*
48. Rosebrock, L., **Arditte Hall, K., Pineles, S. L., Rando, A., & Liverant, G. I.** *Rumination and emotion regulation strategies in veterans with depression and posttraumatic stress disorder.*
49. Sabbah, L., **Curreri, A. J., Suvak, M., Pineles, S. L., Fonda, J., Iverson, K. M., Milberg, W., & McGlinchey, R.** *Structural equation modeling exploratory factor analysis of the Clinician Administered PTSD Scale and the Neurobehavioral Symptom Inventory.*
50. Sanders, W., **Vogt, D., & Smith, B. N.** *The role of the family in the link between veteran mental health problems and post-military family functioning.*
51. **Stoop, T., Sperbeck, E., Wolf, E. J., & Miller, M. W.** *Influences of temperament and personality disorders on the longitudinal course of PTSD.*
52. **Weinstein, E., Smidt, K., Fisher, L. M., & Niles, B. L.** *Modification or mishap? Program evaluation of evidence based psychotherapies (EBPs) at a Veterans Health Administration (VHA) posttraumatic stress disorder (PTSD) clinic.*

Biological Psychiatry San Diego, CA May 2017

53. **Akiki, T., Averill, C. L., Wrocklage, K. M., Scott, J. C., Alexander-Bloch, A., Southwick, S. M., Krystal, J. H., & Abdallah, C.** *The default mode network in posttraumatic stress disorder (PTSD): A data-driven multimodal approach.*
54. **Driesen, N. R.** *Ketamine and guanfacine effects on activation and connectivity during working memory: A functional magnetic resonance imaging investigation.*
55. **Esterlis, I.** *In vivo evidence of lower synaptic density in depression and associated mood and cognitive deficits: A [¹¹C] UCB-J PET imaging study.*
56. **Esterlis, I.** *In vivo quantification of mGluR5 availability in posttraumatic stress disorder.*
57. **Logue, M. W., Miller, M. W., McGlinchey, R. E., Milberg, W., & Wolf, E. J.** *Neurobiological correlates of PTSD-related accelerated aging. In A. Smith (Chair), Advances in peripheral epigenetic studies of posttraumatic stress disorder.*
58. **Woodward, S. H., & Schaer, M.** *Is the amygdala hyper-myelinated in PTSD?*

International Society for Traumatic Stress Studies Dallas, TX November 2016

59. **Amalathas, A., Curreri, A. J., Resick, P. A., Rasmusson, A. M., Orr, S., & Pineles, S. L.** *Trauma and psychophysiological reactivity: Menstrual phase, posttraumatic stress disorder, and performance on a loud tones task.*
60. Amoroso, T., **Taverna, E., Fox, A. B., Smith, B. N., & Vogt, D.** *Transitioning from combat to campus: Impact of warfare exposure and associated mental health consequences on school enrollment and functioning.*
61. Anglin, D., **Carlson, E. B., Espinosa, A., Polanco-Roman, L., Macia, K., Palmieri, P., & Smith, S.** *The structure of the Dissociative Symptoms Scale across race and ethnicity: A test of measurement invariance using latent class analysis in a non-clinical sample.*
62. **Arditte Hall, K., Bartlett, B. A., Iverson, K. M., & Mitchell, K. S.** *Unique associations between childhood, adult, or military trauma and eating disorder symptomatology in a sample of female veterans.*

International Society for Traumatic Stress Studies Dallas, TX November 2016

63. **Averill, L., Abdallah, C., Nicui, M. J., Fenton, L. R., Fasula, M. K., Jiang, L., Rothman, D. L., Mason, G. F., & Sanacora, G.** *Early life stress and glutamate neurotransmission in major depressive disorder.*
64. Balderrama-Durbin, C., Polusny, M. A., & **Vogt, D.** *Development and psychometric evaluation of the Deployment Communication Inventory (DCI).*
65. **Banducci, A. N., Bonn-Miller, M., Timko, C., Cloitre, M., & Rosen, C. S.** *The impact of inpatient treatment length on PTSD symptomatology and outpatient mental health service utilization among veterans with PTSD.*
66. Bartlett, B., **Iverson, K. M., & Mitchell, K. S.** *Specific trauma-types and their association with physical and mental health among female veterans.*
67. **Bernardy, N. C., Montano, M. A., & Sherrieb, K.** *The use of technology to improve PTSD care in rural areas. In N. C. Bernardy (Chair), Innovative approaches to improving PTSD treatment: Using technology to aid public health.*
68. **Bovin, M. J., Black, S. K., Rodriguez, P., Lunney, C., Weathers, F. W., Schnurr, P. P., Keane, T. M., & Marx, B. P.** *The Inventory of Psychosocial Functioning (IPF): Development and utility of a measure of PTSD-specific impairment. In B. Smith (Chair), Examining the impact of PTSD on work, family, and other related quality of life outcomes in veterans of the wars in Iraq and Afghanistan.*
69. **Carlson, E. B., Macia, K. S., & Cloitre, M.** *Observed emotion regulation patterns in early responses to trauma and their relation to later posttraumatic psychological disorder.*
70. **Cosgrove, K.** *Imaging neuroinflammation in PTSD.*

Appendix E: Fiscal Year 2017 Scientific Presentations

(International Society for Traumatic Stress Studies Continued)

71. **Curreri, A. J.**, Salters-Pedneault, K. A., & **Shipherd, J. C.** *The role of outcome expectancy in reducing intrusive thoughts after brief postdeployment training.*
72. **Dardis, C.**, **Shipherd, J. C.**, & **Iverson, K. M.** *Intimate partner violence among women veterans by sexual orientation.*
73. **Doran, J.**, & DeViva, J. *A naturalistic evaluation of evidence-based treatment for veterans with posttraumatic stress disorder.*
74. **Galovski, T. E.**, **Amalathas, A.**, & **Feingold, Z.** *Comparison of barriers to care in a prospective study of civilians and police officers exposed to violence in Ferguson, MO.*
75. **Galovski, T. E.**, **Feingold, Z.**, & **Amalathas, A.** *Evidence-based practices in traumatized individuals suffering from severe mental illness and diverted from jail.*
76. **Gradus, J. L.** *The longitudinal sequelae of stress disorders in the population of Denmark.*
77. **Gradus, J. L.** *Using machine learning to predict suicidal ideation in OEF/OIF veterans.*
78. **Green, J. D.**, **Marx, B. P.**, **Marx, B. P.**, Rosen, R. C., & **Keane, T. M.** *Mental health utilization in OIF/OEF veterans with PTSD: The role of diagnostic accuracy and service connection as determinants of care seeking.*
79. Greene, T., Gelkopf, M., **Carlson, E. B.**, & Liron, L. *PTSD, emotional valence and instability in civilians exposed to conflict: A proximal intensive assessment study.*
80. Grubbs, K., **Harik, J. M.**, & **Hamblen, J. L.** *Patients' experiences making PTSD treatment decisions.*
81. **Gutner, C. A.**, Pedersen, E., & Drummond, S. *Sleep disturbance, PTSD and depression: Leveraging client preferences for treatment modality in the face of comorbidity.* In K. Walter (Chair), *From epidemiology to treatment delivery and dissemination: The influence of conditions comorbid with PTSD.*
82. **Hamblen, J. L.**, Hundt, N. E., **Bernardy, N. C.**, & **Norman, S. B.** *Preferences for decision making involvement and information about PTSD treatment: A nationally representative online survey of adults who screened positive for PTSD.* In **J. L. Hamblen** (Chair), *Enhancing the quality of online information to support treatment engagement.*
83. **Harik, J. M.**, Grubbs, K., & **Schnurr, P. P.** *Using graphics to communicate information about PTSD treatment effectiveness to patients.* In **J. L. Hamblen** (Chair), *Enhancing the quality of online information to support PTSD treatment engagement.* **Harwell, A. M.**, **Moshier, S. J.**, **Klein, A.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** *War-time atrocity exposure type, PTSD diagnosis and symptom severity prediction among OEF/OIF veterans.*
84. **Heinz, A. J.**, **Cohen, N. L.**, **Ortigo, K. M.**, Herbst, E., Bosch, J., & **McCaslin, S. E.** *The role of cognitively flexible coping, social support, and optimism in posttraumatic growth: A post-deployment examination among Iraq and Afghanistan combat veterans.*
85. Herbst, E., **Kuhn, E. R.**, **McCaslin, S. E.**, Dickter, B., Jones, M., & Pennington, D. *Mobile technology may improve smoking cessation treatment retention in veteran smokers with PTSD: An open pilot study.*
86. Herbst, E., Pennington, D., **McCaslin, S. E.**, & Cohen, B. *Effect of smoking and alcohol use on 24-hour urinary catecholamines, dopamine, and cortisol in veterans with posttraumatic stress disorder.*
87. **Iverson, K. M.**, **Vogt, D.**, **Amoroso, T.**, **Maskin, R.**, & **Smith, B. N.** *Intimate partner violence, mental health, and occupational functioning among OEF/OIF veterans: A gender comparison.*
88. Javorka, M., **Wong, A. C.**, Lewis, E. T., Zulman, D. M., & **Kimerling, R.** *Differences in engagement in VA health care among veterans with and without posttraumatic stress disorder.*
89. **Kehle-Forbes, S.**, & **Spoont, M.** *Gender differences in rates and predictors of individual psychotherapy initiation and engagement among veterans newly diagnosed with PTSD.*
90. **Kehle-Forbes, S.**, Back, S., **Norman, S. B.**, & Asnaani, A. *Role of alcohol use disorder in PTSD treatment engagement among treatment seeking veterans.* In **S. Kehle-Forbes** (Chair), *The treatment of co-occurring PTSD and substance-related disorders.*
91. **Kehle-Forbes, S.**, Drapkin, M., Foa, E., Koffel, E., Polusny, M., Van Horn, D., Yusko, D., & Oslin, D. *A randomized clinical trial of sequential versus integrated treatment for veterans with co-occurring PTSD and substance use disorders.*
92. Kelley, E., **Dardis, C.**, & Gidycz, C. A. *The role of PTSD symptom clusters in sexual functioning in women with a history of sexual assault.* In L. C. Wilson (Chair), *Sexual assault/military assault.*
93. **Klein, A.**, **Moshier, S. J.**, **Harwell, A. M.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** *Associations between treatment satisfaction and one-year clinical outcomes in OEF/OIF veterans with PTSD.*
94. Kredlow, M. A., **Pineles, S. L.**, Inslicht, S. S., Milad, M. R., Otto, M. W., & Orr, S. P. *Assessment of skin conductance in African American and non-African American participants in fear conditioning research: Implications for PTSD research.*
95. **Loflin, M. J.** *A review of the therapeutic potential of cannabinoids for PTSD.*
96. **Loflin, M. J.** *Medicinal versus recreational cannabis use: An investigation of characteristics and correlates among veterans with PTSD.* In E. Dworkin (Chair), *Clarifying connections between cannabis use and PTSD: Moving from the laboratory to the treatment clinic.* **Macia, K. S.**, **Carlson, E. B.**, Waelde, L., & Palmieri, P. *Heterogeneity in manifestations of dissociation across individuals from diverse clinical and non-clinical samples.*
97. **Marx, B. P.**, **Bovin, M. J.**, **Lee, D. J.**, **Parker-Guilbert, K.**, Rosen, R. C., & **Keane, T. M.** *Examining the longitudinal associations among functional impairment, quality of life outcomes, and PTSD status with OEF/OIF veterans.*
98. **Matteo, R.**, **Harik, J. M.**, **Hermann, B. A.**, & **Hamblen, J. L.** *What people with PTSD symptoms do (and don't) know about PTSD: A national survey.*
99. **McCaslin, S. E.**, Davenport-Becket, C., Chapin, B., Dinh, J., Choucroun, G., & Herbst, E. *Military acculturation and transition to the civilian setting.*
100. **McCaslin, S. E.**, Maguen, S., Metzler, T., Bosch, J., Neylan, T. C., & Marmar, C. *Perceived impact of PTSD symptoms on work, social, and quality of life outcomes in veterans: Exploring the potential benefits of a PTSD specific functioning measure.* In **B. N. Smith** (Chair), *Examining the impact of PTSD on work, family, and other related quality of life outcomes in veterans of the wars in Iraq and Afghanistan.*
101. **Mitchell, K. S.**, **Wolf, E. J.**, **Bovin, M. J.**, **Lee, D. J.**, **Green, J. D.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** *Network models of DSM-5 posttraumatic stress disorder: Implications for ICD-11.*

Appendix E: Fiscal Year 2017 Scientific Presentations

(International Society for Traumatic Stress Studies Continued)

102. **Mitchell, K. S., Wolf, E. J., Bovin, M. J., Rosen, R. C., Keane, T. M., & Marx, B. P.** *Network models of DSM-5 PTSD: Implications for ICD-11.*
103. **Montano, M. A., Sherrieb, K., & Bernardy, N. C.** *Sleep on this: Changing prescribing, access and attitudes through rural provider education.*
104. **Moshier, S. J., Erb, S. E., Parker-Guilbert, K., Trachtenberg, F., Rosen, R. C., Keane, T. M., & Marx, B. P.** *Less symptomatic but more impaired: Correlates of early treatment termination among returning veterans with PTSD.*
105. **Moshier, S. J., Klein, A., Harwell, A. M., Parker-Guilbert, K., Erb, S. E., Trachtenberg, F., Rosen, R. C., Keane, T. M., & Marx, B. P.** *Who can't get no satisfaction? Satisfaction with VA and non-VA mental health care among OIF/OEF veterans with PTSD.*
106. **Nilni, Y. I., Irvine, J., Webb, A., Resick, P. A., Orr, S., Rasmusson, A. M., & Pineles, S. L.** Differences in ovarian hormone steroids across the menstrual cycle among women with and without PTSD. In **Y. I. Nilni** (Chair), *Trauma, PTSD and women's reproductive health.*
107. **Norman, S. B., Bernardy, N. C., Finley, E., Jeffreys, M., & Spoont, M.** Innovative approaches to improving PTSD treatment: Using technology to aid public health. In **N. Bernardy** (Chair), *Innovative approaches to improving PTSD treatment: Using technology to aid public health.*
108. **Norman, S. B., Eaton, E., Bolton, E., Cameron, A., & Gauthier, J.** Addressing self-conscious emotions in trauma related treatment with military veterans. In **C. Capone** (Chair), *Addressing self-conscious emotions in trauma related treatment with military veterans.*
109. **Norman, S. B., Zwiebach, L., Charney, M., & LoSavio, S.** Using technology to support sustained implementation of evidence based treatments through consultation and education for veterans in community settings. In **M. Charney** (Chair), *Disseminating Prolonged Exposure and Cognitive Processing Therapy into community settings.*
110. **Ortigo, K. M., Owen, J. E., & Carlson, E. B.** Veteran preferences for alternative methods for mental health care delivery. In **K. Possemato** (Chair), *Innovative online services to increase treatment access and engagement for veterans.*
111. **Osei-Bonsu, P., Bass, D., Friedman, M. J., Nugent, S., Hagel-Campbell, E., & Spoont, M.** *Supporting adherence to clinical practice guidelines through provider training and a decision support tool.*
112. **Paige, L., Bergmann, J., Renshaw, K. D., & Heinz, A. J.** *The role of personality traits in the post-trauma outcomes of combat veterans: An examination of posttraumatic stress and posttraumatic growth.*
113. **Pineles, S. L., Irvine, J., Webb, A., Nilni, Y. I., Resick, P. A., & Rasmusson, A. M.** Neurobiological mechanisms of menstrual cycle effects on extinction retention among women with and without PTSD. In **K. Fellingham** (Chair), *The effects of stress and sex hormones on mechanisms of posttraumatic stress disorder.*
114. **Rasmusson, A. M., King, M. W., Gregor, K., Scioli-Salter, E. R., Pineles, S. L., Valovski, I., Hamouda, M., & Pinna, G.** Sex differences in the enzyme site at which GABAergic neuroactive steroid synthesis is blocked in PTSD: Implications for targeting of PTSD therapeutics. In **Y. I. Nilni** (Chair), *Sex specificity in posttraumatic stress disorder: From biological mechanisms to treatment response.*
115. **Ratanatharathorn, A., Logue, M. W., Miller, M. W., & PGC-PTSD.** Epigenetics workgroup DNA methylation at NRG1 may be an epigenetic biomarker of PTSD in civilian cohorts. In **A. B. Amstadter & N. R. Nugent** (Chairs), *Updates from the psychiatric genomics consortium for PTSD: GWAS, EWAS, expression, and imaging.*
116. **Rosen, C. S., Matthieu, M., Cook, J., & Wiltsey-Stirman, S.** *Research on implementation of CPT and PE in the U. S. Veterans Health Administration: Synthesis of findings from 19 studies.*
117. **Schnurr, P. P.** (2016, November). Discussion. In **T. Jensen** (Chair), *Moving from research to practice to meet the needs of trauma-exposed populations across the globe.*
118. **Schnurr, P. P., Bryant, R., Berliner, L., Kilpatrick, D. G., Rizzo, A., & Ruzek, J. I.** *What I changed my mind about and why.*
119. **Siegel, E., Myers, U., Haller, M., Angkaw, A., & Norman, S. B.** *Reintegration stress and guilt among veterans pursuing PTSD treatment.*
120. **Sippel, L. M., Han, S., Watkins, L. E., Harpaz-Rotem, I., Southwick, S. M., Krystal, J. H., Gelernter, J., & Pietrzak, R. H.** *Interaction of oxytocin receptor gene and social support in predicting resilience in U.S. military veterans.* **Smith, B. N., Taverna, E., Fox-Galalis, A. B., Schnurr, P. P., Matteo, R., & Vogt, D.** The roles of PTSD, depression, and alcohol misuse symptomatology in linking deployment stressors and work and family outcomes in male and female veterans. In **B. N. Smith** (Chair), *The roles of PTSD, depression, and alcohol misuse symptomatology in linking deployment stressors and work and family outcomes in male and female veterans.*
121. **Smith, Noelle, Tsai, J., Pietrzak, R. H., Cook, J., Hoff, R., & Harpaz-Rotem, I.** *Predictors of psychotherapy after initial diagnosis among Iraq and Afghanistan veterans.*
122. **Spadoni-Townsend, A., Taylor, C., Norman, S. B., & Simmons, A. N.** *The neural correlates of loss of consciousness during vector memory.*
123. **Spoont, M., Bass, D., Osei-Bonsu, P., O'Dougherty, M., Vang, D., Hagedorn, H., Friedman, M. J., Felker, B., & Post, E.** Engaging primary care providers in VA community clinics to provide evidence based pharmacotherapy for PTSD. In **N. Bernardy** (Chair), *Innovative approaches to improving PTSD treatment: Using technology to aid public health.*
124. **Street, A. E., Rosselini, A., Ursano, R., Stein, M., Zaslavsky, A., & Kessler, R.** *Developing a risk model to target high-risk preventive interventions for sexual assault victimization among female U.S. Army soldiers.*
125. **Taverna, E., Vogt, D., & Smith, B. N.** *Childhood abuse: Long-term implications for interpersonal-related quality of life through mental and physical health sequelae experienced during adulthood.*
126. **Vento, S., Gradus, J. L., & Street, A. E.** *Factors that moderate associations between deployment stressors and PTSD among male and female veterans of the wars in Afghanistan and Iraq.* **Vogt, D., Smith, B. N., Fox, A. B., & Schnurr, P. P.** Consequences of PTSD for work and family quality of life of female and male U.S. Afghanistan and Iraq war veterans. In **B. N. Smith** (Chair), *Examining the impact of PTSD on work, family, and other related quality of life outcomes in veterans of the wars in Iraq and Afghanistan.*
127. **Waelde, L., Macia, K. S., & Carlson, E. B.** *Development and validation of a short form of the Dissociative Symptoms Scale.*

Appendix E: Fiscal Year 2017 Scientific Presentations

(International Society for Traumatic Stress Studies Continued)

128. **Woodward, S. H.**, Schaer, M., & Kaloupek, D. G. *Regional cortical gyrification is reduced in chronic severe PTSD.*
129. **Yoder, M. S.**, & Tuerk, P. W. *Home-based PTSD treatment: Predictors of treatment outcome.*

Science of Dissemination and Implementation in Health Washington, DC December 2016

130. **Bernardy, N. C., Montano, M. A., Sherrieb, K., & Rosen, C. S.** Engaging clinicians and veterans in efforts to decrease benzodiazepines in posttraumatic stress disorder (PTSD): De-implementing through academic detailing. In **C. S. Rosen** (Chair), *Strategies for improving evidence-based mental health care for veterans: Implementation, de-implementation, and addressing system complexity.*
131. Sayer, N., & **Rosen, C. S.** Organizational factors differentiating VHA PTSD outpatient teams with high and low delivery of evidence based psychotherapy. In **C. S. Rosen** (Chair), *Strategies for improving evidence-based mental health care for veterans: Implementation, de-implementation, and addressing system complexity.*
132. **Wiltsey Stirman, S.**, Carreno, P., **Mallard, K. N.**, Masina, T., & Monson, C. Strategies for assessing fidelity to evidence-based interventions: A comparison of feasibility, accuracy, and associations with clinical outcomes. In **S. Wiltsey Stirman** (Chair), *Assessing fidelity to evidence-based interventions. How far will different strategies take us?* Symposium conducted at the 9th Annual Conference on the Science of Dissemination and Implementation in Health, Washington DC.
133. **Zimmerman, L. E., Rosen, C. S., Kimerling, R.**, Trafton, J., & Lindley, S. Participatory system dynamics: Triangulating electronic health records, stakeholder expertise and simulation modeling to expand evidence-based practices. In **C. S. Rosen** (Chair), *Strategies for improving evidence-based mental health care for veterans: Implementation, de-implementation, and addressing system complexity.*

U.S. Department of Veterans Affairs

134. **Averill, L.** (2016, December). *Ketamine trials at the NCPTSD: A brief review of where we've been, where we are, and where we are going.* Presented at the New York Harbor VA Medical Center, Brooklyn, NY.
135. Blonigen, D., Manfredi, L., Bi, X., Suarez, P., Nevedal, A., **Heinz, A. J.**, Vashi, A., Wagner, T., & Timko, C. (2017, July). *Veterans who frequently utilize psychiatric emergency services: A qualitative study of barriers and facilitators to reducing service utilization.* Poster presentation at the VA Health Service Research and Development Annual Meeting, Washington, DC.
136. Diaz, M. A., Williams, M. W., Lin, X., **Harik, J. M.**, Lee, K., Milliken, L., Haller, O., & Newsome, M. (2016, October). *Group-based exposure therapy's impact on the functional connectivity of veterans with mild traumatic brain injury during recovery from PTSD: Preliminary data.* Poster presented at the 2nd annual Michael E. DeBakey VA Research Meeting, Houston, TX.
137. **Galovski, T. E.** (2016, November). *Head injuries during assaults against women: Implications for recovery from PTSD.* 5th Annual Joining Forces BUMC and VA Boston Healthcare System TBI/PTSD Conference, Boston, MA.
138. **Galovski, T. E.** (2017, February). *PTSD research/clinical trials.* Congressional Staff Briefing (VISON 1), Bedford, MA.
139. **Galovski, T. E.** (2017, June). *Identifying and mitigating the potential toll of military service on women's health, functioning, and well-being.* VA Women's Health Services and Research Meeting, Boston, MA.
140. **Gradus, J. L.** (2017, March). *Cross-population trauma epidemiology and suicidal behavior outcomes.* Department of Veteran's Affairs Serious Mental Illness Treatment Resource and Evaluation Center, Ann Arbor, MI.
141. **Gradus, J. L.** (2017, March). *Gender differences in machine learning models of trauma and suicidal ideation in OEF/OIF veterans.* Department of Veterans Affairs Center of Excellence for Suicide Prevention, Canandaigua, NY.
142. Pogoda, T. K., **Iverson, K. M.**, Charns, M. P., Stolzmann, K., Suri, P., Gormley, K., Kregel, M. H., & Sayer, N. (2017, July). *Predicting employment status in OEF/OIF/OND veterans three years after evaluation for traumatic brain injury.* Presentation at the 2017 National Meeting of VA Health Services Research and Development Service (HSR&D), Crystal City, VA.
143. Saechao, F. S., Hamilton, A., Phibbs, C. S., Berg, E., **Kimerling, R.**, Finlay, A. K., Breland, J., Washington, D., Yano, E., Maisel, N., Balasubramanian, V., Hoggatt, K., & Frayne, S. M. (2017, July). *Revolving doors: Portal of entry to VA for new women Veteran patients influences speed of exit.* VA Health Services Research & Development/QUERI Conference, Arlington, VA.
144. **Schnurr, P. P.** (2017, July). *Psychotherapy for PTSD: An update on the evidence* [Webinar]. Presented for the Seattle VA Medical Center Psychology Lecture Series.
145. **Schnurr, P. P.**, McGuire, M., Sayer, N., & **Wiltsey-Stirman, S.** (2017, July). *Perspectives on implementing evidence-based psychotherapy for PTSD.* Panel discussion presented at the HSR&D/QUERI National Conference, Washington, DC.
146. Shaw, J. G., Schmitt, S. K., Frayne, S. M., Shaw, K. A., Danielsen, B., **Kimerling, R.**, Joyce, V. R., Asch, S. M., & Phibbs, C. S. (2017, July). *Are mothers who rely on VA coverage for maternity care a higher risk obstetric population?* VA Health Services Research & Development/QUERI Conference, Arlington, VA.
147. **Street, A. E.**, Shin, M., Gormley, K., **Bell, M. E.**, Hamilton, A., **Vogt, D.**, Sadler, A., & **Schnurr, P. P.** (2017, July). *Patient perspectives on military sexual trauma (MST) screening: Are veterans satisfied with their experiences?* VA Health Services Research & Development/QUERI Conference, Arlington, VA.
148. Tobin, C., **Meffert, B.**, Lai, J., **Bonn-Miller, M.**, & **Heinz, A. J.** (2017, March). *Relations between performance on neuropsychological assessments and perceived real-world psychosocial functioning among veterans with traumatic brain injury, alcohol use disorder, and PTSD.* Presentation at the 7th Annual Traumatic Brain Injury Research Forum of the Defense and Veterans Brain Injury Center and Polytrauma Services of VA Palo Alto Health Care System, Palo Alto, CA.

Appendix E: Fiscal Year 2017 Scientific Presentations

(U.S. Department of Veterans Affairs Continued)

149. **Vogt, D.** (2017, April). *Post-transition well-being of post-9/11 veterans*. Invited presentation to U.S. Department of Veterans Affairs Office of Policy and Planning Staff, Bethesda, MD.
150. **Wiltsey Stirman, S.** (2017, July). Considering fidelity in implementation. In **P. P. Schnurr** (Chair), *Perspectives on implementation of evidence-based psychotherapy for PTSD*. Presentation at the 2017 National Meeting of VA Health Services Research and Development Service (HSR&D), Crystal City, VA.

Other

151. **Abdallah, C.** (2017, April). *Ketamine's mechanism of action: Evidence from clinical studies*. Presented for the Biological Sciences Training Program (BSTP) Seminar, New Haven, CT.
152. **Abdallah, C.** (2017, April). *Neuroplasticity: Transient stressors but lifelong psychopathology*. Presented for Grand Rounds, University of Missouri Kansas City (UMKC) School of Medicine, Kansas City, MO.
153. **Abdallah, C.** (2017, April). *The putative mechanisms of ketamine's action in the brain—impact on depressive symptoms*. Presented at Psychedelic Science, Oakland, CA.
154. **Azevedo, K. J.,** Factor, A., Kumar, A., Hailu, E., Ramirez, J., Lindley, S. E., & **Jain, S.** (2017, May). *VA peer support specialist program support trauma-affected veteran families in California's Central Valley: Implications for violence prevention*. Violence Prevention Conference, Los Angeles, CA.
155. **Azevedo, K. J.,** Kumar, A., Hailu, E., Factor, A., Ramirez, J., **Azevedo, K. J.,** Lindley, S. E., & **Jain, S.** (2017, June). *Expected role and recovery mechanisms of veteran participation in peer support for PTSD*. Stanford University Neuroscience Conference, Palo Alto, CA.
156. **Babson, K. A.,** & Vandrey, R. (2016, November). The association between long-term and current cannabis use and slow wave sleep. In P. Morgan (Chair), *Human laboratory and clinical advances in sleep and substance use*. Paper accepted for presentation at the 50th Annual Meeting of the Winter Conference on Brain Research, Big Sky, MT.
157. **Berlinger, A., Fox-Galalis, A. B.,** & **Knight, J. A.** (2016, November). *PTSD heterogeneity and clinical symptom pattern variations from the CAPS and PCL*. Paper presented at the 5th BUMC TBI/PTSD Conference, Boston, MA.
158. **Bernardy, N. C., Montano, M. A., Sherrieb, K.,** & **Rosen, C. S.** (2016, November). *Engaging clinicians and veterans in efforts to decrease benzodiazepines in PTSD: De-implementing through academic detailing*. Presentation at the Academy Health meeting, Washington, DC.
159. **Brown, M., Klein, A., Harwell, A. M., Pedersen, S., Lee, D. J., Bovin, M. J.,** Rosen, R. C., **Keane, T. M.,** & **Marx, B. P.** (2017, June). Childhood abuse as a predictor of military sexual trauma. In G. S. Hafstad (Chair), *Child maltreatment*. Symposium conducted at the 15th Annual Meeting of European Society for Traumatic Stress Studies, Odense, Denmark.
160. **Dardis, C.,** Austin, M. J., Bill, A. C., & Gidycz, C. A. (2017, March). "Mis"perception is reality: The influence of college men's perceptions of peer sexual behavior on prosocial bystander intervention. In C. Dardis (Chair), *Intersections of gender and violence: Associations between gendered expectations and attitudes, IPV perpetration, and prosocial bystander intervention*. Symposium conducted at the Annual Meeting of the Association for Women in Psychology, Milwaukee, WI.
161. Davis, L., Duong, H., French, R., & **Tiet, Q. Q.** (2017, August). *Improvement in quality of life in veterans with PTSD after mobile app interventions*. Presentation at the American Psychological Association Annual Convention, Washington, DC.
162. Dichter, M. E., Butler, A., Haywood, T., Bellamy, S. L., Medvedeva, E., Roberts, C. B., & **Iverson, K. M.** (2017, September). *Clinical and health services use characteristics of women screening positive for past-year IPV in the Veterans Health Administration*. National Conference on Health and Domestic Violence, San Francisco, CA.
163. **Duman, R.** (2016, November). *Rapid acting antidepressants stimulate fast synaptic remodeling*. Invited address at the Journal of Labs Research Symposium, San Diego, CA.
164. **Duman, R.** (2016, December). *Blockade of tonic firing GABA interneurons in the PFC is required for the rapid antidepressant actions of ketamine and scopolamine*. Presentation at the American College of Neuropsychopharmacology, Hollywood, FL.
165. **Duman, R.** (2017, February). *Neurobiology of stress, depression and antidepressants: Remodeling synaptic connections*. Invited address at Intracellular Therapies, Inc, New York, NY.
166. **Duong, H. M., Davis, L.,** French, R., **Rosen, C. S.,** & **Tiet, Q. Q.** (2017, April). *PTSD Coach mobile app and seeking mental health treatment*. Presentation at the California Psychological Association, San Francisco, CA.
167. **Duong, H. M., Davis, L.,** Leyva, Y., Smith, C., **Smith, B. N.,** French, R., & **Tiet, Q. Q.** (2017, August). *PTSD Coach mobile app and primary care patients*. Presentation at the American Psychological Association Annual Convention, Washington, DC.
168. **Esterlis, I.** (2016, November). *Imaging the effects of electronic cigarettes at the beta2-nicotinic acetylcholine receptors*. Presented for the Tobacco Centers of Regulatory Science, Bethesda, MD.
169. **Esterlis, I.** (2017, March). *Down with mGluR5, up with synaptic density: Insights from PET studies*. Presented for Harvard University, Cambridge, MA.
170. French, R., Davis, L., Duong, H., & **Tiet, Q. Q.** (2017, August). *Changes in symptoms of depression for veterans after mobile app intervention*. Presentation at the American Psychological Association Annual Convention, Washington, DC.
171. Fuehrlein, B., Arias, A. J., Trevisan, L., **Kachadourian, L., Krystal, J. H., Southwick, S. M.,** & **Pietrzak, R. H.** (2016, December). *Trajectories of alcohol use in U.S. military veterans: Results from the National Health and Resilience Study*. Presentation at the Annual Meeting of the American Academy of Addiction Psychiatry, Bonita Springs, FL.
172. **Galovski, T. E.** (2017, May). *Identifying and mitigating the potential toll of combat employment on women's health, functioning, and well-being*. Institute for Defense and Government Advancement, Washington, DC.

Appendix E: Fiscal Year 2017 Scientific Presentations

(Other Continued)

173. **Gelernter, J.** (2016, October). *Psychiatric genomics consortium: Substance use disorders working group*. Invited address at the World Congress of Psychiatric Genetics, Jerusalem, Israel.
174. **Gradus, J. L.** (2017, February). *Longitudinal sequelae of stress disorders: Data from the Danish population*. Center for Health Equality Research, Brown University, Providence, RI.
175. **Gradus, J. L.** (2017, May). *Gender differences in machine learning models of trauma and suicidal ideation in OEF/OIF Veterans*. Danish Veteran Centre, Ringsted, Denmark.
176. **Gradus, J. L.** (2017, May). *Stress disorders and suicide in Denmark: A review of three studies*. Aarhus University, Department of Clinical Epidemiology, Aarhus, Denmark.
177. **Gradus, J. L.** (2017, June). *Longitudinal outcomes of subsyndromal stress disorders in the population of Denmark*. Paper presented at the annual meeting of the Society for Epidemiologic Research, Seattle, WA.
178. **Green, J. D., Hatgis, C., Kearns, J. C., Nock, M. K., & Marx, B. P.** (2017, June). *Using the Direct and Indirect Self-Harm Inventory (DISH) to explore differences in self-harm among male and female veterans*. Presentation at the 12th annual meeting of the International Society for the Study of Self-Injury, Philadelphia, PA.
179. **Harpaz-Rotem, I.** (2016, November). *Psychodynamic approach to the reconsolidation of traumatic memories within Prolonged Exposure therapy*. Presentation at the Society for Psychotherapy Research, Berkeley, CA.
180. **Harpaz-Rotem, I.** (2017, May). *Be all you can be between a promise and reality, narratives of security and insecurity in U.S. Armed Forces personnel*. Invited talk at Ben Gurion University, Beersheba, Israel.
181. **Harpaz-Rotem, I., Jia, R., Podhajsky, S., & Levy, I.** (2017, September). *Neuroeconomic approach to biomarkers in psychopathology: Aversion to ambiguous losses in PTSD*. Presentation at the Annual Meeting of the Society for Research in Psychopathology, Denver, CO.
182. **Harpaz-Rotem, I., Jia, R., Ruderman, L., Pietrzak, R. H., & Levy, I.** (2017, April). *Neuroeconomic approach to trauma related psychopathology: Aversion to ambiguous losses in PTSD*. Presentation at the European Congress of Psychiatry, Florence, Italy.
183. **Hayes, J. P.** (2017, March). *Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease*. Presentation at the Twelfth World Congress of the International Brain Injury Association, New Orleans, LA. **Heinz, A. J., Meffert, B., Tobin, C., Lai, J., Lee, K., & Bonn-Miller, M. O.** (2017, March). *Mobile cognitive training for military veterans with alcohol use disorder and co-occurring posttraumatic stress disorder*. Poster presented at the Experiential Technology and Neurogaming Conference and Expo, San Francisco, CA.
184. **Iverson, K. M.** (2017, May). *Screening and intervention for intimate partner violence (IPV) for women in VHA*. VA Boston Healthcare System Annual Research Week, Boston, MA.
185. **Jaworski, B. K., & Owen, J. E.** (2017, June). *Exploring the potential of mHealth to alleviate health disparities*. In H. E. Bullock (Chair), *Strategies for alleviating poverty and promoting economic justice*. Symposium conducted at the annual meeting of the Society of the Psychological Study of Social Issues Association, Albuquerque, NM.
186. **Khan, C. T., Woodward, S. H., Jamison, A., & Gala, S. M.** (2017, June). *Improving actigraph-based sleep efficiency estimates*. Presentation to the Associated Professional Sleep Societies, Boston, MA.
187. **Knight, J. A., Berlingeri, A., & Fox, A.** (2017, August). *PTSD clinical heterogeneity: Symptom combination variations across PTSD criteria*. Paper presented at the 125th Meeting of American Psychological Association, Washington, DC.
188. **Knight, J. A., Berlingeri, A., Fox, A., Ebalu, T., Weatherill, R. P., & Taft, C. T.** (2016, November). *Identifying symptom patterns within the Clinician-Administered PTSD Scale (CAPS)*. Poster presented at the 50th Annual Meeting of the Association for Behavior and Cognitive Therapy, New York, NY.
189. **Krystal, J. H.** (2016, October). *Ketamine for antidepressant resistant PTSD*. Presentation at the CAP Combat PTSD Conference, San Antonio, TX.
190. **Krystal, J. H.** (2016, November). *Overcoming the crisis of depression research*. Presentation at the Hope for Depression Research Foundation, New York, NY.
191. **Krystal, J. H.** (2016, December). *Fields to accelerate clinical neuroscience and mental health research*. Presentation at the National Institution of Mental Health Convergence Neuroscience Workshop, University of California, San Francisco, CA.
192. **Krystal, J. H.** (2017, June). *Pathophysiology of PTSD: Rethinking drug targets (PTSD SoSS)*. Presentation at the U.S. Army Medical Research and Materiel Command State of the Science Summit, Shepherdstown, WV.
193. **Lai, J., Cohen, N. L., Tobin, C., Meffert, B., Blonigen, D., Bonn-Miller, M. O., & Heinz, A. J.** (2017, February). *Subjective and objective measures of impulsivity: Relations with clinical symptom severity and psychosocial functioning among military veterans with alcohol use disorder and posttraumatic stress disorder*. Poster presented at the International Society of Neuropsychology 45th Annual Meeting, New Orleans, LA.
194. **Liang, J. J., Romano, A. S., Klein, A., Harwell, A. M., Bovin, M. J., Green, J. D., Marx, B. P., & Rasmusson, A. M.** (2016, November). *VALOR investigation of reproductive/gynecological health problems among deployed women veterans exposed to military sexual trauma*. Joining Forces Conference, Boston, MA.
195. **McGraw, K., McGee-Vincent, P., Houston, J., & Blatt, A.** (2017, August). *Innovative psychological health practice change dissemination: DoD/VA implementation science efforts*. In K. McGraw (Chair), *Innovative psychological health practice change dissemination: DoD/VA implementation science efforts*. Symposium conducted at the American Psychological Association Annual Convention, Washington, DC.
196. **Meshberg-Cohen, S., Black, A. C., Kachadourian, L., & Rosen, M. I.** (2017, June). *Relationship between alcohol use disorder and attitudes toward seeking professional psychological help among veterans filing PTSD claims*. 38th Annual Scientific Meeting of the Research Society on Alcoholism, Denver, CO.
197. **Meyer, E., & Walser, R. D.** (2017, June). *Putting values into action: Examining the connection between values and behavioral assignments from a study of ACT for co-occurring posttraumatic stress disorder and alcohol use disorders*. Association for Contextual Behavioral Science, Seville, Spain.

Appendix E: Fiscal Year 2017 Scientific Presentations

(Other Continued)

198. Meyer, E., **Hermann, B.**, Batten, S., DeBeer, B., **Schnurr, P. P.**, & **Walser, R. D.** (2017, June). *Acceptance and Commitment Therapy (ACT) for co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD) in U.S. military veterans: Preliminary treatment outcomes*. Association for Contextual Behavioral Science, Seville, Spain.
199. **Miller, K. E.**, **Kuhn, E. R.**, **Owen, J. E.**, Taylor, K. L., Yu, J., **Weiss, B. J.**, **Crowley, J. J.**, & Trockel, M. (2017, June). *Clinician perceptions related to the use of the CBT-I Coach mobile app*. SLEEP, Boston, MA.
200. **Miller, M. W.** (2017, January). *Traumatic stress, oxidative stress, and accelerated aging in PTSD*. William James College, Newton, MA.
201. **Mitchell, K. S.**, Bulik, C. M., Koenen, K. C., & Field, A. E. (2016, October). *Network models of comorbid eating disorder and PTSD symptoms*. Paper presented at the meeting of the Eating Disorders Research Society, New York, NY.
202. **Niles, B. L.**, Mori, D. L., **Pless Kaiser, A.**, & Wang, C. (2017, April). Qualitative findings and feasibility of a brief Tai Chi program for PTSD. In **B. L. Niles** (Chair), *Building an evidence base for complementary and integrative treatment approaches for PTSD*. Symposium conducted at the 37th Annual Meeting of the Anxiety Disorders Association of America, San Francisco, CA.
203. **Nilni, Y. I.** (2016, October). *The intersection of women's mental and reproductive health: Identifying mechanisms for intervention*. Colloquium presented to the Division of Prevention and Community Research, Department of Psychiatry, Yale University, New Haven, CT.
204. **Nilni, Y. I.** (2016, October). *The intersection of women's mental and reproductive health: Identifying mechanisms for intervention*. Colloquium presented to Women's Medicine Collaborative at Lifespan, Warren Alpert Medical School of Brown University, Providence, RI.
205. **Pedersen, S.**, **Brown, M.**, **Moshier, S. J.**, **Kleiman, S.**, Seal, K., Trachtenberg, F., Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** (2017, August). *Complementary and integrative health strategies: Use and interest in a sample of veterans with PTSD*. The Military Health System Research Symposium, Kissimmee, FL.
206. **Pedersen, S.**, **Green, J. D.**, **Kearns, J. C.**, Rosen, R. C., **Keane, T. M.**, & **Marx, B. P.** (2017, August). *Suicide prevention & treatment - evaluating the effectiveness of safety plans for military veterans: Do safety plans tailored to veteran characteristics decrease suicide risk?* The Military Health System Research Symposium, Kissimmee, FL.
207. **Petrakis, I.** (2017, April). *Alcohol use disorders and co-occurring PTSD*. Presented for the University of California San Francisco Department of Psychiatry, Grand Rounds, San Francisco, CA.
208. **Pineles, S. L.** (2017, March). *Menstrual phase effects on mechanisms implicated in PTSD maintenance*. Presented for the Massachusetts General Hospital Home Base Program Research Series, Boston, MA.
209. **Pless Kaiser, A.** (2017, July). Later-adulthood trauma reengagement: Findings from discussion groups with older combat veterans. In **A. Pless Kaiser & E. Davison** (Chairs), *Trauma-informed interventions for older adults with PTSD and trauma-related problems*. Symposium conducted at the 21st Meeting of the International Association of Gerontology and Geriatrics, San Francisco, CA.
210. **Rasmusson, A. M.**, Risbrough, V., & Mathew, S. J. (2016, October). *Physiological measures for possible use in development of PTSD biomarkers & therapeutics*. Presented at Cohen Veterans Biosciences Amp-it-Up Preclinical Workshop #2, Tyson's Corner, VA.
211. Rosen, M. I., Black, A. C., Montalvo-Ortiz, J. L., **Levy, I.**, & McMajon, T. J. (2017, June). *An androgen receptor polymorphism (CAG repeats) and risk-taking*. 79th Annual Meeting of the College on Problems of Drug Dependence, Montreal, Canada.
212. Rosen, R. C., **Green, J. D.**, **Bovin, M. J.**, **Kleiman, S.**, **Moshier, S. J.**, Magnavita, A., Rangnathan, G., Trachtenberg, F., **Marx, B. P.**, & **Keane, T. M.** (2017, August). *Optimizing enrollment, retention and successful data collection in large, observational studies in military populations: The Project VALOR experience*. The Military Health System Research Symposium, Kissimmee, FL.
213. Ruderman, L., Jia, R., Ehrlich, D., Salhotra, P., & **Harpaz-Rotem, I.** (2016, November). *The neural correlates of trauma-related symptoms severity in combat veterans: A neuroeconomic approach*. Presentation at the Society for Neuroscience, San Diego, CA.
214. **Sanacora, G.** (2016, November). *Targeting the glutamatergic neurotransmitter system in the development of novel antidepressant medications*. Invited address at the 34th Brazilian Congress of Psychiatry, São Paulo, Brazil.
215. **Sanacora, G.** (2017, April). *Update on the clinical use of ketamine and other "putative" rapidly acting antidepressants*. Keynote Speaker, at the Annual Meeting of the Colorado Psychiatric Society, Denver, CO.
216. **Sanacora, G.** (2017, July). *The glutamatergic approach for treatment of depression*. CINP Thematic Meeting, Prague, Czech Republic.
217. **Satodiya, R.**, **Averill, C. L.**, **Akiki, T.**, **Amoroso, T.**, **Averill, L.**, **Wrocklage, K. M.**, **Scott, J. C.**, **Southwick, S. M.**, **Krystal, J. H.**, & **Abdallah, C.** (2017, May). *Volumetric changes in hippocampal subfields in posttraumatic stress disorder*. Presentation at the 170th Annual Meeting of the American Psychiatric Association (APA), San Diego, CA.
218. Schmidt, E. M., Stock, E., Serpi, T., Cypel, Y., Magruder, K., Kilbourne, A., **Spiro, A.**, **Kimerling, R.**, Cohen, B., & Frayne, S. M. (2017, April). *Diabetes among women veterans four decades after war: The HealthVIEWS study*. Society of General Internal Medicine Annual Meeting, Washington, DC.
219. **Schnurr, P. P.** (2017, May). *Longitudinal investigation of the implementation of two evidence-based psychotherapies for PTSD in VA residential treatment programs*. Presentation at the Annual Meeting of the Dissemination and Implementation Summit, Cohen Veterans Network and Center for Deployment Psychology, Arlington, VA.
220. **Schnurr, P. P.**, Chow, B. K., Suvak, M., Macdonald, A., Monson, C. M., **Resick, P. A.**, & **Caudle, K. L.** (2017, June). *Effects of concurrent medication use on outcome in trials of psychotherapy for PTSD*. Presented at the Department of Defense State of the Summit on Pathophysiology of PTSD: Rethinking Drug Targets, Shepherdstown, WV.
221. **Scioli, E. R.**, Bair, M. J., Hauger, R., Pinna, G., & **Rasmusson, A. M.** (2017, May). *Potential neurobiological mediators of exercise benefits for pain sensitivity in chronic pain and PTSD*. Presentation at the 36th Annual Scientific Meeting of the American Pain Society, Pittsburgh, PA.

Appendix E: Fiscal Year 2017 Scientific Presentations

(Other Continued)

222. **Street, A. E.** (2017, June). Inter-generational and life course stability of relationship violence in the WHO World Mental Health Surveys. In G. S. Hafstad (Chair), *International Society for Traumatic Stress Studies: The effects of child maltreatment in adult samples*. Symposium conducted at the Annual Meeting of the European Society for Traumatic Stress Studies, Odense, Denmark.
223. **Taverna, E., Nillni, Y. I.,** TVMI Study Team, & **Vogt, D.** (2016, November). *Development and validation of the Well-Being Inventory (WBI): A comprehensive tool for the assessment of veterans' status, functioning, and satisfaction with respect to vocation, finances, health, and social relationships*. Poster presented at the Annual Boston University Medical Center and Veteran Affairs Boston Joining Forces TBI/PTSD Conference, Boston, MA.
224. **Thompson-Hollands, J., Azevedo, K. J., Smith, B. N., & Rosen, C. S.** (2016, October). *Change in patient-identified problems and relationships to standard symptom measures among treatment-seeking veterans with PTSD*. Poster presentation at the Annual Convention of the Association of Behavioral and Cognitive Therapies, New York, NY.
225. **Vasterling, J. J.** (2016, December). *Deployment-related polytraumatic injuries: PTSD and mild TBI* [Webinar]. Presented for Department of Defense Pain Fellowship.
226. **Vogt, D.** (2017, April). *Preliminary results from the Veteran Metrics Initiative project*. Invited presentation at the Henry Jackson Foundation, Bethesda, MD.
227. **Wiltsey Stirman, S.,** Ahles, E., Valentine, G. W., Monson, C., & Marques, L. (2016, December). Going off-script: Modifications to Cognitive Processing Therapy (CPT) in a community mental health clinic. In A. Baumann-Walker (Chair), *Cultural adaptation and implementation science: Optimizing the science of adaptation in the context of implementation*. Symposium conducted at the 9th Annual Conference on the Science of Dissemination and Implementation, Washington, DC.
228. **Wolf, E. J.** (2017, June). PTSD and accelerated aging. In W. Milberg & R. McGlinchey (Chairs), *The diagnosis, neurobiology and treatment of deployment trauma: New concepts in understanding the neuropsychological and psychological impact of war*. Symposium conducted at the 15th Annual Meeting of the American Academy of Clinical Neuropsychology, Boston, MA.
229. **Woodward, S. H., Jamison, A., & Gala, S. M.** (2017, June). *Posttraumatic stress disorder, canine companionship, and sleep: Preliminary Findings*. Presentation at the Associated Professional Sleep Societies, Boston, MA.
230. **Zimmerman, L. E., & Lounsbury, D.** (2017, July). *Participatory system dynamics modeling for expanding the timely reach of evidence-based practices in VA outpatient mental health*. Oral presentation at the 35th International System Dynamics Conference, Cambridge, MA
231. **Zimmerman, L. E.,** Javorka, M., Ballinger, A., Mushiana, S., London, M., & **Lounsbury, D.** (2017, June). Participatory system dynamics modeling: Empowering stakeholders to identify, understand and modify drivers of implementation outcomes in health systems. In **L. Zimmerman** (Chair), *Participatory system dynamics modeling: Empowering stakeholders to identify, understand and modify drivers of implementation outcomes in health systems*. Oral Presentation at the 16th Biennial Conference of the Society for Community Research and Action, Ottawa, Canada.
232. **Zimmerman, L. E., Lounsbury, D., Rosen, C. S., Kimerling, R.,** Trafton, J., Bernard, C., & Lindley, S. (2017, June). *Participatory system dynamics modeling: Empowering stakeholders to implement system changes that increase access to timely, high-quality mental health care*. Oral Presentation at the 16th Biennial Conference of the Society for Community Research and Action, Ottawa, Canada.
233. **Zimmerman, L. E., Lounsbury, D., Rosen, C. S., Kimerling, R.,** Trafton, J., Bernard, C., Rust, T., & Lindley, S. (2016, October). *Participatory system dynamics modeling: Collaborating with providers, patients and policy makers to achieve timely, high-quality addiction services*. Presentation at the 2016 Addiction Health Services Research Conference, Seattle, WA.

Appendix F: Fiscal Year 2017 Educational Presentations

International Society of Traumatic Stress Studies, Dallas, TX, November 2016

1. Greene, C., & Prins, A. A preliminary evaluation of *Moving Forward: An online problem-solving skills program*.
2. Merrick, C., & Bippart, V. *Customizing an online PTSD treatment decision aid to improve patient-centered care*.
3. Vogt, D., Iverson, K. M., Gutner, C. A., Wells, S., & Badour, C. *How to submit graduate and early career awards: What you need to know about NIH and VA grants*.
4. Watson, P. Increasing community capacity to respond to disasters. In D. Zatzick (Chair), *Designing and implementing broad-reach early trauma-focused interventions for public health dissemination*.

Other

5. Abdallah, C. (2016, October). *Neurobiology of trauma and stress: Diagnostic & treatment opportunities*. Invited address for Grand Rounds, Department of Psychiatry and Behavioral Sciences, New York Medical School, Valhalla, NY.
6. Armstrong, C., Ciulla, R., & McGee-Vincent, P. (2017, August). *Latest mobile apps, clinical support tools available for service members, veterans, and families* [Webinar]. Presented for the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury Webinar Series. Retrieved from <https://www.dcoe.mil/training/webinars>
7. Batten, S., & Walser, R. D. (2017, June). *Enhancing your clinical supervision skills: Applying contextual behavioral principles to supervisory challenges*. Workshop presented at the Association for Contextual Behavioral Science World Conference, Seville, Spain.
8. Drescher, K., Ruzek, J. I., Walser, R. D., & McCaslin, S. E. (2017, July). *Understanding PTSD among military veterans and first responders*. Presented for the Menlo Park Fire District EMS/Fire personnel, Menlo Park, CA.
9. Galovski, T. E. (2016, October). *Cognitive Processing Therapy and the treatment of PTSD*. State of Texas, San Antonio, TX.
10. Galovski, T. E. (2016, October). *The influence of PTSD on quality of life* [Webinar]. Presented for the Community Clergy Training to Support Rural Veterans Mental Health, National Chaplain Center.
11. Galovski, T. E. (2016, November). *Reducing suicide: The intersection of empiricism and clinical wisdom*. Women in Government: 7th Annual Healthcare Summit, Washington, DC.
12. Galovski, T. E. (2017, January). *Serving the underserved: Addressing health disparities for people with disabilities*. Spaulding Rehabilitation Hospital - Research Panel, Charlestown, MA.
13. Galovski, T. E. (2017, June). *Leadership skills for researchers*. The 25th Annual VA Boston Healthcare System Psychology Education Conference, Boston, MA.
14. Galovski, T. E. (2017, August). *WoVeN peer-leader training*. St. Louis, MO.
15. Galovski, T. E. (2017, September). *Cognitive Processing Therapy and the treatment of PTSD*. Department of Veterans Affairs, Boston, MA.
16. Gelernter, J. (2016, December). *Using genetics to understand addiction biology*. Presentation at the Ramathibodi Hospital, Bangkok, Thailand.
17. Gelernter, J. (2017, February). *Genetics of substance use disorders: GWAS and beyond*. Presentation for the Yale-Chula Drug Dependence throughout the Lifespan Training Program-Course in Epidemiology, Genetics and Brain Imaging in Addiction, Chulalorkorn Faculty of Medicine, Bangkok, Thailand.
18. Gelernter, J. (2017, March). *Genetics of nicotine withdrawal symptoms (and other stories)*. Presentation at the Annual Meeting for the Society for Research on Nicotine and Tobacco, Florence, Italy.
19. Gelernter, J. (2017, June). *Genetics in addictions: What have we learned over the last decade?* Presented at the 11th ALBATROS International Congress of Addictology (Plenary Session), Paris, France.
20. Gillanders, D., Walser, R. D., Welford, M., Bolderston, H., & McHugh. (2016, November). *Travelers: Points of connection and points of distinction between third wave therapies*. Panel at the UK and Ireland Chapter Association of Contextual Behavioral Science, Edinburgh, Scotland.
21. Goldsmiths, J. L., Flaxman, P., McIntosh, R., & Walser, R. D. (2016, November). *Beyond the therapy room: The role of CBS across different sectors*. Panel at the UK and Ireland Chapter Association of Contextual Behavioral Science, Edinburgh, Scotland.
22. Gutner, C. A. (2016, November). *Maximizing worksheets to enhance evidence-based treatments*. Southern Methodist University, Dallas, TX.
23. Havens, K., & McCaslin, S. E. (2017, September). *VA Innovators Network human-centered design workshop*. Presented for the VA Palo Alto Healthcare System, Palo Alto, CA.
24. Iverson, K. M. (2017, March). *Addressing intimate partner violence (IPV) among women veterans*. Presented for Social Work Education Day at the VA Boston Healthcare System, Boston, MA.

Appendix F: Fiscal Year 2017 Educational Presentations

(Other Continued)

25. Kauth, M. R., & Shipherd, J. C. (2017, June). *Overview of VA LGBT veteran health care* [Webinar]. Presented for the Minority Veterans Program Coordinators.
26. Keane, T. M. (2016, November). *Treatment of PTSD in VA*. Presented for the National Press Foundation, Washington, DC.
27. Keane, T. M. (2016, December). *VetChange: Clinical applications of an internet treatment for risky alcohol use and PTSD* [Webinar]. Presented for the Division of Psychologists in Public Service.
28. Keane, T. M. (2017, January). *Recent advances in the psychological treatment of PTSD*. Presentation at Carlos Albizu University Department of Clinical Psychology, Miami, FL.
29. Keane, T. M. (2017, January). *Recent advances in the psychological treatment of PTSD*. Presentation at the University of Miami Department of Psychiatry Grand Rounds, Miami FL.
30. Kjølgaard, R., & Walsler, R. D. (2016, November). *Creative hopelessness*. Workshop presented at the Nordic Chapter of the Association for Contextual Behavioral Science, Copenhagen, Denmark.
31. Kjølgaard, R., & Walsler, R. D. (2017, June). *Uncovering the process of creative hopelessness*. Workshop presented at Association for Contextual Behavioral Science World Conference, Seville, Spain.
32. Knight, J. A. (2017, March). *New approach using transcranial light for treating veterans with TBI & PTSD*. Presentation at the Meeting of the Regional Veterans Council, Framingham, MA.
33. Krystal, J. H. (2017, May). *PTSD: From neurobiology to treatment*. Presentation at Stony Brook University Grand Rounds, Long Island, NY.
34. McCaslin, S. E., Baker, S., Chang, A., Vantsevich, A., & Miller, A. (2017, May). *Version 2.0 of the Community Provider Toolkit*. Envisioning Workshop, Lab at OPM, Washington, DC.
35. McCaslin, S. E., Cannizzarro, K., Lickel, J., & Thiede, J. (2017, January). *Assessing VHA resources to support well-being and academic success*. Panel presented at the Student Veterans of America Annual Conference, Anaheim, CA.
36. McLean, C. P. (2017, February). *Prolonged Exposure therapy for PTSD*. Presented to the clinical psychology graduate students. Department of Psychology, University of California Berkeley, Berkeley, CA.
37. McLean, C. P. (2017, May). *Web treatments for PTSD*. 2017 VA Palo Alto Health Care System Research Week, Palo Alto, CA.
38. Miller, M. W. (2017, May). *Oxidative stress, inflammation, and accelerated aging in veterans with chronic PTSD*. VA Maine Medical Center, Togus, MA.
39. Morris, E., Walsler, R. D., Barnes-Holmes, Y., Gillanders, D., & Bennett, R. (2016, November). *Supervision and training: What can contextual behavioral science bring?* Panel presented at the UK and Ireland Chapter Association of Contextual Behavioral Science, Edinburgh, Scotland.
40. Niles, B. L., Unger, W. S., & Wattenberg, M. (2017, March). *Catharsis and containment: Empirically supported group treatments for handling emotion in groups for PTSD*. Workshop presented at the Annual Meeting of the American Group Psychotherapy Association, New York, NY.
41. Nillni, Y. I., & Miller, Laura (2017, July). *Perinatal PTSD* [Webinar]. Presented for the Women's Mental Health Monthly Clinical Training Teleconference Series. Retrieved from <https://vaww.portal.va.gov/sites/OMHS/WMH/teleconferencedl/Forms/AllItems.aspx>
42. Pineles, S. L. (2016, November). *Gender and PTSD*. Guest Lecture for Psychopathology Graduate Seminar at Suffolk University, Boston, MA.
43. Sanacora, G. (2016, October). *Moving beyond the monoamines*. Presented for the Psychiatry Updates, CME course, New York, NY.
44. Sanacora, G. (2016, November). *Treating major depression, current state*. Presentation for Psychiatry Updates, CME course, Washington, DC.
45. Sanacora, G. (2016, December). *Innovative treatments for major depression*. Invited address at the 3rd Annual Mood Disorders Summit, Miami, FL.
46. Sanacora, G. (2017, January). *Ketamine in treatment resistant depression*. Presented for the Georgia Psychiatric Physician Association Meeting, Atlanta, GA.
47. Sanacora, G. (2017, January). *Update on ketamine and other putative rapid acting antidepressants*. Invited address at the University of Miami, Psychiatry Grand Rounds, Miami, FL.
48. Sanacora, G. (2017, March). *Ketamine treatment of mood disorders: Ready for prime time?* Invited address at Psychiatry Grand Rounds, Indiana University, Indianapolis, IN.
49. Sanacora, G. (2017, March). *Novel glutamatergic agents for the treatment of mood disorders: A clinical perspective*. Invited address for the Rushton Lectures, Florida State University, Tallahassee, FL.
50. Sanacora, G. (2017, March). *Psychiatric drugs in development: Hope on the horizon*. Presentation at the Nevada Psychiatric Association Conference, Las Vegas, NV.
51. Sanacora, G. (2017, June). *Antidepressant effects of NMDA receptor antagonists*. Presented at the World Federation of the Society for Biological Psychiatry, Copenhagen, Denmark.
52. Sanacora, G. (2017, September). *Taking another look at major depression*. Pri-Med CME Conference, Boston MA.
53. Schnurr, P. P. (2017, August). *National Center for PTSD*. Invited address presented at the annual meeting of the American Legion, Reno, NV.
54. Schnurr, P. P. (2017, May). *Understanding the need for medication research on posttraumatic stress disorder*. Presentation at the VA PTSD Psychopharmacology Workshop at the Society for Biological Psychiatry, San Diego, CA.
55. Shipherd, J. C. (2016, October). *Intimate partner violence among lesbian, gay, bisexual, and transgender (LGBT) veterans* [Webinar]. Teleconference on the National IPV Assistance Training call.
56. Southwick, S. M. (2016, October). *The science of resilience: Lessons from the resilient*. Keynote address for Mind Body Medicine: Its Role in Compassionate Care, Harvard University School of Medicine, Boston, MA.
57. Southwick, S. M. (2017, January). *Trauma, PTSD and resilience*. Presentation at the Dart Foundation, Columbia School of Journalism, New York, NY.

Appendix F: Fiscal Year 2017 Educational Presentations

(Other Continued)

58. **Southwick, S. M.** (2017, June). *The science of resilience*. Presented for the Redmond Symposium of the International Association of Firefighters, Vancouver, Canada.
59. **Southwick, S. M.** (2017, May). *Resilience in health care*. Presented for Grand Rounds, Chicago Medical School, Chicago, IL.
60. **Taft, C. T.** (2017, February). *Preventing domestic violence in military veterans*. Presented at Boston University School of Medicine, Boston, MA.
61. Villatte, M., & **Walser, R. D.** (2017, June). *Doing experimental therapy*. Workshop presented at Association for Contextual Behavioral Science World Conference, Seville, Spain.
62. **Walser, R. D.** (2016, November). *Beyond the basics in Acceptance & Commitment Therapy: Advancing through use of the therapeutic relationship and implementing the processes with flexibility & effectiveness*. Workshop presented at the UK and Ireland Chapter Association of Contextual Behavioral Science, Edinburgh, Scotland.
63. **Walser, R. D.** (2016, November). *Life after trauma: Using Acceptance and Commitment Therapy to revitalize interrupted lives*. Workshop presented at the Nordic Chapter Association of Contextual Behavioral Science, Copenhagen, Denmark.
64. **Walser, R. D.** (2016, November). *Living life from the feet up: Creating well-being in the larger context of earth, animals and humans*. Plenary at the UK and Ireland Chapter Association of Contextual Behavioral Science, Edinburgh, Scotland.
65. **Walser, R. D.**, & O'Connell, M. (2017, June). *Training the therapist to be a therapist using ACT and mindfulness*. Workshop presented at the Association for Contextual Behavioral Science World Conference, Seville, Spain.
66. **Walser, R. D.**, & Westrup, D. (2017, June). *Rapid role play: Flexibly engaging act core processes in integrating the ACT core processes in therapy*. Workshop presented at Association for Contextual Behavioral Science World Conference, Seville, Spain.
67. **Wiltsey Stirman, S.** (2017, February). *Implementing CBT for depression in routine care clinical settings: Practical considerations*. Universidad de Monterrey, San Pedro Garza García, NL México.
68. **Wiltsey Stirman, S.** (2017, January). *Implementation and sustainability of a trauma-focused treatment for PTSD*. Psychiatry Grand Rounds, University of Texas Health Sciences Center, San Antonio.
69. **Wiltsey Stirman, S.** (2017, July). *Fireside chat: Sustainability* [Webinar]. Presented for the National Cancer Institute Advanced Topics in Implementation Science. Retrieved from <https://cyberseminar.cancercontrolplanet.org/implementationscience/archive.aspx?ID=41>
70. **Wiltsey Stirman, S.** (2017, May). *Why should I care about implementation science? Applying principles of implementation science to your work across the continuum of research to practice* [Webinar]. Presented for the Association of Cognitive & Behavior Therapies National Webinar Series. Retrieved from <http://www.cmhpsr.org/events/2017/5/19/webinar-why-should-i-care-about-implementation-science-applying-principles-of-implementation-science-to-your-work-across-the-continuum-of-research-to-practice>
71. **Wiltsey Stirman, S.**, Carreno, P., **Mallard, K. N.**, Tasoula Masina, & Monson, C. (2016, October). Which aspects of a learning collaborative are associated with fidelity to and adaptation of an evidence-based psychotherapy? In R. Hanson (Chair), *Peering Into the black box: Are we getting closer to unpacking the learning collaborative implementation model?* Association for Behavioral and Cognitive Therapies, New York City, NY.
72. **Wolf, E. J.** (2016, October). *The genetics of PTSD-related accelerated aging* [Webinar]. PGC Worldwide Lab Meeting
73. **Wolf, E. J.** (2017, February). *The dissociative subtype of PTSD: From genes to diagnostic assessment and treatment*. Presented for the Perspectives on Trauma Series, McLean Hospital, Belmont, MA.
74. **Wolf, E. J.** (2017, March). *Genetic and environmental influences on PTSD and resilience: Evidence for a single spectrum of vulnerability to traumatic stress*. Seminar presented at the Program in Genetic Epidemiology and Statistical Genetics Seminar Series at the Harvard School of Public Health, Boston, MA.

Appendix G:

Fiscal Year 2017 Editorial Board Activities

Administration and Policy in Mental Health Services and Mental Health Services Research

Wiltsey Stirman

American Journal of Medical Genetics, Part B

Gelernter

Asian Biomedicine (Research Reviews and News)

Gelernter

Behavior Therapy

Gutner; Sloan (Editor); Wolf

Behaviour Research and Therapy

Ruzek; Sloan

Biological Psychiatry

Duman; Gelernter; Krystal (Editor); Sanacora

Biological Psychiatry: Cognitive Neuroscience and Imaging

Duman, Gelernter, Sanacora

Brain Stimulation

Duman

Chinese Journal of Psychology

Keane

Chronic Stress

Abdallah (Editor); Duman; Esterlis; Krystal (Associate Editor); Pietrzak; Rasmussen; Sanacora; Southwick; Woodward

Clinical Psychology Review

Pineles (Guest Editor)

Clinical Psychology: Science and Practice

Keane

Cognitive and Behavioral Practice

McLean; Shipherd (Guest Editor)

Community Mental Health Journal

Harpaz-Rotem

Current Psychiatry Reports

Friedman

Depression and Anxiety

Holtzheimer

Eating Behaviors

Mitchell (Associate Editor)

European Journal of Psychotraumatology

Cloitre (Associate Editor)

Frontiers in Neuroscience: Neurogenomics

Miller (Associate Editor); Wolf

Frontiers in Neuroscience: Neurogenesis

Duman (Associate Editor)

International Journal of Emergency Mental Health

Keane

Journal of Abnormal Psychology

Miller; Wolf

Journal of Anxiety Disorders

Pietrzak; Ruzek

Journal of Child and Family Studies

Tiet

Journal of Clinical Psychology

Sloan

Journal of Consulting and Clinical Psychology

Marx; Sloan; Taft

Journal of Contemporary Psychotherapy

Sloan

Journal of Depression and Anxiety

Tiet

Journal of Family Psychology

Taft

Journal of Family Violence

Taft

Journal of Neurochemistry

Duman

Journal of Neuroscience

Levy (Associate Editor)

Appendix G: Fiscal Year 2017 Editorial Activities

Journal of Rehabilitation, Research and Development

Harpaz-Rotem (Associate Editor), Keane

Journal of Trauma and Dissociation

Carlson; Marx

Journal of Traumatic Stress

Galovski (Associate Editor); Miller; Morland; Wolf

mHealth

Ruzek

Molecular Neuropsychiatry

Abdallah

Molecular Pharmacology

Duman

Neuropsychopharmacology

Duman; Gelernter (Associate Editor); Sanacora (Deputy Editor)

Neuroscience Letters

Abdallah (Guest Editor)

Partner Abuse

Taft

PLoS One

Miller

Psychiatric Genetics

Gelernter

Psychological Assessment

Vasterling

Psychology Injury and Law

Pietrzak

Psychological Trauma: Theory, Research, Practice and Policy

Carlson; Keane; Marx; Miller; Ruzek; Smith; Vogt; Wachen

Psychopharmacology


Abdallah; Duman

Psychosomatic Medicine

Sloan

Trauma, Violence, and Abuse

Keane



EXECUTIVE DIVISION

VA Medical Center (116D)
215 North Main Street
White River Junction, VT 05009

BEHAVIORAL SCIENCE DIVISION

VA Boston Healthcare System (116B-2)
150 South Huntington Avenue
Boston, MA 02130

CLINICAL NEUROSCIENCES DIVISION

Psychiatry Service (116A)
VA Medical Center
950 Campbell Avenue
West Haven, CT 06516

DISSEMINATION AND TRAINING DIVISION

VA Palo Alto Health Care System
Building 334-PTSD
795 Willow Road
Menlo Park, CA 94025

EVALUATION DIVISION (NEPEC)

VA Connecticut Healthcare System (182)
950 Campbell Avenue
West Haven, CT 06516

PACIFIC ISLANDS DIVISION

3375 Koapaka Street
Suite 1-560
Honolulu, HI 96819

WOMEN'S HEALTH SCIENCES DIVISION

VA Boston Healthcare System (116B-3)
150 South Huntington Street
Boston, MA 02130



National Center for
PTSD

POSTTRAUMATIC STRESS DISORDER